_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
502252359,7/11/2014 15:15:05,,1320774868,7/11/2014 15:14:53,instagc,1,13763729,USA,"","",75.182.89.225,94,42,,,103,50,HEADACHES,MIGRAINE,HEADACHES.,94,42,MIGRAINE,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches.",94,42,94,42,103,50,-1,RO-has_definitional_manifestation,904909,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches",headaches,migraine
502252359,7/11/2014 15:15:07,,1320774887,7/11/2014 15:14:58,clixsense,1,19190439,GBR,H9,London,86.15.32.131,94,42,,,103,50,HEADACHES,MIGRAINE,HEADACHES.,94,42,MIGRAINE,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches.",94,42,94,42,103,50,-1,RO-has_definitional_manifestation,904909,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches",headaches,migraine
502252359,7/11/2014 15:16:45,,1320775474,7/11/2014 15:16:40,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,94,42,,,103,50,HEADACHES,MIGRAINE,and tension type HEADACHES.,77-81-89-94,19-28-33-42-51-55-65,"primary; this includes MIGRAINE and variants, and","Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches.",94,42,94,42,103,50,-1,RO-has_definitional_manifestation,904909,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches",headaches,migraine
502252359,7/11/2014 15:17:25,,1320775677,7/11/2014 15:16:48,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,94,42,,,103,50,HEADACHES,MIGRAINE,HEADACHES.,94,42,MIGRAINE,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches.",94,42,94,42,103,50,-1,RO-has_definitional_manifestation,904909,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches",headaches,migraine
502252359,7/11/2014 15:19:04,,1320776529,7/11/2014 15:18:54,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,94,42,,,103,50,HEADACHES,MIGRAINE,tension type HEADACHES.,81-89-94,42,MIGRAINE,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches.",94,42,94,42,103,50,-1,RO-has_definitional_manifestation,904909,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches",headaches,migraine
502252359,7/11/2014 15:24:30,,1320779603,7/11/2014 15:24:20,neodev,1,27597779,CAN,AB,Calgary,72.29.251.209,94,42,,,103,50,HEADACHES,MIGRAINE,HEADACHES.,94,42,MIGRAINE,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches.",94,42,94,42,103,50,-1,RO-has_definitional_manifestation,904909,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches",headaches,migraine
502252359,7/11/2014 15:25:31,,1320779889,7/11/2014 15:24:22,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,94,42,,,103,50,HEADACHES,MIGRAINE,migraine and cluster and tension type HEADACHES.,42-69-77-81-89-94-65,42-51-55,"MIGRAINE and variants,","Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches.",94,42,94,42,103,50,-1,RO-has_definitional_manifestation,904909,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches",headaches,migraine
502252359,7/11/2014 15:32:18,,1320782365,7/11/2014 15:32:16,prodege,1,21435737,GBR,J1,Northampton,78.151.200.222,94,42,,,103,50,HEADACHES,MIGRAINE,and tension type HEADACHES.,77-81-89-94,19-28-33-42-51-55-65,"primary; this includes MIGRAINE and variants, and","Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches.",94,42,94,42,103,50,-1,RO-has_definitional_manifestation,904909,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches",headaches,migraine
502252359,7/11/2014 15:36:05,,1320784308,7/11/2014 15:35:38,prodege,1,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,94,42,,,103,50,HEADACHES,MIGRAINE,tension type HEADACHES.,81-89-94,42-51-55-65-69-77-81-89-94,"MIGRAINE and variants, and cluster and tension type headaches.","Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches.",94,42,94,42,103,50,-1,RO-has_definitional_manifestation,904909,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches",headaches,migraine
502252359,7/11/2014 15:44:51,,1320787048,7/11/2014 15:44:25,clixsense,1,28059098,USA,TN,Nashville,165.214.11.70,94,42,,,103,50,HEADACHES,MIGRAINE,cluster and tension type HEADACHES.,69-81-89-94-77,42,MIGRAINE,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches.",94,42,94,42,103,50,-1,RO-has_definitional_manifestation,904909,"Most headaches are primary; this includes migraine and variants, and cluster and tension-type headaches",headaches,migraine
502252360,7/11/2014 15:14:25,,1320774507,7/11/2014 15:14:10,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,23,85,,,39,120,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,PHEOCHROMOCYTOMA,23,85-94-104-114-119,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene.,23,85 94 104 114 119,23,85,39,120,-1,RO-has_manifestation,906351,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene,pheochromocytoma,multiple endocrine neoplasia type 2
502252360,7/11/2014 15:15:04,,1320774861,7/11/2014 15:14:53,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,23,85,,,39,120,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,PHEOCHROMOCYTOMA,23,85-94-104-114-119,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene.,23,85 94 104 114 119,23,85,39,120,-1,RO-has_manifestation,906351,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene,pheochromocytoma,multiple endocrine neoplasia type 2
502252360,7/11/2014 15:16:06,,1320775276,7/11/2014 15:15:54,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,23,85,,,39,120,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,hereditary PHEOCHROMOCYTOMA,12-23,85-94-104-114-119,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene.,23,85 94 104 114 119,23,85,39,120,-1,RO-has_manifestation,906351,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene,pheochromocytoma,multiple endocrine neoplasia type 2
502252360,7/11/2014 15:17:05,,1320775573,7/11/2014 15:17:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,23,85,,,39,120,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests,0-9-12-23-40-44-49,59-72-82-85-94-104-114-119-126-129,established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 2) using,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene.,23,85 94 104 114 119,23,85,39,120,-1,RO-has_manifestation,906351,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene,pheochromocytoma,multiple endocrine neoplasia type 2
502252360,7/11/2014 15:17:42,,1320775840,7/11/2014 15:17:06,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,23,85,,,39,120,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,Analysis of hereditary PHEOCHROMOCYTOMA,0-9-12-23,72-82-85-94-104-114-119,detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene.,23,85 94 104 114 119,23,85,39,120,-1,RO-has_manifestation,906351,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene,pheochromocytoma,multiple endocrine neoplasia type 2
502252360,7/11/2014 15:19:58,,1320777001,7/11/2014 15:19:37,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,23,85,,,39,120,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,hereditary PHEOCHROMOCYTOMA,12-23,85-94-104-114-119-121-126,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2),Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene.,23,85 94 104 114 119,23,85,39,120,-1,RO-has_manifestation,906351,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene,pheochromocytoma,multiple endocrine neoplasia type 2
502252360,7/11/2014 15:20:51,,1320777528,7/11/2014 15:18:43,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,23,85,,,39,120,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,PHEOCHROMOCYTOMA,23,85-94-104-114-119,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene.,23,85 94 104 114 119,23,85,39,120,-1,RO-has_manifestation,906351,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene,pheochromocytoma,multiple endocrine neoplasia type 2
502252360,7/11/2014 15:21:29,,1320777937,7/11/2014 15:21:11,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,23,85,,,39,120,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,hereditary PHEOCHROMOCYTOMA,12-23,85-94-104-114-119,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene.,23,85 94 104 114 119,23,85,39,120,-1,RO-has_manifestation,906351,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene,pheochromocytoma,multiple endocrine neoplasia type 2
502252360,7/11/2014 15:23:43,,1320779334,7/11/2014 15:23:27,prodege,1,26783464,GBR,I6,Milton Keynes,86.169.214.241,23,85,,,39,120,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,PHEOCHROMOCYTOMA,23,85-94-104-114-119,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene.,23,85 94 104 114 119,23,85,39,120,-1,RO-has_manifestation,906351,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene,pheochromocytoma,multiple endocrine neoplasia type 2
502252360,7/11/2014 15:27:40,,1320780692,7/11/2014 15:27:29,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,23,85,,,39,120,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,PHEOCHROMOCYTOMA,23,85-94-104-114-119,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene.,23,85 94 104 114 119,23,85,39,120,-1,RO-has_manifestation,906351,Analysis of hereditary pheochromocytoma two gene tests are established: detection of multiple endocrine neoplasia type 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel-Lindau syndrome using mutational analysis of VHL gene,pheochromocytoma,multiple endocrine neoplasia type 2
502252361,7/11/2014 15:26:43,,1320780387,7/11/2014 15:26:16,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,251,150,,,278,168,VERNAL KERATOCONJUNCTIVITIS,ALLERGIC REACTIONS,VERNAL KERATOCONJUNCTIVITIS),251-258,150-159,ALLERGIC REACTIONS,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis.",251 258,150 159,251,150,278,168,-1,RO-cause_of,900240,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis",vernal keratoconjunctivitis,allergic reactions
502252361,7/11/2014 15:26:55,,1320780456,7/11/2014 15:26:43,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,251,150,,,278,168,VERNAL KERATOCONJUNCTIVITIS,ALLERGIC REACTIONS,"conjunctivitis, VERNAL KERATOCONJUNCTIVITIS) papillary",231-251-258-290,150-159,ALLERGIC REACTIONS,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis.",251 258,150 159,251,150,278,168,-1,RO-cause_of,900240,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis",vernal keratoconjunctivitis,allergic reactions
502252361,7/11/2014 15:31:17,,1320781988,7/11/2014 15:30:57,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,251,150,,,278,168,VERNAL KERATOCONJUNCTIVITIS,ALLERGIC REACTIONS,VERNAL KERATOCONJUNCTIVITIS),251-258,143-148-150-159,type I ALLERGIC REACTIONS,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis.",251 258,150 159,251,150,278,168,-1,RO-cause_of,900240,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis",vernal keratoconjunctivitis,allergic reactions
502252361,7/11/2014 15:37:51,,1320784901,7/11/2014 15:37:24,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,251,150,,,278,168,VERNAL KERATOCONJUNCTIVITIS,ALLERGIC REACTIONS,VERNAL KERATOCONJUNCTIVITIS),251-258,143-148-150-159,type I ALLERGIC REACTIONS,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis.",251 258,150 159,251,150,278,168,-1,RO-cause_of,900240,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis",vernal keratoconjunctivitis,allergic reactions
502252361,7/11/2014 15:42:56,,1320786443,7/11/2014 15:42:33,bitcoinget,1,24792414,USA,"","",166.181.81.197,251,150,,,278,168,VERNAL KERATOCONJUNCTIVITIS,ALLERGIC REACTIONS,VERNAL KERATOCONJUNCTIVITIS),251-258,143-148-150-159,type I ALLERGIC REACTIONS,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis.",251 258,150 159,251,150,278,168,-1,RO-cause_of,900240,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis",vernal keratoconjunctivitis,allergic reactions
502252361,7/11/2014 15:48:04,,1320788265,7/11/2014 15:47:41,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,251,150,,,278,168,VERNAL KERATOCONJUNCTIVITIS,ALLERGIC REACTIONS,VERNAL KERATOCONJUNCTIVITIS),251-258,143-148-150-159,type I ALLERGIC REACTIONS,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis.",251 258,150 159,251,150,278,168,-1,RO-cause_of,900240,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis",vernal keratoconjunctivitis,allergic reactions
502252361,7/11/2014 15:51:23,,1320790379,7/11/2014 15:51:01,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,251,150,,,278,168,VERNAL KERATOCONJUNCTIVITIS,ALLERGIC REACTIONS,VERNAL KERATOCONJUNCTIVITIS),251-258,143-148-150-159,type I ALLERGIC REACTIONS,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis.",251 258,150 159,251,150,278,168,-1,RO-cause_of,900240,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis",vernal keratoconjunctivitis,allergic reactions
502252361,7/11/2014 15:52:50,,1320791554,7/11/2014 15:52:23,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,251,150,,,278,168,VERNAL KERATOCONJUNCTIVITIS,ALLERGIC REACTIONS,"allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",222-231-247-251-258-280-284-290-300,143-148-150-159,type I ALLERGIC REACTIONS,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis.",251 258,150 159,251,150,278,168,-1,RO-cause_of,900240,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis",vernal keratoconjunctivitis,allergic reactions
502252361,7/11/2014 15:55:08,,1320792914,7/11/2014 15:54:49,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,251,150,,,278,168,VERNAL KERATOCONJUNCTIVITIS,ALLERGIC REACTIONS,VERNAL KERATOCONJUNCTIVITIS),251-258,150-159,ALLERGIC REACTIONS,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis.",251 258,150 159,251,150,278,168,-1,RO-cause_of,900240,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis",vernal keratoconjunctivitis,allergic reactions
502252361,7/11/2014 16:05:42,,1320796321,7/11/2014 16:05:07,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,251,150,,,278,168,VERNAL KERATOCONJUNCTIVITIS,ALLERGIC REACTIONS,"allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary",222-231-247-251-258-280-284-290,143-148-150-159-185,"type I ALLERGIC REACTIONS hayfever,","When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis.",251 258,150 159,251,150,278,168,-1,RO-cause_of,900240,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with type I allergic reactions (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and vernal keratoconjunctivitis) and giant papillary conjunctivitis",vernal keratoconjunctivitis,allergic reactions
502252362,7/11/2014 15:13:10,,1320773887,7/11/2014 15:12:58,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,32,48,,,36,63,BONE,OSTEOCHONDROSIS,BONE,32,48,OSTEOCHONDROSIS,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone.,32,48,32,48,36,63,1,RO-disease_has_primary_anatomic_site,902446,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone,bone,osteochondrosis
502252362,7/11/2014 15:13:45,,1320774185,7/11/2014 15:13:26,instagc,1.0,13763729,USA,"","",75.182.89.225,32,48,,,36,63,BONE,OSTEOCHONDROSIS,Kohler's BONE disease,23-32-37,48,OSTEOCHONDROSIS,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone.,32,48,32,48,36,63,1,RO-disease_has_primary_anatomic_site,902446,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone,bone,osteochondrosis
502252362,7/11/2014 15:14:14,,1320774413,7/11/2014 15:14:09,instagc,1.0,27753923,GBR,"","",188.29.78.53,32,48,,,36,63,BONE,OSTEOCHONDROSIS,BONE DISEASE Kohler's BONE disease is osteochondrosis,9-14-23-32-37-45-48,32-37-45-48-64-67-71,bone disease is OSTEOCHONDROSIS of the tarsal,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone.,32,48,32,48,36,63,1,RO-disease_has_primary_anatomic_site,902446,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone,bone,osteochondrosis
502252362,7/11/2014 15:16:23,,1320775360,7/11/2014 15:15:29,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,32,48,,,36,63,BONE,OSTEOCHONDROSIS,Kohler's BONE disease,23-32-37,48,OSTEOCHONDROSIS,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone.,32,48,32,48,36,63,1,RO-disease_has_primary_anatomic_site,902446,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone,bone,osteochondrosis
502252362,7/11/2014 15:17:22,,1320775665,7/11/2014 15:16:14,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,32,48,,,36,63,BONE,OSTEOCHONDROSIS,Kohler's BONE disease,23-32-37,48,OSTEOCHONDROSIS,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone.,32,48,32,48,36,63,1,RO-disease_has_primary_anatomic_site,902446,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone,bone,osteochondrosis
502252362,7/11/2014 15:17:23,,1320775668,7/11/2014 15:16:27,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,32,48,,,36,63,BONE,OSTEOCHONDROSIS,Kohler's BONE disease,23-32-37,48-64-67-71-78-88,OSTEOCHONDROSIS of the tarsal navicular bone.,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone.,32,48,32,48,36,63,1,RO-disease_has_primary_anatomic_site,902446,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone,bone,osteochondrosis
502252362,7/11/2014 15:29:37,,1320781414,7/11/2014 15:29:17,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,32,48,,,36,63,BONE,OSTEOCHONDROSIS,Kohler's BONE disease,23-32-37,48-64-67-71-78-88,OSTEOCHONDROSIS of the tarsal navicular bone.,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone.,32,48,32,48,36,63,1,RO-disease_has_primary_anatomic_site,902446,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone,bone,osteochondrosis
502252362,7/11/2014 15:31:24,,1320782013,7/11/2014 15:30:27,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,32,48,,,36,63,BONE,OSTEOCHONDROSIS,BONE,32,48,OSTEOCHONDROSIS,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone.,32,48,32,48,36,63,1,RO-disease_has_primary_anatomic_site,902446,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone,bone,osteochondrosis
502252362,7/11/2014 15:32:04,,1320782296,7/11/2014 15:31:50,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,32,48,,,36,63,BONE,OSTEOCHONDROSIS,BONE DISEASE Kohler's BONE disease is osteochondrosis,9-14-23-32-37-45-48,32-37-45-48-64-67-71,bone disease is OSTEOCHONDROSIS of the tarsal,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone.,32,48,32,48,36,63,1,RO-disease_has_primary_anatomic_site,902446,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone,bone,osteochondrosis
502252362,7/11/2014 15:36:22,,1320784452,7/11/2014 15:36:03,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,32,48,,,36,63,BONE,OSTEOCHONDROSIS,Kohler's BONE disease,23-32-37,48-64-67-71-78-88,OSTEOCHONDROSIS of the tarsal navicular bone.,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone.,32,48,32,48,36,63,1,RO-disease_has_primary_anatomic_site,902446,KOHLER'S BONE DISEASE  Kohler's bone disease is osteochondrosis of the tarsal navicular bone,bone,osteochondrosis
502252363,7/11/2014 15:12:35,,1320773687,7/11/2014 15:12:25,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,0,29,,,12,39,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,0,29,TUBERCULIN,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases.,0,29,0,29,12,39,1,RO-may_diagnose,906693,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases,Tuberculosis,tuberculin
502252363,7/11/2014 15:16:32,,1320775430,7/11/2014 15:16:25,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,0,29,,,12,39,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS was excluded by,0-13-17-26,13-17-26-29-40-48-52,was excluded by TUBERCULIN testing and bronchoalveolar,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases.,0,29,0,29,12,39,1,RO-may_diagnose,906693,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases,Tuberculosis,tuberculin
502252363,7/11/2014 15:17:48,,1320775877,7/11/2014 15:17:39,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,0,29,,,12,39,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,0,29,TUBERCULIN,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases.,0,29,0,29,12,39,1,RO-may_diagnose,906693,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases,Tuberculosis,tuberculin
502252363,7/11/2014 15:22:22,,1320778577,7/11/2014 15:22:12,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,0,29,,,12,39,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,0,29-40,TUBERCULIN testing,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases.,0,29,0,29,12,39,1,RO-may_diagnose,906693,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases,Tuberculosis,tuberculin
502252363,7/11/2014 15:25:05,,1320779800,7/11/2014 15:24:51,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,0,29,,,12,39,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,0,29-40,TUBERCULIN testing,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases.,0,29,0,29,12,39,1,RO-may_diagnose,906693,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases,Tuberculosis,tuberculin
502252363,7/11/2014 15:26:25,,1320780286,7/11/2014 15:26:08,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,0,29,,,12,39,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,0,29-40,TUBERCULIN testing,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases.,0,29,0,29,12,39,1,RO-may_diagnose,906693,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases,Tuberculosis,tuberculin
502252363,7/11/2014 15:33:15,,1320782716,7/11/2014 15:32:51,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,0,29,,,12,39,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,0,29-40,TUBERCULIN testing,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases.,0,29,0,29,12,39,1,RO-may_diagnose,906693,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases,Tuberculosis,tuberculin
502252363,7/11/2014 15:46:48,,1320787733,7/11/2014 15:46:37,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,0,29,,,12,39,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,0,29,TUBERCULIN,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases.,0,29,0,29,12,39,1,RO-may_diagnose,906693,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases,Tuberculosis,tuberculin
502252363,7/11/2014 15:49:48,,1320789320,7/11/2014 15:49:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,0,29,,,12,39,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,0,29-40,TUBERCULIN testing,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases.,0,29,0,29,12,39,1,RO-may_diagnose,906693,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases,Tuberculosis,tuberculin
502252363,7/11/2014 15:50:41,,1320789847,7/11/2014 15:50:29,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,0,29,,,12,39,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS,0,29-40,TUBERCULIN testing,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases.,0,29,0,29,12,39,1,RO-may_diagnose,906693,Tuberculosis was excluded by tuberculin testing and bronchoalveolar lavage in both cases,Tuberculosis,tuberculin
502252364,7/11/2014 15:14:52,,1320774768,7/11/2014 15:14:41,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,140,82,,,156,92,BIPOLAR DISORDER,OLANZAPINE,BIPOLAR DISORDER:,140-148,82,OLANZAPINE,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.",140 148,82,140,82,156,92,1,RO-may_treat,907595,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial",bipolar disorder,Olanzapine
502252364,7/11/2014 15:16:40,,1320775446,7/11/2014 15:16:24,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,140,82,,,156,92,BIPOLAR DISORDER,OLANZAPINE,BIPOLAR DISORDER:,140-148,82,OLANZAPINE,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.",140 148,82,140,82,156,92,1,RO-may_treat,907595,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial",bipolar disorder,Olanzapine
502252364,7/11/2014 15:16:57,,1320775533,7/11/2014 15:16:42,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,140,82,,,156,92,BIPOLAR DISORDER,OLANZAPINE,BIPOLAR DISORDER: -,140-148-162,82,OLANZAPINE,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.",140 148,82,140,82,156,92,1,RO-may_treat,907595,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial",bipolar disorder,Olanzapine
502252364,7/11/2014 15:18:48,,1320776404,7/11/2014 15:18:27,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,140,82,,,156,92,BIPOLAR DISORDER,OLANZAPINE,BIPOLAR DISORDER:,140-148,82,OLANZAPINE,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.",140 148,82,140,82,156,92,1,RO-may_treat,907595,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial",bipolar disorder,Olanzapine
502252364,7/11/2014 15:19:33,,1320776801,7/11/2014 15:19:20,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,140,82,,,156,92,BIPOLAR DISORDER,OLANZAPINE,BIPOLAR DISORDER:,140-148,82,OLANZAPINE,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.",140 148,82,140,82,156,92,1,RO-may_treat,907595,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial",bipolar disorder,Olanzapine
502252364,7/11/2014 15:21:34,,1320777989,7/11/2014 15:21:14,instagc,1.0,13763729,USA,"","",75.182.89.225,140,82,,,156,92,BIPOLAR DISORDER,OLANZAPINE,BIPOLAR DISORDER:,140-148,82,OLANZAPINE,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.",140 148,82,140,82,156,92,1,RO-may_treat,907595,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial",bipolar disorder,Olanzapine
502252364,7/11/2014 15:30:09,,1320781651,7/11/2014 15:29:57,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,140,82,,,156,92,BIPOLAR DISORDER,OLANZAPINE,BIPOLAR DISORDER:,140-148,82,OLANZAPINE,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.",140 148,82,140,82,156,92,1,RO-may_treat,907595,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial",bipolar disorder,Olanzapine
502252364,7/11/2014 15:30:57,,1320781886,7/11/2014 15:29:58,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,140,82,,,156,92,BIPOLAR DISORDER,OLANZAPINE,BIPOLAR DISORDER:,140-148,82,OLANZAPINE,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.",140 148,82,140,82,156,92,1,RO-may_treat,907595,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial",bipolar disorder,Olanzapine
502252364,7/11/2014 15:31:03,,1320781928,7/11/2014 15:30:53,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,140,82,,,156,92,BIPOLAR DISORDER,OLANZAPINE,"maintenance treatment of BIPOLAR DISORDER: a 12 month,",115-127-137-140-148-158-160-163,71-75-78-82-93-100-108,"BM, et al. OLANZAPINE versus lithium in","1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.",140 148,82,140,82,156,92,1,RO-may_treat,907595,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial",bipolar disorder,Olanzapine
502252364,7/11/2014 15:33:08,,1320782672,7/11/2014 15:32:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,140,82,,,156,92,BIPOLAR DISORDER,OLANZAPINE,treatment of BIPOLAR DISORDER:,127-137-140-148,82-93-100,OLANZAPINE versus lithium,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.",140 148,82,140,82,156,92,1,RO-may_treat,907595,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial",bipolar disorder,Olanzapine
502252365,7/11/2014 15:14:42,,1320774685,7/11/2014 15:14:26,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,120,169,,,137,175,ATOPIC DERMATITIS,ATOPIC,"ATOPIC DERMATITIS,",120-127,169,ATOPIC,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens.",120 127,169,120,169,137,175,-1,RO-cause_of,900476,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens",atopic dermatitis,atopic
502252365,7/11/2014 15:15:22,,1320774970,7/11/2014 15:15:10,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,120,169,,,137,175,ATOPIC DERMATITIS,ATOPIC,"ATOPIC DERMATITIS,",120-127,169-176,ATOPIC disease,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens.",120 127,169,120,169,137,175,-1,RO-cause_of,900476,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens",atopic dermatitis,atopic
502252365,7/11/2014 15:15:57,,1320775202,7/11/2014 15:15:52,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,120,169,,,137,175,ATOPIC DERMATITIS,ATOPIC,"patients: children with ATOPIC DERMATITIS, a family history",96-106-115-120-127-139-141-148,156-159-166-169-176-184-188,of asthma or ATOPIC disease and early,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens.",120 127,169,120,169,137,175,-1,RO-cause_of,900476,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens",atopic dermatitis,atopic
502252365,7/11/2014 15:18:08,,1320776080,7/11/2014 15:17:47,instagc,1.0,13763729,USA,"","",75.182.89.225,120,169,,,137,175,ATOPIC DERMATITIS,ATOPIC,"ATOPIC DERMATITIS,",120-127,169-176,ATOPIC disease,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens.",120 127,169,120,169,137,175,-1,RO-cause_of,900476,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens",atopic dermatitis,atopic
502252365,7/11/2014 15:24:57,,1320779754,7/11/2014 15:24:37,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,120,169,,,137,175,ATOPIC DERMATITIS,ATOPIC,"ATOPIC DERMATITIS,",120-127,169-176,ATOPIC disease,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens.",120 127,169,120,169,137,175,-1,RO-cause_of,900476,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens",atopic dermatitis,atopic
502252365,7/11/2014 15:30:39,,1320781820,7/11/2014 15:30:23,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,120,169,,,137,175,ATOPIC DERMATITIS,ATOPIC,"patients: children with ATOPIC DERMATITIS, a family history",96-106-115-120-127-139-141-148,156-159-166-169-176-184-188,of asthma or ATOPIC disease and early,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens.",120 127,169,120,169,137,175,-1,RO-cause_of,900476,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens",atopic dermatitis,atopic
502252365,7/11/2014 15:40:52,,1320785905,7/11/2014 15:40:25,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,120,169,,,137,175,ATOPIC DERMATITIS,ATOPIC,"ATOPIC DERMATITIS,",120-127,169,ATOPIC,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens.",120 127,169,120,169,137,175,-1,RO-cause_of,900476,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens",atopic dermatitis,atopic
502252365,7/11/2014 15:46:10,,1320787536,7/11/2014 15:45:50,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,120,169,,,137,175,ATOPIC DERMATITIS,ATOPIC,"ATOPIC DERMATITIS,",120-127,159-166-169-176-184-188-194-208-211,asthma or ATOPIC disease and early sensitization to aeroallergens.,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens.",120 127,169,120,169,137,175,-1,RO-cause_of,900476,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens",atopic dermatitis,atopic
502252365,7/11/2014 15:47:23,,1320787949,7/11/2014 15:47:06,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,120,169,,,137,175,ATOPIC DERMATITIS,ATOPIC,"ATOPIC DERMATITIS,",120-127,169-176,ATOPIC disease,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens.",120 127,169,120,169,137,175,-1,RO-cause_of,900476,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens",atopic dermatitis,atopic
502252365,7/11/2014 15:51:54,,1320790772,7/11/2014 15:51:37,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,120,169,,,137,175,ATOPIC DERMATITIS,ATOPIC,"ATOPIC DERMATITIS,",120-127,169-176,ATOPIC disease,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens.",120 127,169,120,169,137,175,-1,RO-cause_of,900476,"The optimal target for pharmaceutical intervention to prevent asthma would seem to be high risk patients: children with atopic dermatitis, a family history of asthma or atopic disease and early sensitization to aeroallergens",atopic dermatitis,atopic
502252366,7/11/2014 15:10:23,,1320772596,7/11/2014 15:10:14,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,87,111,,,96,116,NEPHRITIS,LUPUS,NEPHRITIS,87,111,LUPUS.,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus.,87,111,87,111,96,116,-1,RO-has_manifestation,906305,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus,nephritis,lupus
502252366,7/11/2014 15:17:10,,1320775593,7/11/2014 15:16:58,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,87,111,,,96,116,NEPHRITIS,LUPUS,lupus NEPHRITIS,81-87,100-111,extrarenal LUPUS.,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus.,87,111,87,111,96,116,-1,RO-has_manifestation,906305,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus,nephritis,lupus
502252366,7/11/2014 15:17:41,,1320775825,7/11/2014 15:17:15,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,87,111,,,96,116,NEPHRITIS,LUPUS,lupus NEPHRITIS,81-87,100-111,extrarenal LUPUS.,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus.,87,111,87,111,96,116,-1,RO-has_manifestation,906305,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus,nephritis,lupus
502252366,7/11/2014 15:18:05,,1320776041,7/11/2014 15:17:53,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,87,111,,,96,116,NEPHRITIS,LUPUS,lupus NEPHRITIS,81-87,100-111,extrarenal LUPUS.,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus.,87,111,87,111,96,116,-1,RO-has_manifestation,906305,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus,nephritis,lupus
502252366,7/11/2014 15:18:26,,1320776199,7/11/2014 15:18:12,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,87,111,,,96,116,NEPHRITIS,LUPUS,lupus NEPHRITIS,81-87,111-100,extrarenal LUPUS.,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus.,87,111,87,111,96,116,-1,RO-has_manifestation,906305,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus,nephritis,lupus
502252366,7/11/2014 15:20:19,,1320777183,7/11/2014 15:19:59,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,87,111,,,96,116,NEPHRITIS,LUPUS,history of lupus NEPHRITIS or extrarenal lupus.,70-78-81-87-97-100-111,87-97-100-111-81,lupus nephritis or extrarenal LUPUS.,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus.,87,111,87,111,96,116,-1,RO-has_manifestation,906305,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus,nephritis,lupus
502252366,7/11/2014 15:22:23,,1320778589,7/11/2014 15:22:11,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,87,111,,,96,116,NEPHRITIS,LUPUS,lupus NEPHRITIS,81-87,100-111,extrarenal LUPUS.,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus.,87,111,87,111,96,116,-1,RO-has_manifestation,906305,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus,nephritis,lupus
502252366,7/11/2014 15:29:44,,1320781480,7/11/2014 15:29:40,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,87,111,,,96,116,NEPHRITIS,LUPUS,history of lupus NEPHRITIS or extrarenal lupus.,70-78-81-87-97-100-111,87-97-100-111,nephritis or extrarenal LUPUS.,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus.,87,111,87,111,96,116,-1,RO-has_manifestation,906305,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus,nephritis,lupus
502252366,7/11/2014 15:33:48,,1320782996,7/11/2014 15:33:23,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,87,111,,,96,116,NEPHRITIS,LUPUS,NEPHRITIS,87,111,LUPUS.,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus.,87,111,87,111,96,116,-1,RO-has_manifestation,906305,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus,nephritis,lupus
502252366,7/11/2014 15:35:01,,1320783774,7/11/2014 15:34:45,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,87,111,,,96,116,NEPHRITIS,LUPUS,lupus NEPHRITIS,81-87,87-97-100-111,nephritis or extrarenal LUPUS.,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus.,87,111,87,111,96,116,-1,RO-has_manifestation,906305,Lupus nephritis may develop during pregnancy in patients with a prior history of lupus nephritis or extrarenal lupus,nephritis,lupus
502252367,7/11/2014 15:10:38,,1320772772,7/11/2014 15:10:24,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,15,65,,,42,91,ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY REACTIONS,ALLERGIC CONTACT DERMATITIS,15-24-32,65-82,HYPERSENSITIVITY REACTIONS,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions.",15 24 32,65 82,15,65,42,91,-1,RO-cause_of,900172,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions",allergic contact dermatitis,hypersensitivity reactions
502252367,7/11/2014 15:14:26,,1320774508,7/11/2014 15:14:06,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,15,65,,,42,91,ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY REACTIONS,ALLERGIC CONTACT DERMATITIS,15-24-32,52-65-82-57,drug induced HYPERSENSITIVITY REACTIONS,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions.",15 24 32,65 82,15,65,42,91,-1,RO-cause_of,900172,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions",allergic contact dermatitis,hypersensitivity reactions
502252367,7/11/2014 15:15:44,,1320775109,7/11/2014 15:15:32,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,15,65,,,42,91,ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY REACTIONS,ALLERGIC CONTACT DERMATITIS,15-24-32,65-82,HYPERSENSITIVITY REACTIONS,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions.",15 24 32,65 82,15,65,42,91,-1,RO-cause_of,900172,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions",allergic contact dermatitis,hypersensitivity reactions
502252367,7/11/2014 15:18:46,,1320776383,7/11/2014 15:18:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,15,65,,,42,91,ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY REACTIONS,"In contrast to ALLERGIC CONTACT DERMATITIS however, drug induced",0-3-12-15-24-32-43-52-57,43-52-57-65-82-92-95-99,"however, drug induced HYPERSENSITIVITY REACTIONS of the skin","In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions.",15 24 32,65 82,15,65,42,91,-1,RO-cause_of,900172,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions",allergic contact dermatitis,hypersensitivity reactions
502252367,7/11/2014 15:20:55,,1320777571,7/11/2014 15:20:38,instagc,1.0,13763729,USA,"","",75.182.89.225,15,65,,,42,91,ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY REACTIONS,ALLERGIC CONTACT DERMATITIS,15-24-32,65-82,HYPERSENSITIVITY REACTIONS,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions.",15 24 32,65 82,15,65,42,91,-1,RO-cause_of,900172,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions",allergic contact dermatitis,hypersensitivity reactions
502252367,7/11/2014 15:23:27,,1320779241,7/11/2014 15:23:05,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,15,65,,,42,91,ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY REACTIONS,ALLERGIC CONTACT DERMATITIS,15-24-32,65-82,HYPERSENSITIVITY REACTIONS,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions.",15 24 32,65 82,15,65,42,91,-1,RO-cause_of,900172,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions",allergic contact dermatitis,hypersensitivity reactions
502252367,7/11/2014 15:23:59,,1320779438,7/11/2014 15:23:36,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,15,65,,,42,91,ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY REACTIONS,ALLERGIC CONTACT DERMATITIS,15-24-32,52-57-65-82,drug induced HYPERSENSITIVITY REACTIONS,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions.",15 24 32,65 82,15,65,42,91,-1,RO-cause_of,900172,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions",allergic contact dermatitis,hypersensitivity reactions
502252367,7/11/2014 15:26:42,,1320780386,7/11/2014 15:26:30,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,15,65,,,42,91,ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY REACTIONS,ALLERGIC CONTACT DERMATITIS -,15-24-32-56,65-82,HYPERSENSITIVITY REACTIONS,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions.",15 24 32,65 82,15,65,42,91,-1,RO-cause_of,900172,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions",allergic contact dermatitis,hypersensitivity reactions
502252367,7/11/2014 15:27:29,,1320780626,7/11/2014 15:27:06,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,15,65,,,42,91,ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY REACTIONS,ALLERGIC CONTACT DERMATITIS,15-24-32,52-57-65-82-92-95-99-56,drug - induced HYPERSENSITIVITY REACTIONS of the skin,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions.",15 24 32,65 82,15,65,42,91,-1,RO-cause_of,900172,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions",allergic contact dermatitis,hypersensitivity reactions
502252367,7/11/2014 15:29:39,,1320781438,7/11/2014 15:29:35,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,15,65,,,42,91,ALLERGIC CONTACT DERMATITIS,HYPERSENSITIVITY REACTIONS,"In contrast to ALLERGIC CONTACT DERMATITIS however, drug induced",0-3-12-15-24-32-43-52-57,43-52-57-65-82-92-95-99,"however, drug induced HYPERSENSITIVITY REACTIONS of the skin","In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions.",15 24 32,65 82,15,65,42,91,-1,RO-cause_of,900172,"In contrast to allergic contact dermatitis however, drug-induced hypersensitivity reactions of the skin have enormous variability with regard to their pathophysiological pathways, clinical signs of symptoms, severity, and the drugs which can elicit these reactions",allergic contact dermatitis,hypersensitivity reactions
502252368,7/11/2014 15:14:36,,1320774614,7/11/2014 15:14:16,instagc,1.0,13763729,USA,"","",75.182.89.225,113,77,,,121,85,HEADACHE,MIGRAINE,HEADACHE.,113,77,MIGRAINE,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache.",113,77,113,77,121,85,-1,RO-has_definitional_manifestation,904981,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache",headache,migraine
502252368,7/11/2014 15:15:14,,1320774930,7/11/2014 15:15:10,instagc,1.0,27753923,GBR,"","",188.29.78.53,113,77,,,121,85,HEADACHE,MIGRAINE,prevention of migraine HEADACHE.,90-101-104-113,60-66-74-77-86-90-101,acute attacks of MIGRAINE and prevention of,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache.",113,77,113,77,121,85,-1,RO-has_definitional_manifestation,904981,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache",headache,migraine
502252368,7/11/2014 15:15:41,,1320775099,7/11/2014 15:15:32,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,113,77,,,121,85,HEADACHE,MIGRAINE,migraine HEADACHE.,104-113,77,MIGRAINE,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache.",113,77,113,77,121,85,-1,RO-has_definitional_manifestation,904981,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache",headache,migraine
502252368,7/11/2014 15:24:41,,1320779672,7/11/2014 15:24:30,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,113,77,,,121,85,HEADACHE,MIGRAINE,HEADACHE.,113,77,MIGRAINE,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache.",113,77,113,77,121,85,-1,RO-has_definitional_manifestation,904981,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache",headache,migraine
502252368,7/11/2014 15:27:05,,1320780499,7/11/2014 15:26:45,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,113,77,,,121,85,HEADACHE,MIGRAINE,migraine HEADACHE.,104-113,60-66-74-77,acute attacks of MIGRAINE,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache.",113,77,113,77,121,85,-1,RO-has_definitional_manifestation,904981,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache",headache,migraine
502252368,7/11/2014 15:36:02,,1320784288,7/11/2014 15:35:48,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,113,77,,,121,85,HEADACHE,MIGRAINE,migraine HEADACHE.,104-113,77,MIGRAINE,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache.",113,77,113,77,121,85,-1,RO-has_definitional_manifestation,904981,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache",headache,migraine
502252368,7/11/2014 15:37:23,,1320784773,7/11/2014 15:37:08,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,113,77,,,121,85,HEADACHE,MIGRAINE,migraine HEADACHE.,104-113,77,MIGRAINE,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache.",113,77,113,77,121,85,-1,RO-has_definitional_manifestation,904981,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache",headache,migraine
502252368,7/11/2014 15:47:34,,1320788026,7/11/2014 15:47:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,113,77,,,121,85,HEADACHE,MIGRAINE,migraine HEADACHE.,104-113,77,MIGRAINE,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache.",113,77,113,77,121,85,-1,RO-has_definitional_manifestation,904981,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache",headache,migraine
502252368,7/11/2014 15:49:09,,1320788802,7/11/2014 15:48:49,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,113,77,,,121,85,HEADACHE,MIGRAINE,migraine HEADACHE.,113-104,77,MIGRAINE,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache.",113,77,113,77,121,85,-1,RO-has_definitional_manifestation,904981,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache",headache,migraine
502252368,7/11/2014 15:50:45,,1320789917,7/11/2014 15:50:19,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,113,77,,,121,85,HEADACHE,MIGRAINE,migraine HEADACHE.,104-113,77,MIGRAINE,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache.",113,77,113,77,121,85,-1,RO-has_definitional_manifestation,904981,"Snow V, Weiss K, Wall EM et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache",headache,migraine
502252369,7/11/2014 15:11:05,,1320773043,7/11/2014 15:10:53,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,30,0,,,58,16,HYPERSENSITIVITY PNEUMONITIS,HYPERSENSITIVITY,HYPERSENSITIVITY PNEUMONITIS,30-47,0,HYPERSENSITIVITY,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens.",30 47,0,30,0,58,16,-1,RO-cause_of,900277,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens",Hypersensitivity pneumonitis,Hypersensitivity
502252369,7/11/2014 15:14:47,,1320774728,7/11/2014 15:14:25,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,30,0,,,58,16,HYPERSENSITIVITY PNEUMONITIS,HYPERSENSITIVITY,HYPERSENSITIVITY PNEUMONITIS,30-47,0-17,HYPERSENSITIVITY Pneumonitis,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens.",30 47,0,30,0,58,16,-1,RO-cause_of,900277,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens",Hypersensitivity pneumonitis,Hypersensitivity
502252369,7/11/2014 15:15:41,,1320775098,7/11/2014 15:15:38,instagc,1.0,27753923,GBR,"","",188.29.78.53,30,0,,,58,16,HYPERSENSITIVITY PNEUMONITIS,HYPERSENSITIVITY,Hypersensitivity Pneumonitis HYPERSENSITIVITY PNEUMONITIS or extrinsic,0-17-30-47-65-68,0-17-30-47,HYPERSENSITIVITY Pneumonitis Hypersensitivity pneumonitis,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens.",30 47,0,30,0,58,16,-1,RO-cause_of,900277,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens",Hypersensitivity pneumonitis,Hypersensitivity
502252369,7/11/2014 15:16:41,,1320775449,7/11/2014 15:16:21,instagc,1.0,13763729,USA,"","",75.182.89.225,30,0,,,58,16,HYPERSENSITIVITY PNEUMONITIS,HYPERSENSITIVITY,HYPERSENSITIVITY PNEUMONITIS,30-47,0-17,HYPERSENSITIVITY Pneumonitis,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens.",30 47,0,30,0,58,16,-1,RO-cause_of,900277,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens",Hypersensitivity pneumonitis,Hypersensitivity
502252369,7/11/2014 15:21:43,,1320778091,7/11/2014 15:21:31,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,30,0,,,58,16,HYPERSENSITIVITY PNEUMONITIS,HYPERSENSITIVITY,HYPERSENSITIVITY PNEUMONITIS,30-47,0-17,HYPERSENSITIVITY Pneumonitis,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens.",30 47,0,30,0,58,16,-1,RO-cause_of,900277,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens",Hypersensitivity pneumonitis,Hypersensitivity
502252369,7/11/2014 15:34:20,,1320783355,7/11/2014 15:33:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,30,0,,,58,16,HYPERSENSITIVITY PNEUMONITIS,HYPERSENSITIVITY,"HYPERSENSITIVITY PNEUMONITIS or extrinsic allergic alveolitis,",30-47-68-78-87-65,0-17-65-68-78-87,"HYPERSENSITIVITY Pneumonitis or extrinsic allergic alveolitis,","Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens.",30 47,0,30,0,58,16,-1,RO-cause_of,900277,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens",Hypersensitivity pneumonitis,Hypersensitivity
502252369,7/11/2014 15:36:31,,1320784533,7/11/2014 15:36:05,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,30,0,,,58,16,HYPERSENSITIVITY PNEUMONITIS,HYPERSENSITIVITY,"HYPERSENSITIVITY PNEUMONITIS (HP),",30-47-59,0-17-30-47-59,"HYPERSENSITIVITY Pneumonitis Hypersensitivity pneumonitis (HP),","Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens.",30 47,0,30,0,58,16,-1,RO-cause_of,900277,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens",Hypersensitivity pneumonitis,Hypersensitivity
502252369,7/11/2014 15:49:35,,1320789111,7/11/2014 15:49:09,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,30,0,,,58,16,HYPERSENSITIVITY PNEUMONITIS,HYPERSENSITIVITY,"HYPERSENSITIVITY PNEUMONITIS (HP),",30-47-59,0-17-59,"HYPERSENSITIVITY Pneumonitis (HP),","Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens.",30 47,0,30,0,58,16,-1,RO-cause_of,900277,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens",Hypersensitivity pneumonitis,Hypersensitivity
502252369,7/11/2014 15:49:51,,1320789311,7/11/2014 15:49:23,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,30,0,,,58,16,HYPERSENSITIVITY PNEUMONITIS,HYPERSENSITIVITY,HYPERSENSITIVITY PNEUMONITIS,30-47,0-17,HYPERSENSITIVITY Pneumonitis,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens.",30 47,0,30,0,58,16,-1,RO-cause_of,900277,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens",Hypersensitivity pneumonitis,Hypersensitivity
502252369,7/11/2014 15:50:09,,1320789499,7/11/2014 15:49:45,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,30,0,,,58,16,HYPERSENSITIVITY PNEUMONITIS,HYPERSENSITIVITY,"HYPERSENSITIVITY PNEUMONITIS (HP),",30-47-59,0-17-59,"HYPERSENSITIVITY Pneumonitis (HP),","Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens.",30 47,0,30,0,58,16,-1,RO-cause_of,900277,"Hypersensitivity Pneumonitis  Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, results from inhalation of a variety of organic antigens",Hypersensitivity pneumonitis,Hypersensitivity
502252370,7/11/2014 15:15:55,,1320775184,7/11/2014 15:15:45,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,115,36,,,143,46,PROTEIN CALORIE MALNUTRITION,DEFICIENCY,"PROTEIN CALORIE MALNUTRITION,",115-123-131,36,DEFICIENCY,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies.",115 123 131,36,115,36,143,46,-1,RO-cause_of,900498,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies",protein calorie malnutrition,deficiency
502252370,7/11/2014 15:18:11,,1320776112,7/11/2014 15:17:49,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,115,36,,,143,46,PROTEIN CALORIE MALNUTRITION,DEFICIENCY,"PROTEIN CALORIE MALNUTRITION,",115-123-131,36,DEFICIENCY,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies.",115 123 131,36,115,36,143,46,-1,RO-cause_of,900498,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies",protein calorie malnutrition,deficiency
502252370,7/11/2014 15:19:39,,1320776865,7/11/2014 15:19:18,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,115,36,,,143,46,PROTEIN CALORIE MALNUTRITION,DEFICIENCY,"PROTEIN CALORIE MALNUTRITION,",115-123-131,36,DEFICIENCY,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies.",115 123 131,36,115,36,143,46,-1,RO-cause_of,900498,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies",protein calorie malnutrition,deficiency
502252370,7/11/2014 15:20:00,,1320777031,7/11/2014 15:19:44,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,115,36,,,143,46,PROTEIN CALORIE MALNUTRITION,DEFICIENCY,"PROTEIN CALORIE MALNUTRITION,",115-123-131,36,DEFICIENCY,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies.",115 123 131,36,115,36,143,46,-1,RO-cause_of,900498,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies",protein calorie malnutrition,deficiency
502252370,7/11/2014 15:22:07,,1320778396,7/11/2014 15:21:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,115,36,,,143,46,PROTEIN CALORIE MALNUTRITION,DEFICIENCY,"PROTEIN CALORIE MALNUTRITION, avitaminoses, and mineral and iron deficiencies.",115-123-131-145-159-163-171-175-180,4-10-13-26-33-36,types of malnutrition caused by DEFICIENCY,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies.",115 123 131,36,115,36,143,46,-1,RO-cause_of,900498,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies",protein calorie malnutrition,deficiency
502252370,7/11/2014 15:23:07,,1320779032,7/11/2014 15:22:39,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,115,36,,,143,46,PROTEIN CALORIE MALNUTRITION,DEFICIENCY,"PROTEIN CALORIE MALNUTRITION,",115-123-131,13-26-33-36,malnutrition caused by DEFICIENCY,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies.",115 123 131,36,115,36,143,46,-1,RO-cause_of,900498,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies",protein calorie malnutrition,deficiency
502252370,7/11/2014 15:23:58,,1320779430,7/11/2014 15:23:44,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,115,36,,,143,46,PROTEIN CALORIE MALNUTRITION,DEFICIENCY,"PROTEIN CALORIE MALNUTRITION,",115-123-131,36,DEFICIENCY,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies.",115 123 131,36,115,36,143,46,-1,RO-cause_of,900498,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies",protein calorie malnutrition,deficiency
502252370,7/11/2014 15:28:55,,1320781149,7/11/2014 15:28:45,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,115,36,,,143,46,PROTEIN CALORIE MALNUTRITION,DEFICIENCY,"PROTEIN CALORIE MALNUTRITION, avitaminoses,",115-123-131-145,36,DEFICIENCY,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies.",115 123 131,36,115,36,143,46,-1,RO-cause_of,900498,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies",protein calorie malnutrition,deficiency
502252370,7/11/2014 15:39:47,,1320785510,7/11/2014 15:39:33,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,115,36,,,143,46,PROTEIN CALORIE MALNUTRITION,DEFICIENCY,"countries PROTEIN CALORIE MALNUTRITION,",101-115-123-131,36,DEFICIENCY,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies.",115 123 131,36,115,36,143,46,-1,RO-cause_of,900498,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies",protein calorie malnutrition,deficiency
502252370,7/11/2014 15:46:16,,1320787557,7/11/2014 15:46:00,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,115,36,,,143,46,PROTEIN CALORIE MALNUTRITION,DEFICIENCY,"PROTEIN CALORIE MALNUTRITION,",115-123-131,36,DEFICIENCY,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies.",115 123 131,36,115,36,143,46,-1,RO-cause_of,900498,"The types of malnutrition caused by deficiency and the most frequently encountered in the developing countries are protein calorie malnutrition, avitaminoses, and mineral and iron deficiencies",protein calorie malnutrition,deficiency
502252371,7/11/2014 15:14:57,,1320774806,7/11/2014 15:14:43,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,146,65,,,151,72,FUNGI,MYCOSES,FUNGI,146,65,MYCOSES,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown.",146,65,146,65,151,72,1,RO-has_causative_agent,903797,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown",fungi,mycoses
502252371,7/11/2014 15:16:20,,1320775336,7/11/2014 15:15:58,instagc,1.0,13763729,USA,"","",75.182.89.225,146,65,,,151,72,FUNGI,MYCOSES,FUNGI,146,53-65,superficial MYCOSES,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown.",146,65,146,65,151,72,1,RO-has_causative_agent,903797,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown",fungi,mycoses
502252371,7/11/2014 15:16:52,,1320775507,7/11/2014 15:16:46,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,146,65,,,151,72,FUNGI,MYCOSES,pathogenicity of these FUNGI is largely unknown.,123-137-140-146-152-155-163,43-50-53-65-73-76-83,agents of superficial MYCOSES in humans and,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown.",146,65,146,65,151,72,1,RO-has_causative_agent,903797,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown",fungi,mycoses
502252371,7/11/2014 15:20:20,,1320777202,7/11/2014 15:20:04,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,146,65,,,151,72,FUNGI,MYCOSES,FUNGI,146,53-65,superficial MYCOSES,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown.",146,65,146,65,151,72,1,RO-has_causative_agent,903797,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown",fungi,mycoses
502252371,7/11/2014 15:29:30,,1320781332,7/11/2014 15:29:15,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,146,65,,,151,72,FUNGI,MYCOSES,pathogenicity of these FUNGI is largely unknown.,123-137-140-146-152-155-163,43-50-53-65-73-76-83,agents of superficial MYCOSES in humans and,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown.",146,65,146,65,151,72,1,RO-has_causative_agent,903797,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown",fungi,mycoses
502252371,7/11/2014 15:32:30,,1320782408,7/11/2014 15:31:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,146,65,,,151,72,FUNGI,MYCOSES,molecular basis of the pathogenicity of these FUNGI,100-110-116-119-123-137-140-146,53-65-73-76,superficial MYCOSES in humans,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown.",146,65,146,65,151,72,1,RO-has_causative_agent,903797,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown",fungi,mycoses
502252371,7/11/2014 15:34:45,,1320783593,7/11/2014 15:34:01,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,146,65,,,151,72,FUNGI,MYCOSES,pathogenicity of these FUNGI,123-137-140-146,53-65,superficial MYCOSES,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown.",146,65,146,65,151,72,1,RO-has_causative_agent,903797,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown",fungi,mycoses
502252371,7/11/2014 15:40:36,,1320785808,7/11/2014 15:40:01,bitcoinget,1.0,24792414,USA,"","",166.181.81.197,146,65,,,151,72,FUNGI,MYCOSES,FUNGI,146,65-53,superficial MYCOSES,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown.",146,65,146,65,151,72,1,RO-has_causative_agent,903797,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown",fungi,mycoses
502252371,7/11/2014 15:45:11,,1320787164,7/11/2014 15:44:52,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,146,65,,,151,72,FUNGI,MYCOSES,FUNGI,146,43-50-53-65,agents of superficial MYCOSES,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown.",146,65,146,65,151,72,1,RO-has_causative_agent,903797,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown",fungi,mycoses
502252371,7/11/2014 15:49:13,,1320788852,7/11/2014 15:48:57,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,146,65,,,151,72,FUNGI,MYCOSES,FUNGI,146,65,MYCOSES,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown.",146,65,146,65,151,72,1,RO-has_causative_agent,903797,"Although dermatophytes are the most common agents of superficial mycoses in humans and animals, the molecular basis of the pathogenicity of these fungi is largely unknown",fungi,mycoses
502252372,7/11/2014 15:16:41,,1320775444,7/11/2014 15:16:24,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,78,127,,,92,129,BRONCHIECTASIS,CF,BRONCHIECTASIS,78,127,"CF,","DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",78,127,78,127,92,129,1,RO-has_manifestation,906010,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis",bronchiectasis,CF
502252372,7/11/2014 15:17:38,,1320775777,7/11/2014 15:17:24,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,78,127,,,92,129,BRONCHIECTASIS,CF,BRONCHIECTASIS,78,127-131-138,"CF, immune deficiencies,","DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",78,127,78,127,92,129,1,RO-has_manifestation,906010,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis",bronchiectasis,CF
502252372,7/11/2014 15:17:56,,1320775965,7/11/2014 15:17:39,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,78,127,,,92,129,BRONCHIECTASIS,CF,BRONCHIECTASIS,78,127,"CF,","DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",78,127,78,127,92,129,1,RO-has_manifestation,906010,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis",bronchiectasis,CF
502252372,7/11/2014 15:21:56,,1320778292,7/11/2014 15:21:45,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,78,127,,,92,129,BRONCHIECTASIS,CF,BRONCHIECTASIS,78,127,"CF,","DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",78,127,78,127,92,129,1,RO-has_manifestation,906010,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis",bronchiectasis,CF
502252372,7/11/2014 15:22:18,,1320778494,7/11/2014 15:21:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,78,127,,,92,129,BRONCHIECTASIS,CF,BRONCHIECTASIS,78,127,"CF,","DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",78,127,78,127,92,129,1,RO-has_manifestation,906010,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis",bronchiectasis,CF
502252372,7/11/2014 15:28:42,,1320781028,7/11/2014 15:28:20,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,78,127,,,92,129,BRONCHIECTASIS,CF,BRONCHIECTASIS,78,127,"CF,","DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",78,127,78,127,92,129,1,RO-has_manifestation,906010,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis",bronchiectasis,CF
502252372,7/11/2014 15:30:07,,1320781642,7/11/2014 15:30:04,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,78,127,,,92,129,BRONCHIECTASIS,CF,other causes of BRONCHIECTASIS must be considered;,62-68-75-78-93-98-101,101-113-119-127-131-138-152,"considered; these include CF, immune deficiencies, severe","DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",78,127,78,127,92,129,1,RO-has_manifestation,906010,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis",bronchiectasis,CF
502252372,7/11/2014 15:41:24,,1320786104,7/11/2014 15:40:53,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,78,127,,,92,129,BRONCHIECTASIS,CF,BRONCHIECTASIS,78,127,"CF,","DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",78,127,78,127,92,129,1,RO-has_manifestation,906010,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis",bronchiectasis,CF
502252372,7/11/2014 15:43:28,,1320786630,7/11/2014 15:43:14,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,78,127,,,92,129,BRONCHIECTASIS,CF,BRONCHIECTASIS,78,127,"CF,","DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",78,127,78,127,92,129,1,RO-has_manifestation,906010,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis",bronchiectasis,CF
502252372,7/11/2014 15:47:00,,1320787805,7/11/2014 15:46:29,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,78,127,,,92,129,BRONCHIECTASIS,CF,BRONCHIECTASIS,78,127,"CF,","DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",78,127,78,127,92,129,1,RO-has_manifestation,906010,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of bronchiectasis must be considered; these include CF, immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis",bronchiectasis,CF
502252373,7/11/2014 15:14:09,,1320774344,7/11/2014 15:14:00,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,72,40,,,83,58,LIVER CYSTS,POLYCYSTIC KIDNEYS,LIVER CYSTS.,72-78,40-51,POLYCYSTIC KIDNEYS,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts.,72 78,40 51,72,40,83,58,-1,RO-has_manifestation,906002,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts,liver cysts,polycystic kidneys
502252373,7/11/2014 15:14:25,,1320774506,7/11/2014 15:14:15,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,72,40,,,83,58,LIVER CYSTS,POLYCYSTIC KIDNEYS,LIVER CYSTS.,72-78,40-51,POLYCYSTIC KIDNEYS,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts.,72 78,40 51,72,40,83,58,-1,RO-has_manifestation,906002,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts,liver cysts,polycystic kidneys
502252373,7/11/2014 15:17:24,,1320775671,7/11/2014 15:17:12,instagc,1.0,13763729,USA,"","",75.182.89.225,72,40,,,83,58,LIVER CYSTS,POLYCYSTIC KIDNEYS,LIVER CYSTS.,72-78,40-51,POLYCYSTIC KIDNEYS,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts.,72 78,40 51,72,40,83,58,-1,RO-has_manifestation,906002,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts,liver cysts,polycystic kidneys
502252373,7/11/2014 15:17:51,,1320775923,7/11/2014 15:17:40,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,72,40,,,83,58,LIVER CYSTS,POLYCYSTIC KIDNEYS,LIVER CYSTS.,72-78,40-51,POLYCYSTIC KIDNEYS,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts.,72 78,40 51,72,40,83,58,-1,RO-has_manifestation,906002,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts,liver cysts,polycystic kidneys
502252373,7/11/2014 15:18:30,,1320776220,7/11/2014 15:18:14,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,72,40,,,83,58,LIVER CYSTS,POLYCYSTIC KIDNEYS,LIVER CYSTS.,72-78,40-51,POLYCYSTIC KIDNEYS,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts.,72 78,40 51,72,40,83,58,-1,RO-has_manifestation,906002,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts,liver cysts,polycystic kidneys
502252373,7/11/2014 15:18:30,,1320776231,7/11/2014 15:18:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,72,40,,,83,58,LIVER CYSTS,POLYCYSTIC KIDNEYS,LIVER CYSTS.,72-78,40-51,POLYCYSTIC KIDNEYS,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts.,72 78,40 51,72,40,83,58,-1,RO-has_manifestation,906002,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts,liver cysts,polycystic kidneys
502252373,7/11/2014 15:20:11,,1320777113,7/11/2014 15:19:53,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,72,40,,,83,58,LIVER CYSTS,POLYCYSTIC KIDNEYS,LIVER CYSTS.,72-78,40-51,POLYCYSTIC KIDNEYS,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts.,72 78,40 51,72,40,83,58,-1,RO-has_manifestation,906002,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts,liver cysts,polycystic kidneys
502252373,7/11/2014 15:29:57,,1320781581,7/11/2014 15:29:50,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,72,40,,,83,58,LIVER CYSTS,POLYCYSTIC KIDNEYS,kidneys and multiple LIVER CYSTS.,51-59-63-72-78,23-26-31-40-51-59-63-72,CT scan revealed POLYCYSTIC KIDNEYS and multiple liver,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts.,72 78,40 51,72,40,83,58,-1,RO-has_manifestation,906002,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts,liver cysts,polycystic kidneys
502252373,7/11/2014 15:32:32,,1320782424,7/11/2014 15:32:07,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,72,40,,,83,58,LIVER CYSTS,POLYCYSTIC KIDNEYS,LIVER CYSTS.,72-78,40-51,POLYCYSTIC KIDNEYS,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts.,72 78,40 51,72,40,83,58,-1,RO-has_manifestation,906002,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts,liver cysts,polycystic kidneys
502252373,7/11/2014 15:41:56,,1320786187,7/11/2014 15:41:35,bitcoinget,1.0,24792414,USA,"","",166.181.81.197,72,40,,,83,58,LIVER CYSTS,POLYCYSTIC KIDNEYS,LIVER CYSTS.,72-78,40-51,POLYCYSTIC KIDNEYS,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts.,72 78,40 51,72,40,83,58,-1,RO-has_manifestation,906002,Abdominal echogram and CT scan revealed polycystic kidneys and multiple liver cysts,liver cysts,polycystic kidneys
502252374,7/11/2014 15:12:47,,1320773755,7/11/2014 15:12:36,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,76,103,,,97,117,SARCOMATOUS COMPONENT,CARCINOSARCOMA,SARCOMATOUS COMPONENT,76-88,103,CARCINOSARCOMA,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type.,76 88,103,76,103,97,117,1,RO-disease_has_finding,901809,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type,sarcomatous component,carcinosarcoma
502252374,7/11/2014 15:15:20,,1320774954,7/11/2014 15:15:09,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,76,103,,,97,117,SARCOMATOUS COMPONENT,CARCINOSARCOMA,SARCOMATOUS COMPONENT,76-88,103,CARCINOSARCOMA,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type.,76 88,103,76,103,97,117,1,RO-disease_has_finding,901809,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type,sarcomatous component,carcinosarcoma
502252374,7/11/2014 15:16:14,,1320775328,7/11/2014 15:15:49,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,76,103,,,97,117,SARCOMATOUS COMPONENT,CARCINOSARCOMA,SARCOMATOUS COMPONENT of a carcinosarcoma,76-88-98-101-103,76-88-98-101-103,sarcomatous component of a CARCINOSARCOMA,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type.,76 88,103,76,103,97,117,1,RO-disease_has_finding,901809,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type,sarcomatous component,carcinosarcoma
502252374,7/11/2014 15:18:13,,1320776120,7/11/2014 15:17:53,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,76,103,,,97,117,SARCOMATOUS COMPONENT,CARCINOSARCOMA,SARCOMATOUS COMPONENT,76-88,103,CARCINOSARCOMA,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type.,76 88,103,76,103,97,117,1,RO-disease_has_finding,901809,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type,sarcomatous component,carcinosarcoma
502252374,7/11/2014 15:20:04,,1320777038,7/11/2014 15:19:48,instagc,1.0,13763729,USA,"","",75.182.89.225,76,103,,,97,117,SARCOMATOUS COMPONENT,CARCINOSARCOMA,SARCOMATOUS COMPONENT,76-88,103,CARCINOSARCOMA,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type.,76 88,103,76,103,97,117,1,RO-disease_has_finding,901809,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type,sarcomatous component,carcinosarcoma
502252374,7/11/2014 15:21:38,,1320778036,7/11/2014 15:20:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,76,103,,,97,117,SARCOMATOUS COMPONENT,CARCINOSARCOMA,SARCOMATOUS COMPONENT,76-88,103,CARCINOSARCOMA,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type.,76 88,103,76,103,97,117,1,RO-disease_has_finding,901809,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type,sarcomatous component,carcinosarcoma
502252374,7/11/2014 15:24:16,,1320779547,7/11/2014 15:23:59,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,76,103,,,97,117,SARCOMATOUS COMPONENT,CARCINOSARCOMA,SARCOMATOUS COMPONENT,76-88,103,CARCINOSARCOMA,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type.,76 88,103,76,103,97,117,1,RO-disease_has_finding,901809,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type,sarcomatous component,carcinosarcoma
502252374,7/11/2014 15:26:30,,1320780302,7/11/2014 15:26:18,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,76,103,,,97,117,SARCOMATOUS COMPONENT,CARCINOSARCOMA,SARCOMATOUS COMPONENT carcinosarcoma,76-88-103,103,CARCINOSARCOMA,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type.,76 88,103,76,103,97,117,1,RO-disease_has_finding,901809,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type,sarcomatous component,carcinosarcoma
502252374,7/11/2014 15:36:57,,1320784647,7/11/2014 15:35:05,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,76,103,,,97,117,SARCOMATOUS COMPONENT,CARCINOSARCOMA,SARCOMATOUS COMPONENT of a carcinosarcoma,76-88-98-101-103,76-88-98-101-103,sarcomatous component of a CARCINOSARCOMA,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type.,76 88,103,76,103,97,117,1,RO-disease_has_finding,901809,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type,sarcomatous component,carcinosarcoma
502252374,7/11/2014 15:43:13,,1320786547,7/11/2014 15:42:57,bitcoinget,1.0,24792414,USA,"","",166.181.81.197,76,103,,,97,117,SARCOMATOUS COMPONENT,CARCINOSARCOMA,SARCOMATOUS COMPONENT,76-88,103,CARCINOSARCOMA,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type.,76 88,103,76,103,97,117,1,RO-disease_has_finding,901809,The histogenesis of these tumours is discussed and it is suggested that the sarcomatous component of a carcinosarcoma may be derived from malignant epithelial cells by a process of mesenchymal metaplasia with a switch in intermediate filament type,sarcomatous component,carcinosarcoma
502252375,7/11/2014 15:19:19,,1320776686,7/11/2014 15:18:59,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,33,158,,,40,162,ANXIETY,PTSD,ANXIETY,33,126-131-141-148-157,Post Traumatic Stress Disorder (PTSD),"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles.",33,,33,158,40,162,-1,RO-has_definitional_manifestation,904513,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles",anxiety,PTSD
502252375,7/11/2014 15:19:36,,1320776814,7/11/2014 15:19:09,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,33,158,,,40,162,ANXIETY,PTSD,ANXIETY,33,126-131-141-148-157,Post Traumatic Stress Disorder (PTSD),"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles.",33,,33,158,40,162,-1,RO-has_definitional_manifestation,904513,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles",anxiety,PTSD
502252375,7/11/2014 15:19:58,,1320777003,7/11/2014 15:19:01,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,33,158,,,40,162,ANXIETY,PTSD,"generalised ANXIETY responses post crash,",21-33-41-51-56,80-100-106-113-122-126-131-141-148-157-92,association between Acute Stress Disorder and Post Traumatic Stress Disorder (PTSD),"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles.",33,,33,158,40,162,-1,RO-has_definitional_manifestation,904513,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles",anxiety,PTSD
502252375,7/11/2014 15:27:55,,1320780762,7/11/2014 15:27:41,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,33,158,,,40,162,ANXIETY,PTSD,ANXIETY,33,,,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles.",33,,33,158,40,162,-1,RO-has_definitional_manifestation,904513,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles",anxiety,PTSD
502252375,7/11/2014 15:29:57,,1320781579,7/11/2014 15:29:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,33,158,,,40,162,ANXIETY,PTSD,ANXIETY responses,33-41,126-130-131-141-148-157,Post - Traumatic Stress Disorder (PTSD),"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles.",33,,33,158,40,162,-1,RO-has_definitional_manifestation,904513,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles",anxiety,PTSD
502252375,7/11/2014 15:37:08,,1320784684,7/11/2014 15:36:32,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,33,158,,,40,162,ANXIETY,PTSD,generalised ANXIETY,33-21,126-131-141-148-157,Post Traumatic Stress Disorder (PTSD),"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles.",33,,33,158,40,162,-1,RO-has_definitional_manifestation,904513,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles",anxiety,PTSD
502252375,7/11/2014 15:50:18,,1320789587,7/11/2014 15:49:53,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,33,158,,,40,162,ANXIETY,PTSD,generalised ANXIETY,21-33,126-131-141-148-157,Post Traumatic Stress Disorder (PTSD),"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles.",33,,33,158,40,162,-1,RO-has_definitional_manifestation,904513,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles",anxiety,PTSD
502252375,7/11/2014 15:51:04,,1320790110,7/11/2014 15:50:42,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,33,158,,,40,162,ANXIETY,PTSD,generalised ANXIETY,21-33,126-141-148-157-131,Post Traumatic Stress Disorder (PTSD),"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles.",33,,33,158,40,162,-1,RO-has_definitional_manifestation,904513,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles",anxiety,PTSD
502252375,7/11/2014 15:51:17,,1320790297,7/11/2014 15:50:50,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,33,158,,,40,162,ANXIETY,PTSD,generalised ANXIETY,21-33,126-130-131-141-148-157,Post - Traumatic Stress Disorder (PTSD),"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles.",33,,33,158,40,162,-1,RO-has_definitional_manifestation,904513,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles",anxiety,PTSD
502252375,7/11/2014 15:52:50,,1320791555,7/11/2014 15:52:13,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,33,158,,,40,162,ANXIETY,PTSD,generalised ANXIETY responses,21-33-41,126-131-141-148,Post Traumatic Stress Disorder,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles.",33,,33,158,40,162,-1,RO-has_definitional_manifestation,904513,"This study documents generalised anxiety responses post-crash, and examines the association between Acute Stress Disorder and Post-Traumatic Stress Disorder (PTSD) with personality and coping styles",anxiety,PTSD
502252376,7/11/2014 15:21:41,,1320778069,7/11/2014 15:21:16,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,30,110,,,54,121,VON WILLEBRAND'S DISEASE,FACTOR VIII,VON WILLEBRAND'S DISEASE (VWD),30-34-47-55,110-117-122,FACTOR VIII (FVIII),"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",30 34 47,110 117,30,110,54,121,1,RO-may_treat,908082,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day",von Willebrand's disease,factor VIII
502252376,7/11/2014 15:23:57,,1320779419,7/11/2014 15:23:45,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,30,110,,,54,121,VON WILLEBRAND'S DISEASE,FACTOR VIII,VON WILLEBRAND'S DISEASE,30-34-47,110-117,FACTOR VIII,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",30 34 47,110 117,30,110,54,121,1,RO-may_treat,908082,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day",von Willebrand's disease,factor VIII
502252376,7/11/2014 15:26:06,,1320780152,7/11/2014 15:25:44,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,30,110,,,54,121,VON WILLEBRAND'S DISEASE,FACTOR VIII,VON WILLEBRAND'S DISEASE (VWD),30-34-47-55,110-117-122-130,FACTOR VIII (FVIII) levels,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",30 34 47,110 117,30,110,54,121,1,RO-may_treat,908082,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day",von Willebrand's disease,factor VIII
502252376,7/11/2014 15:30:44,,1320781838,7/11/2014 15:30:40,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,30,110,,,54,121,VON WILLEBRAND'S DISEASE,FACTOR VIII,severe forms of VON WILLEBRAND'S DISEASE may have,14-21-27-30-34-47-61-65,79-94-105-110-117-130-137,"haemarthroses, especially when FACTOR VIII levels are","Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",30 34 47,110 117,30,110,54,121,1,RO-may_treat,908082,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day",von Willebrand's disease,factor VIII
502252376,7/11/2014 15:45:59,,1320787468,7/11/2014 15:44:52,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,30,110,,,54,121,VON WILLEBRAND'S DISEASE,FACTOR VIII,VON WILLEBRAND'S DISEASE,30-34-47,110-117,FACTOR VIII,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",30 34 47,110 117,30,110,54,121,1,RO-may_treat,908082,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day",von Willebrand's disease,factor VIII
502252376,7/11/2014 15:47:08,,1320787856,7/11/2014 15:46:53,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,30,110,,,54,121,VON WILLEBRAND'S DISEASE,FACTOR VIII,VON WILLEBRAND'S DISEASE (VWD),30-34-47-55,110-117-122,FACTOR VIII (FVIII),"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",30 34 47,110 117,30,110,54,121,1,RO-may_treat,908082,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day",von Willebrand's disease,factor VIII
502252376,7/11/2014 15:48:49,,1320788602,7/11/2014 15:48:07,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,30,110,,,54,121,VON WILLEBRAND'S DISEASE,FACTOR VIII,VON WILLEBRAND'S DISEASE (VWD),30-34-47-55,110-117-122,FACTOR VIII (FVIII),"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",30 34 47,110 117,30,110,54,121,1,RO-may_treat,908082,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day",von Willebrand's disease,factor VIII
502252376,7/11/2014 15:50:06,,1320789466,7/11/2014 15:49:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,30,110,,,54,121,VON WILLEBRAND'S DISEASE,FACTOR VIII,VON WILLEBRAND'S DISEASE,30-34-47,110-117-130-122,FACTOR VIII (FVIII) levels,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",30 34 47,110 117,30,110,54,121,1,RO-may_treat,908082,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day",von Willebrand's disease,factor VIII
502252376,7/11/2014 15:54:25,,1320792651,7/11/2014 15:54:12,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,30,110,,,54,121,VON WILLEBRAND'S DISEASE,FACTOR VIII,VON WILLEBRAND'S DISEASE,30-34-47,110-117,FACTOR VIII,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",30 34 47,110 117,30,110,54,121,1,RO-may_treat,908082,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day",von Willebrand's disease,factor VIII
502252376,7/11/2014 15:55:26,,1320793003,7/11/2014 15:55:09,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,30,110,,,54,121,VON WILLEBRAND'S DISEASE,FACTOR VIII,VON WILLEBRAND'S DISEASE,30-34-47,110-117,FACTOR VIII,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",30 34 47,110 117,30,110,54,121,1,RO-may_treat,908082,"Patients with severe forms of von Willebrand's disease (VWD) may have frequent haemarthroses, especially when factor VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day",von Willebrand's disease,factor VIII
502252377,7/11/2014 15:12:37,,1320773711,7/11/2014 15:12:20,instagc,1.0,13763729,USA,"","",75.182.89.225,95,106,,,102,115,NUMBERS,ALLERGIES,NUMBERS of allergies,95-103-106,106,ALLERGIES,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer.",95,106,95,106,102,115,-1,RO-cause_of,900060,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer",numbers,allergies
502252377,7/11/2014 15:14:56,,1320774799,7/11/2014 15:14:19,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,95,106,,,102,115,NUMBERS,ALLERGIES,NUMBERS,95,106,ALLERGIES,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer.",95,106,95,106,102,115,-1,RO-cause_of,900060,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer",numbers,allergies
502252377,7/11/2014 15:17:06,,1320775574,7/11/2014 15:17:02,instagc,1.0,27753923,GBR,"","",188.29.78.53,95,106,,,102,115,NUMBERS,ALLERGIES,history and increasing NUMBERS of allergies was,72-80-84-95-103-106-116,84-95-103-106-116-120-131,increasing numbers of ALLERGIES was associated with,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer.",95,106,95,106,102,115,-1,RO-cause_of,900060,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer",numbers,allergies
502252377,7/11/2014 15:17:11,,1320775598,7/11/2014 15:16:53,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,95,106,,,102,115,NUMBERS,ALLERGIES,NUMBERS of allergies,95-103-106,106,ALLERGIES,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer.",95,106,95,106,102,115,-1,RO-cause_of,900060,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer",numbers,allergies
502252377,7/11/2014 15:20:03,,1320777037,7/11/2014 15:19:48,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,95,106,,,102,115,NUMBERS,ALLERGIES,NUMBERS,95,106,ALLERGIES,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer.",95,106,95,106,102,115,-1,RO-cause_of,900060,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer",numbers,allergies
502252377,7/11/2014 15:22:31,,1320778662,7/11/2014 15:22:11,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,95,106,,,102,115,NUMBERS,ALLERGIES,increasing NUMBERS of allergies,84-95-103-106,84-95-103-106,increasing numbers of ALLERGIES,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer.",95,106,95,106,102,115,-1,RO-cause_of,900060,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer",numbers,allergies
502252377,7/11/2014 15:30:22,,1320781724,7/11/2014 15:30:09,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,95,106,,,102,115,NUMBERS,ALLERGIES,and NUMBERS,80-95,106,ALLERGIES,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer.",95,106,95,106,102,115,-1,RO-cause_of,900060,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer",numbers,allergies
502252377,7/11/2014 15:32:33,,1320782433,7/11/2014 15:32:30,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,95,106,,,102,115,NUMBERS,ALLERGIES,history and increasing NUMBERS of allergies was,72-80-84-95-103-106-116,84-95-103-106-116-120-131,increasing numbers of ALLERGIES was associated with,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer.",95,106,95,106,102,115,-1,RO-cause_of,900060,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer",numbers,allergies
502252377,7/11/2014 15:35:37,,1320784115,7/11/2014 15:35:11,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,95,106,,,102,115,NUMBERS,ALLERGIES,NUMBERS,95,106,ALLERGIES,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer.",95,106,95,106,102,115,-1,RO-cause_of,900060,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer",numbers,allergies
502252377,7/11/2014 15:44:16,,1320786934,7/11/2014 15:44:01,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,95,106,,,102,115,NUMBERS,ALLERGIES,NUMBERS,95,106,ALLERGIES,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer.",95,106,95,106,102,115,-1,RO-cause_of,900060,"However, ovarian cancer risk was decreased in persons with any allergic history and increasing numbers of allergies was associated with decreasing risk of this form of cancer",numbers,allergies
502252378,7/11/2014 15:16:11,,1320775315,7/11/2014 15:16:05,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,125,167,,,134,183,HEADACHES,PHEOCHROMOCYTOMA,"elevated blood pressure, HEADACHES, palpitations, and diaphoresis",100-109-115-125-136-150-154,136-150-154-167-184-187,"palpitations, and diaphoresis PHEOCHROMOCYTOMA is rare.","Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare.",125,167,125,167,134,183,-1,RO-disease_may_have_finding,902746,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare",headaches,Pheochromocytoma
502252378,7/11/2014 15:16:42,,1320775451,7/11/2014 15:16:37,instagc,1.0,27753923,GBR,"","",188.29.78.53,125,167,,,134,183,HEADACHES,PHEOCHROMOCYTOMA,"elevated blood pressure, HEADACHES, palpitations, and diaphoresis",100-109-115-125-136-150-154,136-150-154-167-184-187,"palpitations, and diaphoresis PHEOCHROMOCYTOMA is rare.","Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare.",125,167,125,167,134,183,-1,RO-disease_may_have_finding,902746,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare",headaches,Pheochromocytoma
502252378,7/11/2014 15:18:25,,1320776183,7/11/2014 15:18:09,instagc,1.0,13763729,USA,"","",75.182.89.225,125,167,,,134,183,HEADACHES,PHEOCHROMOCYTOMA,"HEADACHES,",125,167,PHEOCHROMOCYTOMA,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare.",125,167,125,167,134,183,-1,RO-disease_may_have_finding,902746,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare",headaches,Pheochromocytoma
502252378,7/11/2014 15:23:53,,1320779396,7/11/2014 15:22:55,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,125,167,,,134,183,HEADACHES,PHEOCHROMOCYTOMA,"elevated blood pressure, HEADACHES,",100-109-115-125,100-109-115-136-150-154-167-125,"elevated blood pressure, headaches, palpitations, and diaphoresis PHEOCHROMOCYTOMA","Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare.",125,167,125,167,134,183,-1,RO-disease_may_have_finding,902746,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare",headaches,Pheochromocytoma
502252378,7/11/2014 15:24:01,,1320779467,7/11/2014 15:22:46,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,125,167,,,134,183,HEADACHES,PHEOCHROMOCYTOMA,"HEADACHES, diaphoresis",125-154,154-167,diaphoresis PHEOCHROMOCYTOMA,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare.",125,167,125,167,134,183,-1,RO-disease_may_have_finding,902746,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare",headaches,Pheochromocytoma
502252378,7/11/2014 15:25:43,,1320780011,7/11/2014 15:25:19,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,125,167,,,134,183,HEADACHES,PHEOCHROMOCYTOMA,"HEADACHES,",125,167,PHEOCHROMOCYTOMA,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare.",125,167,125,167,134,183,-1,RO-disease_may_have_finding,902746,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare",headaches,Pheochromocytoma
502252378,7/11/2014 15:26:23,,1320780274,7/11/2014 15:26:04,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,125,167,,,134,183,HEADACHES,PHEOCHROMOCYTOMA,"elevated HEADACHES,",100-125,154-167,diaphoresis PHEOCHROMOCYTOMA,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare.",125,167,125,167,134,183,-1,RO-disease_may_have_finding,902746,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare",headaches,Pheochromocytoma
502252378,7/11/2014 15:29:34,,1320781386,7/11/2014 15:29:31,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,125,167,,,134,183,HEADACHES,PHEOCHROMOCYTOMA,"elevated blood pressure, HEADACHES, palpitations, and diaphoresis",100-109-115-125-136-150-154,136-150-154-167-184-187,"palpitations, and diaphoresis PHEOCHROMOCYTOMA is rare.","Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare.",125,167,125,167,134,183,-1,RO-disease_may_have_finding,902746,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare",headaches,Pheochromocytoma
502252378,7/11/2014 15:39:32,,1320785439,7/11/2014 15:39:08,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,125,167,,,134,183,HEADACHES,PHEOCHROMOCYTOMA,"HEADACHES,",125,167-154,diaphoresis PHEOCHROMOCYTOMA,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare.",125,167,125,167,134,183,-1,RO-disease_may_have_finding,902746,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare",headaches,Pheochromocytoma
502252378,7/11/2014 15:41:33,,1320786128,7/11/2014 15:40:56,bitcoinget,1.0,24792414,USA,"","",166.181.81.197,125,167,,,134,183,HEADACHES,PHEOCHROMOCYTOMA,"HEADACHES,",125,167,PHEOCHROMOCYTOMA,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare.",125,167,125,167,134,183,-1,RO-disease_may_have_finding,902746,"Usually accompanied by change in mental status tvml Pheochromocytomatvml   Adrenergic symptoms with elevated blood pressure, headaches, palpitations, and diaphoresis  Pheochromocytoma is rare",headaches,Pheochromocytoma
502252379,7/11/2014 15:17:29,,1320775718,7/11/2014 15:17:21,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,74,144,,,80,155,EMESIS,ONDANSETRON,EMESIS,74,144,ONDANSETRON.,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron.",74,144,74,144,80,155,1,RO-may_prevent,907203,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron",emesis,ondansetron
502252379,7/11/2014 15:17:56,,1320775972,7/11/2014 15:17:51,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,74,144,,,80,155,EMESIS,ONDANSETRON,"in controlling acute EMESIS and nausea, and",53-56-68-74-81-85-93,121-129-140-144,patient preference for ONDANSETRON.,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron.",74,144,74,144,80,155,1,RO-may_prevent,907203,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron",emesis,ondansetron
502252379,7/11/2014 15:18:08,,1320776079,7/11/2014 15:17:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,74,144,,,80,155,EMESIS,ONDANSETRON,"acute EMESIS and nausea,",68-74-81-85,121-129-140-144,patient preference for ONDANSETRON.,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron.",74,144,74,144,80,155,1,RO-may_prevent,907203,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron",emesis,ondansetron
502252379,7/11/2014 15:19:16,,1320776646,7/11/2014 15:19:03,instagc,1.0,13763729,USA,"","",75.182.89.225,74,144,,,80,155,EMESIS,ONDANSETRON,acute EMESIS,68-74,144,ONDANSETRON.,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron.",74,144,74,144,80,155,1,RO-may_prevent,907203,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron",emesis,ondansetron
502252379,7/11/2014 15:19:27,,1320776762,7/11/2014 15:19:17,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,74,144,,,80,155,EMESIS,ONDANSETRON,acute EMESIS,68-74,144,ONDANSETRON.,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron.",74,144,74,144,80,155,1,RO-may_prevent,907203,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron",emesis,ondansetron
502252379,7/11/2014 15:19:31,,1320776792,7/11/2014 15:19:11,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,74,144,,,80,155,EMESIS,ONDANSETRON,acute EMESIS,68-74,144,ONDANSETRON.,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron.",74,144,74,144,80,155,1,RO-may_prevent,907203,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron",emesis,ondansetron
502252379,7/11/2014 15:26:15,,1320780231,7/11/2014 15:25:44,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,74,144,,,80,155,EMESIS,ONDANSETRON,EMESIS,74,144,ONDANSETRON.,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron.",74,144,74,144,80,155,1,RO-may_prevent,907203,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron",emesis,ondansetron
502252379,7/11/2014 15:30:13,,1320781679,7/11/2014 15:30:08,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,74,144,,,80,155,EMESIS,ONDANSETRON,"in controlling acute EMESIS and nausea, and",53-56-68-74-81-85-93,121-129-140-144,patient preference for ONDANSETRON.,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron.",74,144,74,144,80,155,1,RO-may_prevent,907203,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron",emesis,ondansetron
502252379,7/11/2014 15:30:33,,1320781790,7/11/2014 15:30:22,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,74,144,,,80,155,EMESIS,ONDANSETRON,EMESIS,74,144,ONDANSETRON.,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron.",74,144,74,144,80,155,1,RO-may_prevent,907203,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron",emesis,ondansetron
502252379,7/11/2014 15:47:18,,1320787927,7/11/2014 15:47:02,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,74,144,,,80,155,EMESIS,ONDANSETRON,acute EMESIS,68-74,144,ONDANSETRON.,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron.",74,144,74,144,80,155,1,RO-may_prevent,907203,"Ondansetron was superior to high-dose metoclopramide in controlling acute emesis and nausea, and there was a significant patient preference for ondansetron",emesis,ondansetron
502252380,7/11/2014 15:12:48,,1320773759,7/11/2014 15:12:20,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,147,172,,,155,186,DIARRHEA,CHOLESTYRAMINE,INEFFECTive diarrhea,147-197,222,cholestyramine,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes.,147,,147,172,155,186,1,RO-may_treat,907471,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes,diarrhea,cholestyramine
502252380,7/11/2014 15:14:46,,1320774723,7/11/2014 15:14:42,instagc,1.0,27753923,GBR,"","",188.29.78.53,147,172,,,155,186,DIARRHEA,CHOLESTYRAMINE,����渇�膩����申 octreotide is INEFFECTive or not tolerated,120-133-144-147-159-162-166,159-162-166-197-206,or not toleraTED diarrhea with,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes.,147,,147,172,155,186,1,RO-may_treat,907471,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes,diarrhea,cholestyramine
502252380,7/11/2014 15:21:25,,1320777891,7/11/2014 15:20:20,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,147,172,,,155,186,DIARRHEA,CHOLESTYRAMINE,octreotide is INEFFECTive or not tolerated,144-147-159-162-166-133,197-206-211-219-222,diarrhea with codeine or cholestyramine,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes.,147,,147,172,155,186,1,RO-may_treat,907471,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes,diarrhea,cholestyramine
502252380,7/11/2014 15:21:52,,1320778201,7/11/2014 15:21:18,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,147,172,,,155,186,DIARRHEA,CHOLESTYRAMINE,����渇�膩����申 INEFFECTive,120-147,222,cholestyramine,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes.,147,,147,172,155,186,1,RO-may_treat,907471,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes,diarrhea,cholestyramine
502252380,7/11/2014 15:23:27,,1320779231,7/11/2014 15:23:06,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,147,172,,,155,186,DIARRHEA,CHOLESTYRAMINE,����渇�膩����申 INEFFECTive,120-147,222,cholestyramine,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes.,147,,147,172,155,186,1,RO-may_treat,907471,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes,diarrhea,cholestyramine
502252380,7/11/2014 15:27:39,,1320780691,7/11/2014 15:26:48,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,147,172,,,155,186,DIARRHEA,CHOLESTYRAMINE,INEFFECTive diarrhea,147-197,222,cholestyramine,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes.,147,,147,172,155,186,1,RO-may_treat,907471,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes,diarrhea,cholestyramine
502252380,7/11/2014 15:44:51,,1320787046,7/11/2014 15:44:18,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,147,172,,,155,186,DIARRHEA,CHOLESTYRAMINE,INEFFECTive,147,,,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes.,147,,147,172,155,186,1,RO-may_treat,907471,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes,diarrhea,cholestyramine
502252380,7/11/2014 15:48:45,,1320788579,7/11/2014 15:48:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,147,172,,,155,186,DIARRHEA,CHOLESTYRAMINE,INEFFECTive,147,222,cholestyramine,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes.,147,,147,172,155,186,1,RO-may_treat,907471,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes,diarrhea,cholestyramine
502252380,7/11/2014 15:48:55,,1320788670,7/11/2014 15:48:39,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,147,172,,,155,186,DIARRHEA,CHOLESTYRAMINE,INEFFECTive,147,197,diarrhea,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes.,147,,147,172,155,186,1,RO-may_treat,907471,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes,diarrhea,cholestyramine
502252380,7/11/2014 15:52:23,,1320791198,7/11/2014 15:51:53,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,147,172,,,155,186,DIARRHEA,CHOLESTYRAMINE,INEFFECTive,147,197,diarrhea,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes.,147,,147,172,155,186,1,RO-may_treat,907471,C]  Specific recommendation: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�eat: 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ushing and diarrhea with octreotide or interferon-����渇�膩����申 octreotide is ineffective or not tolerated 鐃緒申鐃緒申羝�申��申鐃緒申鐃順�ld diarrhea with codeine or cholestyramine in patients with distal ileal resection and pancreatic enzymes,diarrhea,cholestyramine
502252381,7/11/2014 15:09:38,,1320772103,7/11/2014 15:08:50,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,107,75,,,126,85,NEURAL TUBE DEFECTS,FOLIC ACID,NEURAL TUBE DEFECTS.,107-114-119,75-81,FOLIC ACID,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects.,107 114 119,75 81,107,75,126,85,1,RO-may_prevent,907098,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects,neural tube defects,folic acid
502252381,7/11/2014 15:15:24,,1320774976,7/11/2014 15:15:18,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,107,75,,,126,85,NEURAL TUBE DEFECTS,FOLIC ACID,the prevention of NEURAL TUBE DEFECTS.,89-93-104-107-114-119,58-67-72-75-81-86-89-93,specific role of FOLIC ACID in the prevention,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects.,107 114 119,75 81,107,75,126,85,1,RO-may_prevent,907098,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects,neural tube defects,folic acid
502252381,7/11/2014 15:18:35,,1320776282,7/11/2014 15:18:21,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,107,75,,,126,85,NEURAL TUBE DEFECTS,FOLIC ACID,NEURAL TUBE DEFECTS.,107-114-119,75-81,FOLIC ACID,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects.,107 114 119,75 81,107,75,126,85,1,RO-may_prevent,907098,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects,neural tube defects,folic acid
502252381,7/11/2014 15:18:42,,1320776372,7/11/2014 15:17:56,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,107,75,,,126,85,NEURAL TUBE DEFECTS,FOLIC ACID,NEURAL TUBE DEFECTS.,107-114-119,75-81,FOLIC ACID,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects.,107 114 119,75 81,107,75,126,85,1,RO-may_prevent,907098,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects,neural tube defects,folic acid
502252381,7/11/2014 15:21:03,,1320777670,7/11/2014 15:20:54,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,107,75,,,126,85,NEURAL TUBE DEFECTS,FOLIC ACID,NEURAL TUBE DEFECTS.,107-114-119,75-81,FOLIC ACID,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects.,107 114 119,75 81,107,75,126,85,1,RO-may_prevent,907098,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects,neural tube defects,folic acid
502252381,7/11/2014 15:24:12,,1320779507,7/11/2014 15:23:58,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,107,75,,,126,85,NEURAL TUBE DEFECTS,FOLIC ACID,NEURAL TUBE DEFECTS.,107-114-119,75-81,FOLIC ACID,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects.,107 114 119,75 81,107,75,126,85,1,RO-may_prevent,907098,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects,neural tube defects,folic acid
502252381,7/11/2014 15:27:59,,1320780779,7/11/2014 15:27:41,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,107,75,,,126,85,NEURAL TUBE DEFECTS,FOLIC ACID,prevention of NEURAL TUBE DEFECTS.,104-107-114-119-93,75-81,FOLIC ACID,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects.,107 114 119,75 81,107,75,126,85,1,RO-may_prevent,907098,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects,neural tube defects,folic acid
502252381,7/11/2014 15:30:02,,1320781606,7/11/2014 15:29:58,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,107,75,,,126,85,NEURAL TUBE DEFECTS,FOLIC ACID,the prevention of NEURAL TUBE DEFECTS.,89-93-104-107-114-119,58-67-72-75-81-86-89-93,specific role of FOLIC ACID in the prevention,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects.,107 114 119,75 81,107,75,126,85,1,RO-may_prevent,907098,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects,neural tube defects,folic acid
502252381,7/11/2014 15:38:28,,1320785114,7/11/2014 15:38:13,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,107,75,,,126,85,NEURAL TUBE DEFECTS,FOLIC ACID,NEURAL TUBE DEFECTS.,107-114-119,75-81,FOLIC ACID,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects.,107 114 119,75 81,107,75,126,85,1,RO-may_prevent,907098,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects,neural tube defects,folic acid
502252381,7/11/2014 15:49:44,,1320789245,7/11/2014 15:49:33,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,107,75,,,126,85,NEURAL TUBE DEFECTS,FOLIC ACID,NEURAL TUBE DEFECTS.,107-114-119,75-81,FOLIC ACID,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects.,107 114 119,75 81,107,75,126,85,1,RO-may_prevent,907098,The results of the MRC Vitamin Study have established the specific role of folic acid in the prevention of neural tube defects,neural tube defects,folic acid
502252382,7/11/2014 15:12:08,,1320773503,7/11/2014 15:11:59,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,46,103,,,61,110,ALLERGIC ASTHMA,ALLERGY,ALLERGIC ASTHMA,46-55,103,ALLERGY.,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy.",46 55,103,46,103,61,110,1,RO-cause_of,900298,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy",allergic asthma,allergy
502252382,7/11/2014 15:15:32,,1320775019,7/11/2014 15:15:28,instagc,1.0,27753923,GBR,"","",188.29.78.53,46,103,,,61,110,ALLERGIC ASTHMA,ALLERGY,"respiratory allergies, i.e., ALLERGIC ASTHMA and rhinitis, represent",17-29-40-46-55-62-66-76,86-90-100-103,the hallmarks of ALLERGY.,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy.",46 55,103,46,103,61,110,1,RO-cause_of,900298,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy",allergic asthma,allergy
502252382,7/11/2014 15:17:36,,1320775762,7/11/2014 15:17:24,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,46,103,,,61,110,ALLERGIC ASTHMA,ALLERGY,ALLERGIC ASTHMA,46-55,103,ALLERGY.,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy.",46 55,103,46,103,61,110,1,RO-cause_of,900298,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy",allergic asthma,allergy
502252382,7/11/2014 15:18:16,,1320776127,7/11/2014 15:18:07,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,46,103,,,61,110,ALLERGIC ASTHMA,ALLERGY,ALLERGIC ASTHMA,46-55,103,ALLERGY.,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy.",46 55,103,46,103,61,110,1,RO-cause_of,900298,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy",allergic asthma,allergy
502252382,7/11/2014 15:19:08,,1320776569,7/11/2014 15:18:50,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,46,103,,,61,110,ALLERGIC ASTHMA,ALLERGY,ALLERGIC ASTHMA,46-55,103,ALLERGY.,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy.",46 55,103,46,103,61,110,1,RO-cause_of,900298,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy",allergic asthma,allergy
502252382,7/11/2014 15:22:39,,1320778753,7/11/2014 15:22:24,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,46,103,,,61,110,ALLERGIC ASTHMA,ALLERGY,ALLERGIC ASTHMA,46-55,103,ALLERGY.,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy.",46 55,103,46,103,61,110,1,RO-cause_of,900298,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy",allergic asthma,allergy
502252382,7/11/2014 15:28:07,,1320780842,7/11/2014 15:27:56,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,46,103,,,61,110,ALLERGIC ASTHMA,ALLERGY,"ALLERGIC ASTHMA rhinitis,",46-55-66,103,ALLERGY.,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy.",46 55,103,46,103,61,110,1,RO-cause_of,900298,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy",allergic asthma,allergy
502252382,7/11/2014 15:29:19,,1320781292,7/11/2014 15:28:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,46,103,,,61,110,ALLERGIC ASTHMA,ALLERGY,"respiratory allergies, i.e., ALLERGIC ASTHMA and rhinitis,",17-29-40-46-55-62-66,86-90-100-103,the hallmarks of ALLERGY.,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy.",46 55,103,46,103,61,110,1,RO-cause_of,900298,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy",allergic asthma,allergy
502252382,7/11/2014 15:32:56,,1320782609,7/11/2014 15:32:33,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,46,103,,,61,110,ALLERGIC ASTHMA,ALLERGY,ALLERGIC ASTHMA,46-55,103,ALLERGY.,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy.",46 55,103,46,103,61,110,1,RO-cause_of,900298,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy",allergic asthma,allergy
502252382,7/11/2014 15:44:00,,1320786836,7/11/2014 15:43:46,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,46,103,,,61,110,ALLERGIC ASTHMA,ALLERGY,ALLERGIC ASTHMA,46-55,103,ALLERGY.,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy.",46 55,103,46,103,61,110,1,RO-cause_of,900298,"In many aspects, respiratory allergies, i.e., allergic asthma and rhinitis, represent the hallmarks of allergy",allergic asthma,allergy
502252383,7/11/2014 15:13:26,,1320774029,7/11/2014 15:13:12,instagc,1.0,13763729,USA,"","",75.182.89.225,17,88,,,39,96,GASTROINTESTINAL TRACT,DIARRHEA,GASTROINTESTINAL TRACT,17-34,88,DIARRHEA,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",17 34,88,17,88,39,96,1,RO-has_finding_site,905080,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration",gastrointestinal tract,diarrhea
502252383,7/11/2014 15:14:30,,1320774524,7/11/2014 15:14:24,instagc,1.0,27753923,GBR,"","",188.29.78.53,17,88,,,39,96,GASTROINTESTINAL TRACT,DIARRHEA,"All patients had GASTROINTESTINAL TRACT symptoms, with 30",0-4-13-17-34-40-50-55,67-73-85-88-97-101-104,(91%) complaining of DIARRHEA and 23 patients,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",17 34,88,17,88,39,96,1,RO-has_finding_site,905080,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration",gastrointestinal tract,diarrhea
502252383,7/11/2014 15:16:24,,1320775377,7/11/2014 15:16:18,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,17,88,,,39,96,GASTROINTESTINAL TRACT,DIARRHEA,"All patients had GASTROINTESTINAL TRACT symptoms, with 30",0-4-13-17-34-40-50-55,67-73-85-88-97-101-104,(91%) complaining of DIARRHEA and 23 patients,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",17 34,88,17,88,39,96,1,RO-has_finding_site,905080,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration",gastrointestinal tract,diarrhea
502252383,7/11/2014 15:16:40,,1320775447,7/11/2014 15:16:29,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,17,88,,,39,96,GASTROINTESTINAL TRACT,DIARRHEA,GASTROINTESTINAL TRACT,17-34,88,DIARRHEA,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",17 34,88,17,88,39,96,1,RO-has_finding_site,905080,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration",gastrointestinal tract,diarrhea
502252383,7/11/2014 15:17:42,,1320775841,7/11/2014 15:17:30,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,17,88,,,39,96,GASTROINTESTINAL TRACT,DIARRHEA,GASTROINTESTINAL TRACT,17-34,88,DIARRHEA,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",17 34,88,17,88,39,96,1,RO-has_finding_site,905080,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration",gastrointestinal tract,diarrhea
502252383,7/11/2014 15:19:17,,1320776664,7/11/2014 15:18:59,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,17,88,,,39,96,GASTROINTESTINAL TRACT,DIARRHEA,"GASTROINTESTINAL TRACT symptoms,",17-34-40,88,DIARRHEA,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",17 34,88,17,88,39,96,1,RO-has_finding_site,905080,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration",gastrointestinal tract,diarrhea
502252383,7/11/2014 15:28:31,,1320780964,7/11/2014 15:28:20,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,17,88,,,39,96,GASTROINTESTINAL TRACT,DIARRHEA,GASTROINTESTINAL TRACT,17-34,88,DIARRHEA,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",17 34,88,17,88,39,96,1,RO-has_finding_site,905080,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration",gastrointestinal tract,diarrhea
502252383,7/11/2014 15:42:32,,1320786303,7/11/2014 15:42:15,bitcoinget,1.0,24792414,USA,"","",166.181.81.197,17,88,,,39,96,GASTROINTESTINAL TRACT,DIARRHEA,GASTROINTESTINAL TRACT,17-34,88,DIARRHEA,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",17 34,88,17,88,39,96,1,RO-has_finding_site,905080,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration",gastrointestinal tract,diarrhea
502252383,7/11/2014 15:43:46,,1320786766,7/11/2014 15:43:29,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,17,88,,,39,96,GASTROINTESTINAL TRACT,DIARRHEA,"GASTROINTESTINAL TRACT symptoms,",17-34-40,88,DIARRHEA,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",17 34,88,17,88,39,96,1,RO-has_finding_site,905080,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration",gastrointestinal tract,diarrhea
502252383,7/11/2014 15:46:20,,1320787580,7/11/2014 15:46:07,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,17,88,,,39,96,GASTROINTESTINAL TRACT,DIARRHEA,GASTROINTESTINAL TRACT,17-34,88,DIARRHEA,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",17 34,88,17,88,39,96,1,RO-has_finding_site,905080,"All patients had gastrointestinal tract symptoms, with 30 patients (91%) complaining of diarrhea and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration",gastrointestinal tract,diarrhea
502252384,7/11/2014 15:09:58,,1320772301,7/11/2014 15:09:40,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,122,68,,,134,89,METRORRHAGIA,ENDOMETRIAL CARCINOMA,METRORRHAGIA,122,68-80,ENDOMETRIAL CARCINOMA,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women.",122,68 80,122,68,134,89,1,RO-disease_may_have_finding,902742,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women",metrorrhagia,endometrial carcinoma
502252384,7/11/2014 15:15:19,,1320774953,7/11/2014 15:15:15,instagc,1,27753923,GBR,"","",188.29.78.53,122,68,,,134,89,METRORRHAGIA,ENDOMETRIAL CARCINOMA,frequent cause for METRORRHAGIA in the postmenopausal,103-112-118-122-135-138-142,43-58-64-68-80-90-94-98,"perimenopause, while the ENDOMETRIAL CARCINOMA was the most","The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women.",122,68 80,122,68,134,89,1,RO-disease_may_have_finding,902742,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women",metrorrhagia,endometrial carcinoma
502252384,7/11/2014 15:16:59,,1320775555,7/11/2014 15:16:52,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,122,68,,,134,89,METRORRHAGIA,ENDOMETRIAL CARCINOMA,frequent cause for METRORRHAGIA in the postmenopausal,103-112-118-122-135-138-142,43-58-64-68-80-90-94-98,"perimenopause, while the ENDOMETRIAL CARCINOMA was the most","The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women.",122,68 80,122,68,134,89,1,RO-disease_may_have_finding,902742,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women",metrorrhagia,endometrial carcinoma
502252384,7/11/2014 15:17:20,,1320775645,7/11/2014 15:16:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,122,68,,,134,89,METRORRHAGIA,ENDOMETRIAL CARCINOMA,METRORRHAGIA,122,68-80,ENDOMETRIAL CARCINOMA,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women.",122,68 80,122,68,134,89,1,RO-disease_may_have_finding,902742,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women",metrorrhagia,endometrial carcinoma
502252384,7/11/2014 15:17:46,,1320775851,7/11/2014 15:17:25,instagc,1.0,13763729,USA,"","",75.182.89.225,122,68,,,134,89,METRORRHAGIA,ENDOMETRIAL CARCINOMA,METRORRHAGIA,122,68-80,ENDOMETRIAL CARCINOMA,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women.",122,68 80,122,68,134,89,1,RO-disease_may_have_finding,902742,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women",metrorrhagia,endometrial carcinoma
502252384,7/11/2014 15:19:00,,1320776514,7/11/2014 15:18:09,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,122,68,,,134,89,METRORRHAGIA,ENDOMETRIAL CARCINOMA,endometrial carcinoma frequent cause for METRORRHAGIA in the postmenopausal women.,68-80-103-112-118-122-135-138-142-157,64-68-80,the ENDOMETRIAL CARCINOMA,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women.",122,68 80,122,68,134,89,1,RO-disease_may_have_finding,902742,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women",metrorrhagia,endometrial carcinoma
502252384,7/11/2014 15:20:56,,1320777591,7/11/2014 15:20:42,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,122,68,,,134,89,METRORRHAGIA,ENDOMETRIAL CARCINOMA,METRORRHAGIA,122,68-80,ENDOMETRIAL CARCINOMA,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women.",122,68 80,122,68,134,89,1,RO-disease_may_have_finding,902742,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women",metrorrhagia,endometrial carcinoma
502252384,7/11/2014 15:20:58,,1320777604,7/11/2014 15:20:28,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,122,68,,,134,89,METRORRHAGIA,ENDOMETRIAL CARCINOMA,METRORRHAGIA,122,68-80,ENDOMETRIAL CARCINOMA,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women.",122,68 80,122,68,134,89,1,RO-disease_may_have_finding,902742,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women",metrorrhagia,endometrial carcinoma
502252384,7/11/2014 15:22:07,,1320778373,7/11/2014 15:21:40,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,122,68,,,134,89,METRORRHAGIA,ENDOMETRIAL CARCINOMA,METRORRHAGIA,122,68-80,ENDOMETRIAL CARCINOMA,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women.",122,68 80,122,68,134,89,1,RO-disease_may_have_finding,902742,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women",metrorrhagia,endometrial carcinoma
502252384,7/11/2014 15:22:48,,1320778853,7/11/2014 15:22:32,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,122,68,,,134,89,METRORRHAGIA,ENDOMETRIAL CARCINOMA,METRORRHAGIA,122,68-80,ENDOMETRIAL CARCINOMA,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women.",122,68 80,122,68,134,89,1,RO-disease_may_have_finding,902742,"The simple hyperplasia predominates in the perimenopause, while the endometrial carcinoma was the most frequent cause for metrorrhagia in the postmenopausal women",metrorrhagia,endometrial carcinoma
502252385,7/11/2014 15:15:17,,1320774937,7/11/2014 15:15:12,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,22,86,,,30,101,PROSTATE,PROSTATE CANCER,imaging of the PROSTATE results in a,7-15-18-22-31-39-42,68-72-83-86-95-102-106-108,the appearance of PROSTATE CANCER and a heightened,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate.,22,86 95,22,86,30,101,1,RO-disease_has_primary_anatomic_site,902004,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate,prostate,prostate cancer
502252385,7/11/2014 15:15:19,,1320774952,7/11/2014 15:15:05,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,22,86,,,30,101,PROSTATE,PROSTATE CANCER,PROSTATE,22,86-95,PROSTATE CANCER,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate.,22,86 95,22,86,30,101,1,RO-disease_has_primary_anatomic_site,902004,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate,prostate,prostate cancer
502252385,7/11/2014 15:20:58,,1320777606,7/11/2014 15:20:37,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,22,86,,,30,101,PROSTATE,PROSTATE CANCER,PROSTATE,22,86-95,PROSTATE CANCER,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate.,22,86 95,22,86,30,101,1,RO-disease_has_primary_anatomic_site,902004,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate,prostate,prostate cancer
502252385,7/11/2014 15:21:14,,1320777756,7/11/2014 15:20:56,instagc,1.0,13763729,USA,"","",75.182.89.225,22,86,,,30,101,PROSTATE,PROSTATE CANCER,PROSTATE,22,86-95,PROSTATE CANCER,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate.,22,86 95,22,86,30,101,1,RO-disease_has_primary_anatomic_site,902004,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate,prostate,prostate cancer
502252385,7/11/2014 15:21:48,,1320778134,7/11/2014 15:21:30,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,22,86,,,30,101,PROSTATE,PROSTATE CANCER,PROSTATE,22,86-95,PROSTATE CANCER,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate.,22,86 95,22,86,30,101,1,RO-disease_has_primary_anatomic_site,902004,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate,prostate,prostate cancer
502252385,7/11/2014 15:25:42,,1320779980,7/11/2014 15:25:17,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,22,86,,,30,101,PROSTATE,PROSTATE CANCER,PROSTATE,22,86-95,PROSTATE CANCER,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate.,22,86 95,22,86,30,101,1,RO-disease_has_primary_anatomic_site,902004,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate,prostate,prostate cancer
502252385,7/11/2014 15:34:10,,1320783244,7/11/2014 15:33:49,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,22,86,,,30,101,PROSTATE,PROSTATE CANCER,PROSTATE,22,86-95,PROSTATE CANCER,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate.,22,86 95,22,86,30,101,1,RO-disease_has_primary_anatomic_site,902004,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate,prostate,prostate cancer
502252385,7/11/2014 15:41:04,,1320785961,7/11/2014 15:40:50,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,22,86,,,30,101,PROSTATE,PROSTATE CANCER,PROSTATE,22,86-95,PROSTATE CANCER,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate.,22,86 95,22,86,30,101,1,RO-disease_has_primary_anatomic_site,902004,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate,prostate,prostate cancer
502252385,7/11/2014 15:45:48,,1320787403,7/11/2014 15:45:36,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,22,86,,,30,101,PROSTATE,PROSTATE CANCER,PROSTATE in,22-39,86-95,PROSTATE CANCER,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate.,22,86 95,22,86,30,101,1,RO-disease_has_primary_anatomic_site,902004,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate,prostate,prostate cancer
502252385,7/11/2014 15:47:22,,1320787946,7/11/2014 15:47:09,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,22,86,,,30,101,PROSTATE,PROSTATE CANCER,PROSTATE,22,86-95,PROSTATE CANCER,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate.,22,86 95,22,86,30,101,1,RO-disease_has_primary_anatomic_site,902004,Better imaging of the prostate results in a better understanding of the appearance of prostate cancer and a heightened awareness of cancer location within the prostate,prostate,prostate cancer
502252386,7/11/2014 15:11:58,,1320773443,7/11/2014 15:11:44,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,77,29,,,89,45,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,77,29,PHEOCHROMOCYTOMA,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy.,77,29,77,29,89,45,1,RO-disease_may_have_finding,902506,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy,hypertension,pheochromocytoma
502252386,7/11/2014 15:15:30,,1320775004,7/11/2014 15:15:12,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,77,29,,,89,45,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,77,29,PHEOCHROMOCYTOMA,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy.,77,29,77,29,89,45,1,RO-disease_may_have_finding,902506,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy,hypertension,pheochromocytoma
502252386,7/11/2014 15:16:53,,1320775516,7/11/2014 15:16:51,instagc,1.0,27753923,GBR,"","",188.29.78.53,77,29,,,89,45,HYPERTENSION,PHEOCHROMOCYTOMA,de novo appeared HYPERTENSION in a young,60-63-68-77-90-93-95,19-21-26-29-46-55-58,a case of PHEOCHROMOCYTOMA revealed by a,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy.,77,29,77,29,89,45,1,RO-disease_may_have_finding,902506,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy,hypertension,pheochromocytoma
502252386,7/11/2014 15:18:53,,1320776444,7/11/2014 15:18:39,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,77,29,,,89,45,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,77,29,PHEOCHROMOCYTOMA,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy.,77,29,77,29,89,45,1,RO-disease_may_have_finding,902506,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy,hypertension,pheochromocytoma
502252386,7/11/2014 15:22:57,,1320778957,7/11/2014 15:22:19,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,77,29,,,89,45,HYPERTENSION,PHEOCHROMOCYTOMA,de novo appeared HYPERTENSION,60-63-68-77,29,PHEOCHROMOCYTOMA,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy.,77,29,77,29,89,45,1,RO-disease_may_have_finding,902506,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy,hypertension,pheochromocytoma
502252386,7/11/2014 15:24:13,,1320779514,7/11/2014 15:23:59,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,77,29,,,89,45,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,77,29,PHEOCHROMOCYTOMA,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy.,77,29,77,29,89,45,1,RO-disease_may_have_finding,902506,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy,hypertension,pheochromocytoma
502252386,7/11/2014 15:28:19,,1320780919,7/11/2014 15:27:46,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,77,29,,,89,45,HYPERTENSION,PHEOCHROMOCYTOMA,appeared HYPERTENSION,68-77,29,PHEOCHROMOCYTOMA,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy.,77,29,77,29,89,45,1,RO-disease_may_have_finding,902506,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy,hypertension,pheochromocytoma
502252386,7/11/2014 15:29:08,,1320781238,7/11/2014 15:28:55,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,77,29,,,89,45,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,77,29,PHEOCHROMOCYTOMA,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy.,77,29,77,29,89,45,1,RO-disease_may_have_finding,902506,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy,hypertension,pheochromocytoma
502252386,7/11/2014 15:43:13,,1320786551,7/11/2014 15:42:56,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,77,29,,,89,45,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,77,29,PHEOCHROMOCYTOMA,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy.,77,29,77,29,89,45,1,RO-disease_may_have_finding,902506,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy,hypertension,pheochromocytoma
502252386,7/11/2014 15:44:25,,1320786957,7/11/2014 15:42:59,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,77,29,,,89,45,HYPERTENSION,PHEOCHROMOCYTOMA,de novo HYPERTENSION,63-77-60,29,PHEOCHROMOCYTOMA,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy.,77,29,77,29,89,45,1,RO-disease_may_have_finding,902506,The authors report a case of pheochromocytoma revealed by a de novo appeared hypertension in a young female patient at her 3rd trimester of pregnancy,hypertension,pheochromocytoma
502252387,7/11/2014 15:13:14,,1320773917,7/11/2014 15:13:02,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,87,38,,,93,55,LIVERS,CHRONIC HEPATITIS,LIVERS,87,38-46,CHRONIC HEPATITIS,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung.,87,38 46,87,38,93,55,1,RO-disease_has_primary_anatomic_site,902285,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung,livers,chronic hepatitis
502252387,7/11/2014 15:15:48,,1320775125,7/11/2014 15:15:31,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,87,38,,,93,55,LIVERS,CHRONIC HEPATITIS,LIVERS,87,38-46,CHRONIC HEPATITIS,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung.,87,38 46,87,38,93,55,1,RO-disease_has_primary_anatomic_site,902285,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung,livers,chronic hepatitis
502252387,7/11/2014 15:16:56,,1320775530,7/11/2014 15:16:42,instagc,1.0,13763729,USA,"","",75.182.89.225,87,38,,,93,55,LIVERS,CHRONIC HEPATITIS,LIVERS,87,38-46,CHRONIC HEPATITIS,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung.,87,38 46,87,38,93,55,1,RO-disease_has_primary_anatomic_site,902285,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung,livers,chronic hepatitis
502252387,7/11/2014 15:17:38,,1320775775,7/11/2014 15:17:33,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,87,38,,,93,55,LIVERS,CHRONIC HEPATITIS,seen in the LIVERS of a majority,75-80-83-87-94-97-99,13-19-28-38-46-56-60-70,liver diseases including CHRONIC HEPATITIS and cirrhosis were,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung.,87,38 46,87,38,93,55,1,RO-disease_has_primary_anatomic_site,902285,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung,livers,chronic hepatitis
502252387,7/11/2014 15:17:54,,1320775946,7/11/2014 15:17:43,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,87,38,,,93,55,LIVERS,CHRONIC HEPATITIS,LIVERS,87,38-46,CHRONIC HEPATITIS,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung.,87,38 46,87,38,93,55,1,RO-disease_has_primary_anatomic_site,902285,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung,livers,chronic hepatitis
502252387,7/11/2014 15:19:42,,1320776884,7/11/2014 15:19:28,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,87,38,,,93,55,LIVERS,CHRONIC HEPATITIS,LIVERS,87,38-46,CHRONIC HEPATITIS,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung.,87,38 46,87,38,93,55,1,RO-disease_has_primary_anatomic_site,902285,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung,livers,chronic hepatitis
502252387,7/11/2014 15:19:47,,1320776904,7/11/2014 15:19:35,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,87,38,,,93,55,LIVERS,CHRONIC HEPATITIS,LIVERS,87,38-46,CHRONIC HEPATITIS,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung.,87,38 46,87,38,93,55,1,RO-disease_has_primary_anatomic_site,902285,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung,livers,chronic hepatitis
502252387,7/11/2014 15:24:19,,1320779548,7/11/2014 15:24:02,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,87,38,,,93,55,LIVERS,CHRONIC HEPATITIS,LIVERS,87,38-46-60,CHRONIC HEPATITIS cirrhosis,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung.,87,38 46,87,38,93,55,1,RO-disease_has_primary_anatomic_site,902285,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung,livers,chronic hepatitis
502252387,7/11/2014 15:31:32,,1320782062,7/11/2014 15:31:28,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,87,38,,,93,55,LIVERS,CHRONIC HEPATITIS,seen in the LIVERS of a majority,75-80-83-87-94-97-99,13-19-28-38-46-56-60-70,liver diseases including CHRONIC HEPATITIS and cirrhosis were,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung.,87,38 46,87,38,93,55,1,RO-disease_has_primary_anatomic_site,902285,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung,livers,chronic hepatitis
502252387,7/11/2014 15:33:22,,1320782787,7/11/2014 15:32:57,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,87,38,,,93,55,LIVERS,CHRONIC HEPATITIS,LIVERS,87,38-46,CHRONIC HEPATITIS,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung.,87,38 46,87,38,93,55,1,RO-disease_has_primary_anatomic_site,902285,A variety of liver diseases including chronic hepatitis and cirrhosis were seen in the livers of a majority of the ducks from Chi-tung,livers,chronic hepatitis
502252388,7/11/2014 15:14:06,,1320774312,7/11/2014 15:13:50,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,44,111,,,60,138,THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA,maternal THROMBOCYTOPENIA,35-44,111-122,AUTOIMMUNE THROMBOCYTOPENIA.,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia.,44,111 122,44,111,60,138,-1,RO-has_definitional_manifestation,904798,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia,thrombocytopenia,autoimmune thrombocytopenia
502252388,7/11/2014 15:15:31,,1320775009,7/11/2014 15:15:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,44,111,,,60,138,THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA,THROMBOCYTOPENIA,44,111-122,AUTOIMMUNE THROMBOCYTOPENIA.,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia.,44,111 122,44,111,60,138,-1,RO-has_definitional_manifestation,904798,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia,thrombocytopenia,autoimmune thrombocytopenia
502252388,7/11/2014 15:16:21,,1320775341,7/11/2014 15:15:52,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,44,111,,,60,138,THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA,THROMBOCYTOPENIA,44,111-122,AUTOIMMUNE THROMBOCYTOPENIA.,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia.,44,111 122,44,111,60,138,-1,RO-has_definitional_manifestation,904798,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia,thrombocytopenia,autoimmune thrombocytopenia
502252388,7/11/2014 15:16:36,,1320775439,7/11/2014 15:16:33,instagc,1.0,27753923,GBR,"","",188.29.78.53,44,111,,,60,138,THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA,causes of maternal THROMBOCYTOPENIA in pregnancy are,25-32-35-44-61-64-74,78-90-107-111-122,gestational thrombocytopenia and AUTOIMMUNE THROMBOCYTOPENIA.,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia.,44,111 122,44,111,60,138,-1,RO-has_definitional_manifestation,904798,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia,thrombocytopenia,autoimmune thrombocytopenia
502252388,7/11/2014 15:25:16,,1320779855,7/11/2014 15:24:58,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,44,111,,,60,138,THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA,maternal THROMBOCYTOPENIA,35-44,111-122,AUTOIMMUNE THROMBOCYTOPENIA.,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia.,44,111 122,44,111,60,138,-1,RO-has_definitional_manifestation,904798,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia,thrombocytopenia,autoimmune thrombocytopenia
502252388,7/11/2014 15:35:29,,1320784035,7/11/2014 15:35:16,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,44,111,,,60,138,THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA,maternal THROMBOCYTOPENIA in pregnancy,35-44-61-64,78-90-107-111-122,gestational thrombocytopenia and AUTOIMMUNE THROMBOCYTOPENIA.,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia.,44,111 122,44,111,60,138,-1,RO-has_definitional_manifestation,904798,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia,thrombocytopenia,autoimmune thrombocytopenia
502252388,7/11/2014 15:40:24,,1320785710,7/11/2014 15:40:01,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,44,111,,,60,138,THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA,THROMBOCYTOPENIA,44,111-122,AUTOIMMUNE THROMBOCYTOPENIA.,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia.,44,111 122,44,111,60,138,-1,RO-has_definitional_manifestation,904798,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia,thrombocytopenia,autoimmune thrombocytopenia
502252388,7/11/2014 15:50:59,,1320790071,7/11/2014 15:50:46,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,44,111,,,60,138,THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA,maternal THROMBOCYTOPENIA,35-44,111-122,AUTOIMMUNE THROMBOCYTOPENIA.,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia.,44,111 122,44,111,60,138,-1,RO-has_definitional_manifestation,904798,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia,thrombocytopenia,autoimmune thrombocytopenia
502252388,7/11/2014 15:51:36,,1320790552,7/11/2014 15:51:22,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,44,111,,,60,138,THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA,maternal THROMBOCYTOPENIA,35-44,111-122,AUTOIMMUNE THROMBOCYTOPENIA.,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia.,44,111 122,44,111,60,138,-1,RO-has_definitional_manifestation,904798,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia,thrombocytopenia,autoimmune thrombocytopenia
502252388,7/11/2014 15:52:06,,1320790942,7/11/2014 15:51:48,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,44,111,,,60,138,THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA,maternal THROMBOCYTOPENIA,35-44,111-122,AUTOIMMUNE THROMBOCYTOPENIA.,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia.,44,111 122,44,111,60,138,-1,RO-has_definitional_manifestation,904798,The clinically important causes of maternal thrombocytopenia in pregnancy are gestational thrombocytopenia and autoimmune thrombocytopenia,thrombocytopenia,autoimmune thrombocytopenia
502252389,7/11/2014 15:12:24,,1320773596,7/11/2014 15:12:09,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,111,62,,,130,71,ATRIAL FIBRILLATION,DILTIAZEM,ATRIAL FIBRillation,119-126,62,"AGENTS,","a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response.",,62,111,62,130,71,1,RO-may_treat,907547,"a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response",atrial fibrillation,diltiazem
502252389,7/11/2014 15:15:44,,1320775107,7/11/2014 15:15:39,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,111,62,,,130,71,ATRIAL FIBRILLATION,DILTIAZEM,first line therAPY ATRIAL FIBRillation and,96-102-107-119-126-139,25-32-53-62-70-81-92,"(e.g., 鐃緒申鐃緒申薜合���申renergic blocking AGENTS, Diltiazem, magnesium) are","a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response.",,62,111,62,130,71,1,RO-may_treat,907547,"a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response",atrial fibrillation,diltiazem
502252389,7/11/2014 15:16:09,,1320775280,7/11/2014 15:14:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,111,62,,,130,71,ATRIAL FIBRILLATION,DILTIAZEM,therAPY FOR ATRIAL FIBRillation and rapid ventricular response.,107-115-119-126-139-145-151-163,3-9-53-62-70-81,"Other antiarrhythmics blocking AGENTS, Diltiazem, magnesium)","a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response.",,62,111,62,130,71,1,RO-may_treat,907547,"a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response",atrial fibrillation,diltiazem
502252389,7/11/2014 15:20:37,,1320777394,7/11/2014 15:20:05,instagc,1.0,13763729,USA,"","",75.182.89.225,111,62,,,130,71,ATRIAL FIBRILLATION,DILTIAZEM,ATRIAL FIBRillation,119-126,53-62-70,"blocking AGENTS, Diltiazem,","a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response.",,62,111,62,130,71,1,RO-may_treat,907547,"a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response",atrial fibrillation,diltiazem
502252389,7/11/2014 15:20:52,,1320777575,7/11/2014 15:20:35,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,111,62,,,130,71,ATRIAL FIBRILLATION,DILTIAZEM,ATRIAL FIBRillation,119-126,25-32-53-62,"(e.g., 鐃緒申鐃緒申薜合���申renergic blocking AGENTS,","a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response.",,62,111,62,130,71,1,RO-may_treat,907547,"a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response",atrial fibrillation,diltiazem
502252389,7/11/2014 15:23:04,,1320778996,7/11/2014 15:22:37,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,111,62,,,130,71,ATRIAL FIBRILLATION,DILTIAZEM,ATRIAL FIBRillation,119-126,62-70,"AGENTS, Diltiazem,","a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response.",,62,111,62,130,71,1,RO-may_treat,907547,"a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response",atrial fibrillation,diltiazem
502252389,7/11/2014 15:32:10,,1320782332,7/11/2014 15:32:05,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,111,62,,,130,71,ATRIAL FIBRILLATION,DILTIAZEM,first line therAPY ATRIAL FIBRillation and,96-102-107-119-126-139,25-32-53-62-70-81-92,"(e.g., 鐃緒申鐃緒申薜合���申renergic blocking AGENTS, Diltiazem, magnesium) are","a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response.",,62,111,62,130,71,1,RO-may_treat,907547,"a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response",atrial fibrillation,diltiazem
502252389,7/11/2014 15:36:44,,1320784594,7/11/2014 15:36:23,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,111,62,,,130,71,ATRIAL FIBRILLATION,DILTIAZEM,ATRIAL FIBRillation,119-126,62-53,"blocking AGENTS,","a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response.",,62,111,62,130,71,1,RO-may_treat,907547,"a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response",atrial fibrillation,diltiazem
502252389,7/11/2014 15:49:22,,1320788945,7/11/2014 15:48:37,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,111,62,,,130,71,ATRIAL FIBRILLATION,DILTIAZEM,ATRIAL FIBRillation,119-126,62,"AGENTS,","a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response.",,62,111,62,130,71,1,RO-may_treat,907547,"a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response",atrial fibrillation,diltiazem
502252389,7/11/2014 15:51:52,,1320790774,7/11/2014 15:51:18,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,111,62,,,130,71,ATRIAL FIBRILLATION,DILTIAZEM,ATRIAL FIBRillation,119-126,9-32-53-62-70-81-25,"antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking AGENTS, Diltiazem, magnesium)","a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response.",,62,111,62,130,71,1,RO-may_treat,907547,"a  Other antiarrhythmics (e.g., 鐃緒申鐃緒申薜合���申renergic blocking agents, diltiazem, magnesium) are first-line therapy for atrial fibrillation and a rapid ventricular response",atrial fibrillation,diltiazem
502252390,7/11/2014 15:12:57,,1320773836,7/11/2014 15:12:48,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,142,101,,,152,108,DEPRESSION,DOXEPIN,DEPRESSION.,142,101,DOXEPIN,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.",142,101,142,101,152,108,1,RO-may_treat,907617,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression",depression,doxepin
502252390,7/11/2014 15:14:21,,1320774474,7/11/2014 15:14:17,instagc,1.0,27753923,GBR,"","",188.29.78.53,142,101,,,152,108,DEPRESSION,DOXEPIN,patients with major DEPRESSION.,122-131-136-142,83-86-97-101-109-112-122,of paroxetine and DOXEPIN in geriatric patients,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.",142,101,142,101,152,108,1,RO-may_treat,907617,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression",depression,doxepin
502252390,7/11/2014 15:15:39,,1320775071,7/11/2014 15:15:24,instagc,1.0,13763729,USA,"","",75.182.89.225,142,101,,,152,108,DEPRESSION,DOXEPIN,DEPRESSION.,142,101,DOXEPIN,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.",142,101,142,101,152,108,1,RO-may_treat,907617,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression",depression,doxepin
502252390,7/11/2014 15:16:29,,1320775407,7/11/2014 15:16:17,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,142,101,,,152,108,DEPRESSION,DOXEPIN,DEPRESSION.,142,101,DOXEPIN,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.",142,101,142,101,152,108,1,RO-may_treat,907617,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression",depression,doxepin
502252390,7/11/2014 15:18:45,,1320776382,7/11/2014 15:18:31,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,142,101,,,152,108,DEPRESSION,DOXEPIN,DEPRESSION.,142,101,DOXEPIN,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.",142,101,142,101,152,108,1,RO-may_treat,907617,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression",depression,doxepin
502252390,7/11/2014 15:21:11,,1320777719,7/11/2014 15:20:51,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,142,101,,,152,108,DEPRESSION,DOXEPIN,major DEPRESSION.,136-142,101,DOXEPIN,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.",142,101,142,101,152,108,1,RO-may_treat,907617,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression",depression,doxepin
502252390,7/11/2014 15:21:54,,1320778235,7/11/2014 15:21:39,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,142,101,,,152,108,DEPRESSION,DOXEPIN,major DEPRESSION.,136-142,101,DOXEPIN,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.",142,101,142,101,152,108,1,RO-may_treat,907617,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression",depression,doxepin
502252390,7/11/2014 15:22:08,,1320778384,7/11/2014 15:21:54,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,142,101,,,152,108,DEPRESSION,DOXEPIN,major DEPRESSION.,136-142,101,DOXEPIN,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.",142,101,142,101,152,108,1,RO-may_treat,907617,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression",depression,doxepin
502252390,7/11/2014 15:26:17,,1320780246,7/11/2014 15:26:07,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,142,101,,,152,108,DEPRESSION,DOXEPIN,DEPRESSION.,142,86-101,paroxetine DOXEPIN,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.",142,101,142,101,152,108,1,RO-may_treat,907617,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression",depression,doxepin
502252390,7/11/2014 15:30:18,,1320781702,7/11/2014 15:30:14,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,142,101,,,152,108,DEPRESSION,DOXEPIN,patients with major DEPRESSION.,122-131-136-142,83-86-97-101-109-112-122,of paroxetine and DOXEPIN in geriatric patients,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.",142,101,142,101,152,108,1,RO-may_treat,907617,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression",depression,doxepin
502252391,7/11/2014 15:10:13,,1320772487,7/11/2014 15:09:59,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,196,189,,,215,193,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS,196,188,(DCIS);,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%.",196,,196,189,215,193,1,RO-disease_may_have_finding,902656,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%",microcalcifications,DCIS
502252391,7/11/2014 15:12:56,,1320773826,7/11/2014 15:12:32,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,196,189,,,215,193,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS,196,163-170-180-183-188,ductal carcinoma in situ (DCIS);,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%.",196,,196,189,215,193,1,RO-disease_may_have_finding,902656,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%",microcalcifications,DCIS
502252391,7/11/2014 15:15:24,,1320774975,7/11/2014 15:15:06,instagc,1.0,13763729,USA,"","",75.182.89.225,196,189,,,215,193,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS,196,188,(DCIS);,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%.",196,,196,189,215,193,1,RO-disease_may_have_finding,902656,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%",microcalcifications,DCIS
502252391,7/11/2014 15:19:53,,1320776970,7/11/2014 15:19:33,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,196,189,,,215,193,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS,196,163-170-180-183-188,ductal carcinoma in situ (DCIS);,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%.",196,,196,189,215,193,1,RO-disease_may_have_finding,902656,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%",microcalcifications,DCIS
502252391,7/11/2014 15:23:35,,1320779283,7/11/2014 15:22:58,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,196,189,,,215,193,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS,196,163-170-180-188-183,ductal carcinoma in situ (DCIS);,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%.",196,,196,189,215,193,1,RO-disease_may_have_finding,902656,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%",microcalcifications,DCIS
502252391,7/11/2014 15:24:28,,1320779591,7/11/2014 15:24:01,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,196,189,,,215,193,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS,196,188,(DCIS);,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%.",196,,196,189,215,193,1,RO-disease_may_have_finding,902656,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%",microcalcifications,DCIS
502252391,7/11/2014 15:38:04,,1320784950,7/11/2014 15:37:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,196,189,,,215,193,MICROCALCIFICATIONS,DCIS,ductal carcinoma in situ (DCIS); MICROCALCIFICATIONS,163-180-183-188-196-170,163-170-180-183-188-196,ductal carcinoma in situ (DCIS); microcalcifications,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%.",196,,196,189,215,193,1,RO-disease_may_have_finding,902656,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%",microcalcifications,DCIS
502252391,7/11/2014 15:40:07,,1320785633,7/11/2014 15:39:48,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,196,189,,,215,193,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS,196,196,microcalcifications,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%.",196,,196,189,215,193,1,RO-disease_may_have_finding,902656,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%",microcalcifications,DCIS
502252391,7/11/2014 15:42:01,,1320786210,7/11/2014 15:41:28,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,196,189,,,215,193,MICROCALCIFICATIONS,DCIS,ductal carcinoma in situ (DCIS); MICROCALCIFICATIONS,163-170-180-183-188-196,170-180-183-188-196-163,ductal carcinoma in situ (DCIS); microcalcifications,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%.",196,,196,189,215,193,1,RO-disease_may_have_finding,902656,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%",microcalcifications,DCIS
502252391,7/11/2014 15:47:39,,1320788053,7/11/2014 15:47:24,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,196,189,,,215,193,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS,196,196,microcalcifications,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%.",196,,196,189,215,193,1,RO-disease_may_have_finding,902656,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van-Nuys, and Lagios classifications in 37 cases of ductal carcinoma in situ (DCIS); microcalcifications alone were seen in 59.4%, microcalcifications with associated mass in 19%, and mass alone in 21.6%",microcalcifications,DCIS
502252392,7/11/2014 15:11:17,,1320773172,7/11/2014 15:11:06,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,118,90,,,130,109,HYPERTENSION,HYDROCHLOROTHIAZIDE,HYPERTENSION,118,90,HYDROCHLOROTHIAZIDE,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old.,118,90,118,90,130,109,1,RO-may_treat,908310,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old,hypertension,hydrochlorothiazide
502252392,7/11/2014 15:24:57,,1320779753,7/11/2014 15:24:30,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,118,90,,,130,109,HYPERTENSION,HYDROCHLOROTHIAZIDE,HYPERTENSION,118,90,HYDROCHLOROTHIAZIDE,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old.,118,90,118,90,130,109,1,RO-may_treat,908310,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old,hypertension,hydrochlorothiazide
502252392,7/11/2014 15:35:27,,1320784027,7/11/2014 15:34:49,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,118,90,,,130,109,HYPERTENSION,HYDROCHLOROTHIAZIDE,HYPERTENSION,118,90-110-118,HYDROCHLOROTHIAZIDE against hypertension,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old.,118,90,118,90,130,109,1,RO-may_treat,908310,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old,hypertension,hydrochlorothiazide
502252392,7/11/2014 15:39:17,,1320785331,7/11/2014 15:36:57,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,118,90,,,130,109,HYPERTENSION,HYDROCHLOROTHIAZIDE,HYPERTENSION,118,35-41-53-56-58-61-64-75-79-84-87-90,fixed combination of 5 mg of cilazapril and 12.5 mg of HYDROCHLOROTHIAZIDE,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old.,118,90,118,90,130,109,1,RO-may_treat,908310,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old,hypertension,hydrochlorothiazide
502252392,7/11/2014 15:48:16,,1320788359,7/11/2014 15:48:05,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,118,90,,,130,109,HYPERTENSION,HYDROCHLOROTHIAZIDE,HYPERTENSION,118,90,HYDROCHLOROTHIAZIDE,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old.,118,90,118,90,130,109,1,RO-may_treat,908310,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old,hypertension,hydrochlorothiazide
502252392,7/11/2014 15:51:53,,1320790785,7/11/2014 15:51:37,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,118,90,,,130,109,HYPERTENSION,HYDROCHLOROTHIAZIDE,HYPERTENSION,118,90,HYDROCHLOROTHIAZIDE,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old.,118,90,118,90,130,109,1,RO-may_treat,908310,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old,hypertension,hydrochlorothiazide
502252392,7/11/2014 15:52:51,,1320791562,7/11/2014 15:52:24,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,118,90,,,130,109,HYPERTENSION,HYDROCHLOROTHIAZIDE,HYPERTENSION,118,90,HYDROCHLOROTHIAZIDE,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old.,118,90,118,90,130,109,1,RO-may_treat,908310,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old,hypertension,hydrochlorothiazide
502252392,7/11/2014 15:54:41,,1320792749,7/11/2014 15:54:26,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,118,90,,,130,109,HYPERTENSION,HYDROCHLOROTHIAZIDE,HYPERTENSION,118,90,HYDROCHLOROTHIAZIDE,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old.,118,90,118,90,130,109,1,RO-may_treat,908310,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old,hypertension,hydrochlorothiazide
502252392,7/11/2014 15:54:48,,1320792793,7/11/2014 15:54:26,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,118,90,,,130,109,HYPERTENSION,HYDROCHLOROTHIAZIDE,HYPERTENSION,118,90,HYDROCHLOROTHIAZIDE,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old.,118,90,118,90,130,109,1,RO-may_treat,908310,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old,hypertension,hydrochlorothiazide
502252392,7/11/2014 16:07:53,,1320797310,7/11/2014 16:07:22,prodege,1,21318648,GBR,G7,Kingston Upon Thames,81.157.193.175,118,90,,,130,109,HYPERTENSION,HYDROCHLOROTHIAZIDE,cilazapril hydrochlorothiazide HYPERTENSION,64-90-118,64-90-118,cilazapril HYDROCHLOROTHIAZIDE hypertension,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old.,118,90,118,90,130,109,1,RO-may_treat,908310,The efficacy and tolerability of a fixed combination of 5 mg of cilazapril and 12.5 mg of hydrochlorothiazide against hypertension was evaluated in 36 patients (26 men and 10 women) between 33-68 years old,hypertension,hydrochlorothiazide
502252393,7/11/2014 15:13:59,,1320774253,7/11/2014 15:13:44,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,142,165,,,151,199,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"DYSPLASIA,",142,165-174-190,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV.",142,165 174 190,142,165,151,199,1,RO-disease_has_finding,901750,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV",dysplasia,cervical intraepithelial neoplasia
502252393,7/11/2014 15:14:57,,1320774805,7/11/2014 15:14:54,instagc,1.0,27753923,GBR,"","",188.29.78.53,142,165,,,151,199,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"and importance of DYSPLASIA, also termed cervical",124-128-139-142-153-158-165,142-153-158-165-174-190-207-211,"dysplasia, also termed CERVICAL INTRAEPITHELIAL NEOPLASIA and more","Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV.",142,165 174 190,142,165,151,199,1,RO-disease_has_finding,901750,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV",dysplasia,cervical intraepithelial neoplasia
502252393,7/11/2014 15:18:18,,1320776128,7/11/2014 15:18:05,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,142,165,,,151,199,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"DYSPLASIA,",142,165-174-190,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV.",142,165 174 190,142,165,151,199,1,RO-disease_has_finding,901750,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV",dysplasia,cervical intraepithelial neoplasia
502252393,7/11/2014 15:18:52,,1320776420,7/11/2014 15:18:47,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,142,165,,,151,199,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"and importance of DYSPLASIA, also termed cervical",124-128-139-142-153-158-165,142-153-158-165-174-190-207-211,"dysplasia, also termed CERVICAL INTRAEPITHELIAL NEOPLASIA and more","Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV.",142,165 174 190,142,165,151,199,1,RO-disease_has_finding,901750,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV",dysplasia,cervical intraepithelial neoplasia
502252393,7/11/2014 15:20:32,,1320777347,7/11/2014 15:20:16,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,142,165,,,151,199,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"DYSPLASIA,",142,165-174-190,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV.",142,165 174 190,142,165,151,199,1,RO-disease_has_finding,901750,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV",dysplasia,cervical intraepithelial neoplasia
502252393,7/11/2014 15:22:38,,1320778730,7/11/2014 15:22:23,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,142,165,,,151,199,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"DYSPLASIA,",142,165-174-190,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV.",142,165 174 190,142,165,151,199,1,RO-disease_has_finding,901750,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV",dysplasia,cervical intraepithelial neoplasia
502252393,7/11/2014 15:42:15,,1320786233,7/11/2014 15:41:57,bitcoinget,1.0,24792414,USA,"","",166.181.81.197,142,165,,,151,199,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"DYSPLASIA,",142,165-174-190,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV.",142,165 174 190,142,165,151,199,1,RO-disease_has_finding,901750,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV",dysplasia,cervical intraepithelial neoplasia
502252393,7/11/2014 15:47:39,,1320788046,7/11/2014 15:47:18,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,142,165,,,151,199,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"DYSPLASIA,",142,165-174-190,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV.",142,165 174 190,142,165,151,199,1,RO-disease_has_finding,901750,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV",dysplasia,cervical intraepithelial neoplasia
502252393,7/11/2014 15:48:57,,1320788660,7/11/2014 15:48:46,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,142,165,,,151,199,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"DYSPLASIA,",142,165-174-190,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV.",142,165 174 190,142,165,151,199,1,RO-disease_has_finding,901750,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV",dysplasia,cervical intraepithelial neoplasia
502252393,7/11/2014 15:49:32,,1320789106,7/11/2014 15:49:14,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,142,165,,,151,199,DYSPLASIA,CERVICAL INTRAEPITHELIAL NEOPLASIA,"DYSPLASIA,",142,165-174-190,CERVICAL INTRAEPITHELIAL NEOPLASIA,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV.",142,165 174 190,142,165,151,199,1,RO-disease_has_finding,901750,"Over the past 25 years, new understanding of the natural history of cervical epithelial neoplasia has defined the existence and importance of dysplasia, also termed cervical intraepithelial neoplasia (CIN), and more recently, its probable link to human papilloma virus (HPV",dysplasia,cervical intraepithelial neoplasia
502252394,7/11/2014 15:11:55,,1320773436,7/11/2014 15:11:43,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,109,119,,,115,133,SUBSET,BREAST CANCERS,SUBSET,109,107-119-126,"a BREAST CANCERS,","Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear.",109,119 126,109,119,115,133,-1,RO-has_manifestation,906171,"Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear",subset,breast cancers
502252394,7/11/2014 15:13:13,,1320773914,7/11/2014 15:12:57,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,109,119,,,115,133,SUBSET,BREAST CANCERS,"SUBSET of breast cancers,",109-116-119-126,109-116-119-126,"subset of BREAST CANCERS,","Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear.",109,119 126,109,119,115,133,-1,RO-has_manifestation,906171,"Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear",subset,breast cancers
502252394,7/11/2014 15:14:14,,1320774417,7/11/2014 15:14:00,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,109,119,,,115,133,SUBSET,BREAST CANCERS,SUBSET,109,119-126,"BREAST CANCERS,","Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear.",109,119 126,109,119,115,133,-1,RO-has_manifestation,906171,"Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear",subset,breast cancers
502252394,7/11/2014 15:16:00,,1320775224,7/11/2014 15:15:57,instagc,1.0,27753923,GBR,"","",188.29.78.53,109,119,,,115,133,SUBSET,BREAST CANCERS,"development of a SUBSET of breast cancers,",92-104-107-109-116-119-126,107-109-116-119-126-135-144-148,"a subset of BREAST CANCERS, although the major","Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear.",109,119 126,109,119,115,133,-1,RO-has_manifestation,906171,"Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear",subset,breast cancers
502252394,7/11/2014 15:17:19,,1320775644,7/11/2014 15:17:13,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,109,119,,,115,133,SUBSET,BREAST CANCERS,"development of a SUBSET of breast cancers,",92-104-107-109-116-119-126,107-109-116-119-126-135-144-148,"a subset of BREAST CANCERS, although the major","Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear.",109,119 126,109,119,115,133,-1,RO-has_manifestation,906171,"Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear",subset,breast cancers
502252394,7/11/2014 15:23:05,,1320779016,7/11/2014 15:22:54,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,109,119,,,115,133,SUBSET,BREAST CANCERS,SUBSET,109,119-126,"BREAST CANCERS,","Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear.",109,119 126,109,119,115,133,-1,RO-has_manifestation,906171,"Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear",subset,breast cancers
502252394,7/11/2014 15:25:10,,1320779843,7/11/2014 15:24:57,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,109,119,,,115,133,SUBSET,BREAST CANCERS,SUBSET,109,119-126,"BREAST CANCERS,","Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear.",109,119 126,109,119,115,133,-1,RO-has_manifestation,906171,"Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear",subset,breast cancers
502252394,7/11/2014 15:29:16,,1320781270,7/11/2014 15:28:43,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,109,119,,,115,133,SUBSET,BREAST CANCERS,"SUBSET of breast cancers,",109-119-126-116,109-116-119-126,"subset of BREAST CANCERS,","Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear.",109,119 126,109,119,115,133,-1,RO-has_manifestation,906171,"Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear",subset,breast cancers
502252394,7/11/2014 15:36:54,,1320784642,7/11/2014 15:36:06,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,109,119,,,115,133,SUBSET,BREAST CANCERS,"development of a SUBSET of breast cancers,",92-104-107-109-116-119-126,92-107-109-116-119-126-104,"development of a subset of BREAST CANCERS,","Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear.",109,119 126,109,119,115,133,-1,RO-has_manifestation,906171,"Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear",subset,breast cancers
502252394,7/11/2014 15:40:31,,1320785775,7/11/2014 15:40:08,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,109,119,,,115,133,SUBSET,BREAST CANCERS,SUBSET,109,119-126,"BREAST CANCERS,","Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear.",109,119 126,109,119,115,133,-1,RO-has_manifestation,906171,"Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a subset of breast cancers, although the major tumor suppressor function of this gene remains unclear",subset,breast cancers
502252395,7/11/2014 15:12:55,,1320773810,7/11/2014 15:12:38,instagc,1.0,13763729,USA,"","",75.182.89.225,90,0,,,98,16,HEADACHE,CLUSTER HEADACHE,HEADACHE,90,0-8,CLUSTER HEADACHE,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating.",90,0 8,90,0,98,16,-1,RO-has_definitional_manifestation,904987,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating",headache,Cluster headache
502252395,7/11/2014 15:13:31,,1320774067,7/11/2014 15:13:14,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,90,0,,,98,16,HEADACHE,CLUSTER HEADACHE,individual HEADACHE attacks,79-90-99,0-8,CLUSTER HEADACHE,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating.",90,0 8,90,0,98,16,-1,RO-has_definitional_manifestation,904987,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating",headache,Cluster headache
502252395,7/11/2014 15:14:51,,1320774760,7/11/2014 15:14:48,instagc,1.0,27753923,GBR,"","",188.29.78.53,90,0,,,98,16,HEADACHE,CLUSTER HEADACHE,as the individual HEADACHE attacks that are,72-75-79-90-99-107-112,0-8-17-23-26,CLUSTER HEADACHE needs to be,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating.",90,0 8,90,0,98,16,-1,RO-has_definitional_manifestation,904987,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating",headache,Cluster headache
502252395,7/11/2014 15:17:25,,1320775678,7/11/2014 15:17:21,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,90,0,,,98,16,HEADACHE,CLUSTER HEADACHE,as the individual HEADACHE attacks that are,72-75-79-90-99-107-112,0-8-17-23-26,CLUSTER HEADACHE needs to be,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating.",90,0 8,90,0,98,16,-1,RO-has_definitional_manifestation,904987,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating",headache,Cluster headache
502252395,7/11/2014 15:19:27,,1320776761,7/11/2014 15:19:15,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,90,0,,,98,16,HEADACHE,CLUSTER HEADACHE,HEADACHE,90,0-8,CLUSTER HEADACHE,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating.",90,0 8,90,0,98,16,-1,RO-has_definitional_manifestation,904987,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating",headache,Cluster headache
502252395,7/11/2014 15:22:53,,1320778877,7/11/2014 15:22:39,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,90,0,,,98,16,HEADACHE,CLUSTER HEADACHE,HEADACHE attacks,90-99,0-8,CLUSTER HEADACHE,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating.",90,0 8,90,0,98,16,-1,RO-has_definitional_manifestation,904987,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating",headache,Cluster headache
502252395,7/11/2014 15:30:48,,1320781853,7/11/2014 15:30:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,90,0,,,98,16,HEADACHE,CLUSTER HEADACHE,individual HEADACHE attacks,79-90-99,0-8,CLUSTER HEADACHE,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating.",90,0 8,90,0,98,16,-1,RO-has_definitional_manifestation,904987,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating",headache,Cluster headache
502252395,7/11/2014 15:35:15,,1320783923,7/11/2014 15:35:01,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,90,0,,,98,16,HEADACHE,CLUSTER HEADACHE,HEADACHE,90,0-8,CLUSTER HEADACHE,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating.",90,0 8,90,0,98,16,-1,RO-has_definitional_manifestation,904987,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating",headache,Cluster headache
502252395,7/11/2014 15:40:49,,1320785864,7/11/2014 15:40:20,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,90,0,,,98,16,HEADACHE,CLUSTER HEADACHE,HEADACHE attacks,90-99,0-8,CLUSTER HEADACHE,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating.",90,0 8,90,0,98,16,-1,RO-has_definitional_manifestation,904987,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating",headache,Cluster headache
502252395,7/11/2014 15:47:05,,1320787845,7/11/2014 15:46:48,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,90,0,,,98,16,HEADACHE,CLUSTER HEADACHE,HEADACHE,90,0-8,CLUSTER HEADACHE,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating.",90,0 8,90,0,98,16,-1,RO-has_definitional_manifestation,904987,"Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating",headache,Cluster headache
502252396,7/11/2014 15:14:49,,1320774747,7/11/2014 15:14:27,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,78,45,,,85,69,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES,78,45-60-32,superimposed HEPATOCELLULAR CARCINOMA,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately.,78,45 60,78,45,85,69,-1,RO-disease_may_have_finding,902881,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately,ascites,hepatocellular carcinoma
502252396,7/11/2014 15:20:27,,1320777302,7/11/2014 15:20:16,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,78,45,,,85,69,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES,78,45-60,HEPATOCELLULAR CARCINOMA,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately.,78,45 60,78,45,85,69,-1,RO-disease_may_have_finding,902881,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately,ascites,hepatocellular carcinoma
502252396,7/11/2014 15:20:36,,1320777386,7/11/2014 15:20:19,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,78,45,,,85,69,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES,78,32-45-60,superimposed HEPATOCELLULAR CARCINOMA,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately.,78,45 60,78,45,85,69,-1,RO-disease_may_have_finding,902881,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately,ascites,hepatocellular carcinoma
502252396,7/11/2014 15:23:43,,1320779341,7/11/2014 15:23:28,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,78,45,,,85,69,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES,78,45-60,HEPATOCELLULAR CARCINOMA,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately.,78,45 60,78,45,85,69,-1,RO-disease_may_have_finding,902881,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately,ascites,hepatocellular carcinoma
502252396,7/11/2014 15:25:17,,1320779867,7/11/2014 15:24:58,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,78,45,,,85,69,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES,78,45-60,HEPATOCELLULAR CARCINOMA,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately.,78,45 60,78,45,85,69,-1,RO-disease_may_have_finding,902881,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately,ascites,hepatocellular carcinoma
502252396,7/11/2014 15:32:14,,1320782340,7/11/2014 15:32:11,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,78,45,,,85,69,ASCITES,HEPATOCELLULAR CARCINOMA,carcinoma in whom ASCITES was of uncertain,60-70-73-78-86-90-93,18-27-32-45-60-70-73-78,patients with superimposed HEPATOCELLULAR CARCINOMA in whom ascites,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately.,78,45 60,78,45,85,69,-1,RO-disease_may_have_finding,902881,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately,ascites,hepatocellular carcinoma
502252396,7/11/2014 15:39:07,,1320785286,7/11/2014 15:38:48,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,78,45,,,85,69,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES,78,32-45-60,superimposed HEPATOCELLULAR CARCINOMA,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately.,78,45 60,78,45,85,69,-1,RO-disease_may_have_finding,902881,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately,ascites,hepatocellular carcinoma
502252396,7/11/2014 15:48:23,,1320788394,7/11/2014 15:48:05,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,78,45,,,85,69,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES,78,32-45-60,superimposed HEPATOCELLULAR CARCINOMA,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately.,78,45 60,78,45,85,69,-1,RO-disease_may_have_finding,902881,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately,ascites,hepatocellular carcinoma
502252396,7/11/2014 15:51:24,,1320790381,7/11/2014 15:51:06,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,78,45,,,85,69,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES,78,45-60,HEPATOCELLULAR CARCINOMA,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately.,78,45 60,78,45,85,69,-1,RO-disease_may_have_finding,902881,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately,ascites,hepatocellular carcinoma
502252396,7/11/2014 15:52:12,,1320791005,7/11/2014 15:51:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,78,45,,,85,69,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES,78,32-45-60,superimposed HEPATOCELLULAR CARCINOMA,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately.,78,45 60,78,45,85,69,-1,RO-disease_may_have_finding,902881,Sixteen cirrhotic patients with superimposed hepatocellular carcinoma in whom ascites was of uncertain etiology were considered separately,ascites,hepatocellular carcinoma
502252397,7/11/2014 15:16:10,,1320775313,7/11/2014 15:15:57,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,47,98,,,59,114,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,47,98,PHEOCHROMOCYTOMA,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29.",47,98,47,98,59,114,-1,RO-disease_may_have_finding,902985,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29",hypertension,pheochromocytoma
502252397,7/11/2014 15:16:39,,1320775445,7/11/2014 15:16:33,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,47,98,,,59,114,HYPERTENSION,PHEOCHROMOCYTOMA,"expert review, postoperative HYPERTENSION occurs in up",18-25-33-47-60-67-70,80-83-92-98-115-127,of patients after PHEOCHROMOCYTOMA resection 29.,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29.",47,98,47,98,59,114,-1,RO-disease_may_have_finding,902985,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29",hypertension,pheochromocytoma
502252397,7/11/2014 15:19:58,,1320776994,7/11/2014 15:19:45,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,47,98,,,59,114,HYPERTENSION,PHEOCHROMOCYTOMA,postoperative HYPERTENSION,33-47,98-115,PHEOCHROMOCYTOMA resection,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29.",47,98,47,98,59,114,-1,RO-disease_may_have_finding,902985,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29",hypertension,pheochromocytoma
502252397,7/11/2014 15:20:34,,1320777356,7/11/2014 15:20:19,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,47,98,,,59,114,HYPERTENSION,PHEOCHROMOCYTOMA,postoperative HYPERTENSION,33-47,98,PHEOCHROMOCYTOMA,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29.",47,98,47,98,59,114,-1,RO-disease_may_have_finding,902985,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29",hypertension,pheochromocytoma
502252397,7/11/2014 15:31:20,,1320781990,7/11/2014 15:30:49,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,47,98,,,59,114,HYPERTENSION,PHEOCHROMOCYTOMA,postoperative HYPERTENSION,33-47,92-98-115,after PHEOCHROMOCYTOMA resection,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29.",47,98,47,98,59,114,-1,RO-disease_may_have_finding,902985,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29",hypertension,pheochromocytoma
502252397,7/11/2014 15:31:54,,1320782218,7/11/2014 15:31:41,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,47,98,,,59,114,HYPERTENSION,PHEOCHROMOCYTOMA,postoperative HYPERTENSION,33-47,98-115,PHEOCHROMOCYTOMA resection,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29.",47,98,47,98,59,114,-1,RO-disease_may_have_finding,902985,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29",hypertension,pheochromocytoma
502252397,7/11/2014 15:42:57,,1320786448,7/11/2014 15:42:43,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,47,98,,,59,114,HYPERTENSION,PHEOCHROMOCYTOMA,postoperative HYPERTENSION,33-47,98-115,PHEOCHROMOCYTOMA resection,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29.",47,98,47,98,59,114,-1,RO-disease_may_have_finding,902985,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29",hypertension,pheochromocytoma
502252397,7/11/2014 15:45:22,,1320787246,7/11/2014 15:44:17,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,47,98,,,59,114,HYPERTENSION,PHEOCHROMOCYTOMA,postoperative HYPERTENSION,33-47,98-115,PHEOCHROMOCYTOMA resection,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29.",47,98,47,98,59,114,-1,RO-disease_may_have_finding,902985,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29",hypertension,pheochromocytoma
502252397,7/11/2014 15:46:35,,1320787656,7/11/2014 15:46:17,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,47,98,,,59,114,HYPERTENSION,PHEOCHROMOCYTOMA,postoperative HYPERTENSION,33-47,98-115,PHEOCHROMOCYTOMA resection,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29.",47,98,47,98,59,114,-1,RO-disease_may_have_finding,902985,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29",hypertension,pheochromocytoma
502252397,7/11/2014 15:47:17,,1320787911,7/11/2014 15:47:02,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,47,98,,,59,114,HYPERTENSION,PHEOCHROMOCYTOMA,postoperative HYPERTENSION,47-33,98-115,PHEOCHROMOCYTOMA resection,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29.",47,98,47,98,59,114,-1,RO-disease_may_have_finding,902985,"? According to an expert review, postoperative hypertension occurs in up to 50% of patients after pheochromocytoma resection ( 29",hypertension,pheochromocytoma
502252398,7/11/2014 15:14:10,,1320774363,7/11/2014 15:13:57,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,118,34,,,134,52,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY,118,34-43,ALLERGIC REACTIONS,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis.,118,34 43,118,34,134,52,-1,RO-cause_of,900040,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis,hypersensitivity,allergic reactions
502252398,7/11/2014 15:15:31,,1320775007,7/11/2014 15:15:25,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,118,34,,,134,52,HYPERSENSITIVITY,ALLERGIC REACTIONS,local reaction of HYPERSENSITIVITY of the slow,100-106-115-118-135-138-142,17-25-31-34-43-53-56-61,various kinds of ALLERGIC REACTIONS of both the,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis.,118,34 43,118,34,134,52,-1,RO-cause_of,900040,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis,hypersensitivity,allergic reactions
502252398,7/11/2014 15:20:02,,1320777032,7/11/2014 15:19:40,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,118,34,,,134,52,HYPERSENSITIVITY,ALLERGIC REACTIONS,of HYPERSENSITIVITY,115-118,34-43,ALLERGIC REACTIONS,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis.,118,34 43,118,34,134,52,-1,RO-cause_of,900040,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis,hypersensitivity,allergic reactions
502252398,7/11/2014 15:20:41,,1320777443,7/11/2014 15:20:29,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,118,34,,,134,52,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY,118,34-43,ALLERGIC REACTIONS,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis.,118,34 43,118,34,134,52,-1,RO-cause_of,900040,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis,hypersensitivity,allergic reactions
502252398,7/11/2014 15:31:48,,1320782200,7/11/2014 15:31:45,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,118,34,,,134,52,HYPERSENSITIVITY,ALLERGIC REACTIONS,local reaction of HYPERSENSITIVITY of the slow,100-106-115-118-135-138-142,17-25-31-34-43-53-56-61,various kinds of ALLERGIC REACTIONS of both the,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis.,118,34 43,118,34,134,52,-1,RO-cause_of,900040,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis,hypersensitivity,allergic reactions
502252398,7/11/2014 15:42:35,,1320786321,7/11/2014 15:42:08,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,118,34,,,134,52,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY,118,34-43,ALLERGIC REACTIONS,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis.,118,34 43,118,34,134,52,-1,RO-cause_of,900040,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis,hypersensitivity,allergic reactions
502252398,7/11/2014 15:45:49,,1320787386,7/11/2014 15:45:25,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,118,34,,,134,52,HYPERSENSITIVITY,ALLERGIC REACTIONS,local reaction of HYPERSENSITIVITY of the slow type,100-106-115-118-135-138-142-147,34-43,ALLERGIC REACTIONS,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis.,118,34 43,118,34,134,52,-1,RO-cause_of,900040,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis,hypersensitivity,allergic reactions
502252398,7/11/2014 15:47:51,,1320788176,7/11/2014 15:47:39,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,118,34,,,134,52,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY,118,34-43,ALLERGIC REACTIONS,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis.,118,34 43,118,34,134,52,-1,RO-cause_of,900040,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis,hypersensitivity,allergic reactions
502252398,7/11/2014 15:51:05,,1320790141,7/11/2014 15:50:46,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,118,34,,,134,52,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY,118,34-43,ALLERGIC REACTIONS,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis.,118,34 43,118,34,134,52,-1,RO-cause_of,900040,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis,hypersensitivity,allergic reactions
502252398,7/11/2014 15:53:06,,1320791690,7/11/2014 15:52:51,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,118,34,,,134,52,HYPERSENSITIVITY,ALLERGIC REACTIONS,HYPERSENSITIVITY,118,34-43,ALLERGIC REACTIONS,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis.,118,34 43,118,34,134,52,-1,RO-cause_of,900040,A combination of various kinds of allergic reactions of both the specific immediate type and of the local reaction of hypersensitivity of the slow type plays its role in the development of acute appendicitis,hypersensitivity,allergic reactions
502252399,7/11/2014 15:12:19,,1320773588,7/11/2014 15:12:09,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,166,84,,,173,102,ALLERGY,ALLERGIC REACTIONS,ALLERGY.,166,84-93,ALLERGIC REACTIONS,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy.",166,84 93,166,84,173,102,-1,RO-cause_of,900178,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy",allergy,allergic reactions
502252399,7/11/2014 15:15:57,,1320775203,7/11/2014 15:15:40,instagc,1.0,13763729,USA,"","",75.182.89.225,166,84,,,173,102,ALLERGY,ALLERGIC REACTIONS,ALLERGY.,166,84-93,ALLERGIC REACTIONS,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy.",166,84 93,166,84,173,102,-1,RO-cause_of,900178,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy",allergy,allergic reactions
502252399,7/11/2014 15:17:14,,1320775620,7/11/2014 15:16:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,166,84,,,173,102,ALLERGY,ALLERGIC REACTIONS,(iodine and tropomyosine ALLERGY.,141-149-153-166,84-93,ALLERGIC REACTIONS,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy.",166,84 93,166,84,173,102,-1,RO-cause_of,900178,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy",allergy,allergic reactions
502252399,7/11/2014 15:17:49,,1320775891,7/11/2014 15:17:45,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,166,84,,,173,102,ALLERGY,ALLERGIC REACTIONS,(iodine and tropomyosine ALLERGY.,141-149-153-166,60-64-74-84-93-103-110-113,"was reviewed, moreover, ALLERGIC REACTIONS caused by iodine","Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy.",166,84 93,166,84,173,102,-1,RO-cause_of,900178,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy",allergy,allergic reactions
502252399,7/11/2014 15:21:17,,1320777784,7/11/2014 15:21:00,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,166,84,,,173,102,ALLERGY,ALLERGIC REACTIONS,(iodine and tropomyosine ALLERGY.,141-153-166-149,84-93,ALLERGIC REACTIONS,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy.",166,84 93,166,84,173,102,-1,RO-cause_of,900178,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy",allergy,allergic reactions
502252399,7/11/2014 15:32:23,,1320782373,7/11/2014 15:32:20,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,166,84,,,173,102,ALLERGY,ALLERGIC REACTIONS,(iodine and tropomyosine ALLERGY.,141-149-153-166,60-64-74-84-93-103-110-113,"was reviewed, moreover, ALLERGIC REACTIONS caused by iodine","Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy.",166,84 93,166,84,173,102,-1,RO-cause_of,900178,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy",allergy,allergic reactions
502252399,7/11/2014 15:41:45,,1320786154,7/11/2014 15:41:26,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,166,84,,,173,102,ALLERGY,ALLERGIC REACTIONS,ALLERGY.,166,84-93,ALLERGIC REACTIONS,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy.",166,84 93,166,84,173,102,-1,RO-cause_of,900178,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy",allergy,allergic reactions
502252399,7/11/2014 15:46:34,,1320787646,7/11/2014 15:46:05,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,166,84,,,173,102,ALLERGY,ALLERGIC REACTIONS,tropomyosine ALLERGY.,153-166,84-93,ALLERGIC REACTIONS,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy.",166,84 93,166,84,173,102,-1,RO-cause_of,900178,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy",allergy,allergic reactions
502252399,7/11/2014 15:49:28,,1320789023,7/11/2014 15:48:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,166,84,,,173,102,ALLERGY,ALLERGIC REACTIONS,(iodine and tropomyosine ALLERGY.,141-153-166-149,84-93,ALLERGIC REACTIONS,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy.",166,84 93,166,84,173,102,-1,RO-cause_of,900178,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy",allergy,allergic reactions
502252399,7/11/2014 15:49:57,,1320789354,7/11/2014 15:49:36,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,166,84,,,173,102,ALLERGY,ALLERGIC REACTIONS,iodine containing chemicals (iodine and tropomyosine ALLERGY.,113-120-141-149-153-166-131,84-93,ALLERGIC REACTIONS,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy.",166,84 93,166,84,173,102,-1,RO-cause_of,900178,"Physiological role and occurrence of iodine in the organism was reviewed, moreover, allergic reactions caused by iodine-containing chemicals (iodine and tropomyosine allergy",allergy,allergic reactions
502252400,7/11/2014 15:16:11,,1320775316,7/11/2014 15:16:06,instagc,1.0,27753923,GBR,"","",188.29.78.53,73,96,,,81,120,JAUNDICE,HEPATOCELLULAR CARCINOMA,"liver cirrhosis, ascites, JAUNDICE and a primary",47-53-64-73-82-86-88,82-86-88-96-111-121-124,and a primary HEPATOCELLULAR CARCINOMA is presented.,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented.",73,96 111,73,96,81,120,-1,RO-disease_may_have_finding,902725,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented",jaundice,hepatocellular carcinoma
502252400,7/11/2014 15:18:40,,1320776350,7/11/2014 15:18:04,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,73,96,,,81,120,JAUNDICE,HEPATOCELLULAR CARCINOMA,"liver cirrhosis, ascites, JAUNDICE and a primary",47-53-64-73-82-86-88,82-86-88-96-111-121-124,and a primary HEPATOCELLULAR CARCINOMA is presented.,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented.",73,96 111,73,96,81,120,-1,RO-disease_may_have_finding,902725,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented",jaundice,hepatocellular carcinoma
502252400,7/11/2014 15:19:44,,1320776893,7/11/2014 15:19:28,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,73,96,,,81,120,JAUNDICE,HEPATOCELLULAR CARCINOMA,JAUNDICE,73,88-96-111,primary HEPATOCELLULAR CARCINOMA,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented.",73,96 111,73,96,81,120,-1,RO-disease_may_have_finding,902725,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented",jaundice,hepatocellular carcinoma
502252400,7/11/2014 15:27:05,,1320780504,7/11/2014 15:26:44,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,73,96,,,81,120,JAUNDICE,HEPATOCELLULAR CARCINOMA,JAUNDICE,73,96-111,HEPATOCELLULAR CARCINOMA,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented.",73,96 111,73,96,81,120,-1,RO-disease_may_have_finding,902725,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented",jaundice,hepatocellular carcinoma
502252400,7/11/2014 15:32:28,,1320782404,7/11/2014 15:32:24,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,73,96,,,81,120,JAUNDICE,HEPATOCELLULAR CARCINOMA,"liver cirrhosis, ascites, JAUNDICE and a primary",47-53-64-73-82-86-88,82-86-88-96-111-121-124,and a primary HEPATOCELLULAR CARCINOMA is presented.,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented.",73,96 111,73,96,81,120,-1,RO-disease_may_have_finding,902725,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented",jaundice,hepatocellular carcinoma
502252400,7/11/2014 15:38:48,,1320785184,7/11/2014 15:38:30,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,73,96,,,81,120,JAUNDICE,HEPATOCELLULAR CARCINOMA,JAUNDICE,73,88-96-111,primary HEPATOCELLULAR CARCINOMA,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented.",73,96 111,73,96,81,120,-1,RO-disease_may_have_finding,902725,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented",jaundice,hepatocellular carcinoma
502252400,7/11/2014 15:48:04,,1320788271,7/11/2014 15:47:35,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,73,96,,,81,120,JAUNDICE,HEPATOCELLULAR CARCINOMA,JAUNDICE,73,88-96-111,primary HEPATOCELLULAR CARCINOMA,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented.",73,96 111,73,96,81,120,-1,RO-disease_may_have_finding,902725,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented",jaundice,hepatocellular carcinoma
502252400,7/11/2014 15:50:49,,1320790002,7/11/2014 15:50:23,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,73,96,,,81,120,JAUNDICE,HEPATOCELLULAR CARCINOMA,JAUNDICE,73,88-96-111,primary HEPATOCELLULAR CARCINOMA,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented.",73,96 111,73,96,81,120,-1,RO-disease_may_have_finding,902725,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented",jaundice,hepatocellular carcinoma
502252400,7/11/2014 15:51:47,,1320790691,7/11/2014 15:51:26,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,73,96,,,81,120,JAUNDICE,HEPATOCELLULAR CARCINOMA,JAUNDICE,73,88-96-111,primary HEPATOCELLULAR CARCINOMA,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented.",73,96 111,73,96,81,120,-1,RO-disease_may_have_finding,902725,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented",jaundice,hepatocellular carcinoma
502252400,7/11/2014 15:52:11,,1320790993,7/11/2014 15:51:54,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,73,96,,,81,120,JAUNDICE,HEPATOCELLULAR CARCINOMA,JAUNDICE,73,88-96-111,primary HEPATOCELLULAR CARCINOMA,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented.",73,96 111,73,96,81,120,-1,RO-disease_may_have_finding,902725,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, jaundice and a primary hepatocellular carcinoma is presented",jaundice,hepatocellular carcinoma
502252401,7/11/2014 15:11:43,,1320773355,7/11/2014 15:11:32,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,68,0,,,74,12,ANEMIA,EPOETIN ALFA,ANEMIA,68,0-8,EPOETIN ALFA,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy.",68,0 8,68,0,74,12,1,RO-may_treat,908038,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy",anemia,Epoetin alfa
502252401,7/11/2014 15:13:57,,1320774242,7/11/2014 15:13:47,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,68,0,,,74,12,ANEMIA,EPOETIN ALFA,ANEMIA,68,0-8,EPOETIN ALFA,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy.",68,0 8,68,0,74,12,1,RO-may_treat,908038,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy",anemia,Epoetin alfa
502252401,7/11/2014 15:17:00,,1320775569,7/11/2014 15:16:55,instagc,1.0,27753923,GBR,"","",188.29.78.53,68,0,,,74,12,ANEMIA,EPOETIN ALFA,the management of ANEMIA in patients with,50-54-65-68-75-78-87,0-8-13-17-28,"EPOETIN ALFA is, therefore, effective","Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy.",68,0 8,68,0,74,12,1,RO-may_treat,908038,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy",anemia,Epoetin alfa
502252401,7/11/2014 15:17:12,,1320775599,7/11/2014 15:16:57,instagc,1.0,13763729,USA,"","",75.182.89.225,68,0,,,74,12,ANEMIA,EPOETIN ALFA,ANEMIA,68,0-8,EPOETIN ALFA,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy.",68,0 8,68,0,74,12,1,RO-may_treat,908038,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy",anemia,Epoetin alfa
502252401,7/11/2014 15:28:14,,1320780876,7/11/2014 15:28:00,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,68,0,,,74,12,ANEMIA,EPOETIN ALFA,ANEMIA,68,0-8,EPOETIN ALFA,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy.",68,0 8,68,0,74,12,1,RO-may_treat,908038,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy",anemia,Epoetin alfa
502252401,7/11/2014 15:35:10,,1320783843,7/11/2014 15:34:48,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,68,0,,,74,12,ANEMIA,EPOETIN ALFA,ANEMIA,68,0-8,EPOETIN ALFA,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy.",68,0 8,68,0,74,12,1,RO-may_treat,908038,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy",anemia,Epoetin alfa
502252401,7/11/2014 15:36:05,,1320784313,7/11/2014 15:35:27,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,68,0,,,74,12,ANEMIA,EPOETIN ALFA,the management of ANEMIA,50-54-65-68,0-8,EPOETIN ALFA,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy.",68,0 8,68,0,74,12,1,RO-may_treat,908038,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy",anemia,Epoetin alfa
502252401,7/11/2014 15:45:25,,1320787275,7/11/2014 15:45:11,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,68,0,,,74,12,ANEMIA,EPOETIN ALFA,ANEMIA,68,0-8,EPOETIN ALFA,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy.",68,0 8,68,0,74,12,1,RO-may_treat,908038,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy",anemia,Epoetin alfa
502252401,7/11/2014 15:45:35,,1320787319,7/11/2014 15:45:23,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,68,0,,,74,12,ANEMIA,EPOETIN ALFA,ANEMIA,68,0-8,EPOETIN ALFA,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy.",68,0 8,68,0,74,12,1,RO-may_treat,908038,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy",anemia,Epoetin alfa
502252401,7/11/2014 15:50:18,,1320789586,7/11/2014 15:50:07,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,68,0,,,74,12,ANEMIA,EPOETIN ALFA,ANEMIA,68,0-8,EPOETIN ALFA,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy.",68,0 8,68,0,74,12,1,RO-may_treat,908038,"Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy",anemia,Epoetin alfa
502252402,7/11/2014 15:13:57,,1320774245,7/11/2014 15:13:46,instagc,1.0,13763729,USA,"","",75.182.89.225,89,0,,,96,25,OVARIES,EPITHELIAL OVARIAN CANCER,OVARIES,89,0-11-19,EPITHELIAL OVARIAN CANCER,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p.,89,0 11 19,89,0,96,25,1,RO-disease_has_primary_anatomic_site,902339,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p,ovaries,Epithelial ovarian cancer
502252402,7/11/2014 15:15:31,,1320775010,7/11/2014 15:15:23,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,89,0,,,96,25,OVARIES,EPITHELIAL OVARIAN CANCER,OVARIES,89,0-11-19,EPITHELIAL OVARIAN CANCER,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p.,89,0 11 19,89,0,96,25,1,RO-disease_has_primary_anatomic_site,902339,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p,ovaries,Epithelial ovarian cancer
502252402,7/11/2014 15:16:17,,1320775334,7/11/2014 15:16:12,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,89,0,,,96,25,OVARIES,EPITHELIAL OVARIAN CANCER,the surface of OVARIES and i.p.,74-78-86-89-97-101,0-11-19-32-39,EPITHELIAL OVARIAN CANCER arises from,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p.,89,0 11 19,89,0,96,25,1,RO-disease_has_primary_anatomic_site,902339,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p,ovaries,Epithelial ovarian cancer
502252402,7/11/2014 15:16:32,,1320775412,7/11/2014 15:16:28,instagc,1.0,27753923,GBR,"","",188.29.78.53,89,0,,,96,25,OVARIES,EPITHELIAL OVARIAN CANCER,the surface of OVARIES and i.p.,74-78-86-89-97-101,0-11-19-32-39,EPITHELIAL OVARIAN CANCER arises from,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p.,89,0 11 19,89,0,96,25,1,RO-disease_has_primary_anatomic_site,902339,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p,ovaries,Epithelial ovarian cancer
502252402,7/11/2014 15:17:38,,1320775776,7/11/2014 15:17:24,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,89,0,,,96,25,OVARIES,EPITHELIAL OVARIAN CANCER,surface of OVARIES,78-86-89,0-11-19-26,EPITHELIAL OVARIAN CANCER (EOC),Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p.,89,0 11 19,89,0,96,25,1,RO-disease_has_primary_anatomic_site,902339,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p,ovaries,Epithelial ovarian cancer
502252402,7/11/2014 15:18:58,,1320776498,7/11/2014 15:18:47,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,89,0,,,96,25,OVARIES,EPITHELIAL OVARIAN CANCER,OVARIES,89,0-11-19,EPITHELIAL OVARIAN CANCER,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p.,89,0 11 19,89,0,96,25,1,RO-disease_has_primary_anatomic_site,902339,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p,ovaries,Epithelial ovarian cancer
502252402,7/11/2014 15:20:27,,1320777291,7/11/2014 15:20:12,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,89,0,,,96,25,OVARIES,EPITHELIAL OVARIAN CANCER,OVARIES,89,0-11-19-26,EPITHELIAL OVARIAN CANCER (EOC),Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p.,89,0 11 19,89,0,96,25,1,RO-disease_has_primary_anatomic_site,902339,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p,ovaries,Epithelial ovarian cancer
502252402,7/11/2014 15:21:15,,1320777766,7/11/2014 15:21:00,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,89,0,,,96,25,OVARIES,EPITHELIAL OVARIAN CANCER,OVARIES,89,0-11-19-26,EPITHELIAL OVARIAN CANCER (EOC),Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p.,89,0 11 19,89,0,96,25,1,RO-disease_has_primary_anatomic_site,902339,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p,ovaries,Epithelial ovarian cancer
502252402,7/11/2014 15:29:44,,1320781494,7/11/2014 15:29:36,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,89,0,,,96,25,OVARIES,EPITHELIAL OVARIAN CANCER,OVARIES,89,0-11-19,EPITHELIAL OVARIAN CANCER,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p.,89,0 11 19,89,0,96,25,1,RO-disease_has_primary_anatomic_site,902339,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p,ovaries,Epithelial ovarian cancer
502252402,7/11/2014 15:30:23,,1320781727,7/11/2014 15:30:19,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,89,0,,,96,25,OVARIES,EPITHELIAL OVARIAN CANCER,the surface of OVARIES and i.p.,74-78-86-89-97-101,0-11-19-32-39,EPITHELIAL OVARIAN CANCER arises from,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p.,89,0 11 19,89,0,96,25,1,RO-disease_has_primary_anatomic_site,902339,Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p,ovaries,Epithelial ovarian cancer
502252403,7/11/2014 15:16:21,,1320775342,7/11/2014 15:16:12,instagc,1.0,27753923,GBR,"","",188.29.78.53,119,191,,,139,200,MAGNESIUM DEFICIENCY,MAGNESIUM,load test suggest MAGNESIUM DEFICIENCY in post menoposal,101-106-111-119-129-140-143-148,172-181-188-191-201,probably caused by MAGNESIUM malabsorption.,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption.",119 129,191,119,191,139,200,1,RO-may_prevent,907364,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption",magnesium deficiency,magnesium
502252403,7/11/2014 15:18:04,,1320776039,7/11/2014 15:17:55,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,119,191,,,139,200,MAGNESIUM DEFICIENCY,MAGNESIUM,MAGNESIUM DEFICIENCY,119-129,191,MAGNESIUM,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption.",119 129,191,119,191,139,200,1,RO-may_prevent,907364,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption",magnesium deficiency,magnesium
502252403,7/11/2014 15:19:01,,1320776516,7/11/2014 15:18:48,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,119,191,,,139,200,MAGNESIUM DEFICIENCY,MAGNESIUM,MAGNESIUM DEFICIENCY,119-129,191,MAGNESIUM,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption.",119 129,191,119,191,139,200,1,RO-may_prevent,907364,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption",magnesium deficiency,magnesium
502252403,7/11/2014 15:26:11,,1320780200,7/11/2014 15:25:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,119,191,,,139,200,MAGNESIUM DEFICIENCY,MAGNESIUM,"MAGNESIUM DEFICIENCY in post menoposal osteoporosis,",119-129-140-143-148-158,191-201,MAGNESIUM malabsorption.,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption.",119 129,191,119,191,139,200,1,RO-may_prevent,907364,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption",magnesium deficiency,magnesium
502252403,7/11/2014 15:27:46,,1320780700,7/11/2014 15:27:30,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,119,191,,,139,200,MAGNESIUM DEFICIENCY,MAGNESIUM,MAGNESIUM DEFICIENCY,119-129,191-201,MAGNESIUM malabsorption.,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption.",119 129,191,119,191,139,200,1,RO-may_prevent,907364,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption",magnesium deficiency,magnesium
502252403,7/11/2014 15:31:43,,1320782163,7/11/2014 15:31:39,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,119,191,,,139,200,MAGNESIUM DEFICIENCY,MAGNESIUM,load test suggest MAGNESIUM DEFICIENCY in post menoposal,101-106-111-119-129-140-143-148,172-181-188-191-201,probably caused by MAGNESIUM malabsorption.,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption.",119 129,191,119,191,139,200,1,RO-may_prevent,907364,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption",magnesium deficiency,magnesium
502252403,7/11/2014 15:38:28,,1320785093,7/11/2014 15:37:50,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,119,191,,,139,200,MAGNESIUM DEFICIENCY,MAGNESIUM,MAGNESIUM DEFICIENCY,119-129,191,MAGNESIUM,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption.",119 129,191,119,191,139,200,1,RO-may_prevent,907364,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption",magnesium deficiency,magnesium
502252403,7/11/2014 15:46:04,,1320787499,7/11/2014 15:45:36,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,119,191,,,139,200,MAGNESIUM DEFICIENCY,MAGNESIUM,MAGNESIUM DEFICIENCY,119-129,191-201,MAGNESIUM malabsorption.,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption.",119 129,191,119,191,139,200,1,RO-may_prevent,907364,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption",magnesium deficiency,magnesium
502252403,7/11/2014 15:48:12,,1320788354,7/11/2014 15:47:59,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,119,191,,,139,200,MAGNESIUM DEFICIENCY,MAGNESIUM,MAGNESIUM DEFICIENCY,119-129,191-201,MAGNESIUM malabsorption.,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption.",119 129,191,119,191,139,200,1,RO-may_prevent,907364,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption",magnesium deficiency,magnesium
502252403,7/11/2014 15:50:45,,1320789910,7/11/2014 15:50:19,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,119,191,,,139,200,MAGNESIUM DEFICIENCY,MAGNESIUM,MAGNESIUM DEFICIENCY,119-129,191-201,MAGNESIUM malabsorption.,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption.",119 129,191,119,191,139,200,1,RO-may_prevent,907364,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest magnesium deficiency in post-menoposal osteoporosis, probably caused by magnesium malabsorption",magnesium deficiency,magnesium
502252404,7/11/2014 15:12:30,,1320773633,7/11/2014 15:12:07,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,36,0,,,53,6,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,36-45,0-7-19,ATOPIC respiratory diseases,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure.",36 45,0,36,0,53,6,-1,RO-cause_of,900043,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure",allergic rhinitis,Atopic
502252404,7/11/2014 15:13:33,,1320774080,7/11/2014 15:13:11,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,36,0,,,53,6,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,36-45,0,ATOPIC,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure.",36 45,0,36,0,53,6,-1,RO-cause_of,900043,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure",allergic rhinitis,Atopic
502252404,7/11/2014 15:15:33,,1320775021,7/11/2014 15:15:22,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,36,0,,,53,6,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,36-45,0,ATOPIC,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure.",36 45,0,36,0,53,6,-1,RO-cause_of,900043,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure",allergic rhinitis,Atopic
502252404,7/11/2014 15:15:53,,1320775167,7/11/2014 15:15:42,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,36,0,,,53,6,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,36-45,0-7-19,ATOPIC respiratory diseases,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure.",36 45,0,36,0,53,6,-1,RO-cause_of,900043,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure",allergic rhinitis,Atopic
502252404,7/11/2014 15:15:55,,1320775188,7/11/2014 15:15:49,instagc,1.0,27753923,GBR,"","",188.29.78.53,36,0,,,53,6,ALLERGIC RHINITIS,ATOPIC,diseases such as ALLERGIC RHINITIS and asthma represent,19-28-33-36-45-54-58-65,0-7-19-28,ATOPIC respiratory diseases such,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure.",36 45,0,36,0,53,6,-1,RO-cause_of,900043,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure",allergic rhinitis,Atopic
502252404,7/11/2014 15:17:23,,1320775670,7/11/2014 15:17:11,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,36,0,,,53,6,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,36-45,0-7-19,ATOPIC respiratory diseases,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure.",36 45,0,36,0,53,6,-1,RO-cause_of,900043,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure",allergic rhinitis,Atopic
502252404,7/11/2014 15:24:21,,1320779580,7/11/2014 15:23:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,36,0,,,53,6,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS and asthma,36-45-54-58,0-7-19,ATOPIC respiratory diseases,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure.",36 45,0,36,0,53,6,-1,RO-cause_of,900043,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure",allergic rhinitis,Atopic
502252404,7/11/2014 15:27:05,,1320780497,7/11/2014 15:26:56,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,36,0,,,53,6,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,36-45,0,ATOPIC,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure.",36 45,0,36,0,53,6,-1,RO-cause_of,900043,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure",allergic rhinitis,Atopic
502252404,7/11/2014 15:29:49,,1320781513,7/11/2014 15:29:45,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,36,0,,,53,6,ALLERGIC RHINITIS,ATOPIC,diseases such as ALLERGIC RHINITIS and asthma represent,19-28-33-36-45-54-58-65,0-7-19-28,ATOPIC respiratory diseases such,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure.",36 45,0,36,0,53,6,-1,RO-cause_of,900043,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure",allergic rhinitis,Atopic
502252404,7/11/2014 15:32:05,,1320782322,7/11/2014 15:31:26,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,36,0,,,53,6,ALLERGIC RHINITIS,ATOPIC,ALLERGIC RHINITIS,36-45,0,ATOPIC,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure.",36 45,0,36,0,53,6,-1,RO-cause_of,900043,"Atopic respiratory diseases such as allergic rhinitis and asthma represent the effects of an immunological response to allergens, mediated through immunoglobulins E. Development of a clinically significant atopic reaction depends on environmental exposure",allergic rhinitis,Atopic
502252405,7/11/2014 15:13:43,,1320774166,7/11/2014 15:13:33,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,217,161,,,225,172,MELANOMA,DACARBAZINE,MELANOMA,217,161,DACARBAZINE,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999.",217,161,217,161,225,172,1,RO-may_treat,907722,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999",melanoma,dacarbazine
502252405,7/11/2014 15:15:47,,1320775121,7/11/2014 15:15:43,instagc,1.0,27753923,GBR,"","",188.29.78.53,217,161,,,225,172,MELANOMA,DACARBAZINE,with metastatic malignant MELANOMA last modified,191-196-207-217-235-240,133-144-157-161-173-179-182,"cisplatin, vinblastine, and DACARBAZINE alone in patients","Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999.",217,161,217,161,225,172,1,RO-may_treat,907722,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999",melanoma,dacarbazine
502252405,7/11/2014 15:17:32,,1320775725,7/11/2014 15:17:27,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,217,161,,,225,172,MELANOMA,DACARBAZINE,with metastatic malignant MELANOMA last modified,191-196-207-217-235-240,133-144-157-161-173-179-182,"cisplatin, vinblastine, and DACARBAZINE alone in patients","Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999.",217,161,217,161,225,172,1,RO-may_treat,907722,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999",melanoma,dacarbazine
502252405,7/11/2014 15:18:30,,1320776221,7/11/2014 15:18:17,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,217,161,,,225,172,MELANOMA,DACARBAZINE,metastatic malignant MELANOMA,196-207-217,161,DACARBAZINE,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999.",217,161,217,161,225,172,1,RO-may_treat,907722,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999",melanoma,dacarbazine
502252405,7/11/2014 15:20:46,,1320777510,7/11/2014 15:20:32,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,217,161,,,225,172,MELANOMA,DACARBAZINE,malignant MELANOMA,207-217,161,DACARBAZINE,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999.",217,161,217,161,225,172,1,RO-may_treat,907722,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999",melanoma,dacarbazine
502252405,7/11/2014 15:23:59,,1320779444,7/11/2014 15:23:36,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,217,161,,,225,172,MELANOMA,DACARBAZINE,MELANOMA,217,161,DACARBAZINE,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999.",217,161,217,161,225,172,1,RO-may_treat,907722,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999",melanoma,dacarbazine
502252405,7/11/2014 15:26:45,,1320780430,7/11/2014 15:26:12,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,217,161,,,225,172,MELANOMA,DACARBAZINE,metastatic malignant MELANOMA,196-207-217,133-144-157-161,"cisplatin, vinblastine, and DACARBAZINE","Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999.",217,161,217,161,225,172,1,RO-may_treat,907722,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999",melanoma,dacarbazine
502252405,7/11/2014 15:40:19,,1320785695,7/11/2014 15:39:18,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,217,161,,,225,172,MELANOMA,DACARBAZINE,metastatic malignant MELANOMA,196-207-217,19-30-46-51-62-75-88-99-100-103-107-118-123-133-144-157-161-126,"concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin - 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE","Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999.",217,161,217,161,225,172,1,RO-may_treat,907722,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999",melanoma,dacarbazine
502252405,7/11/2014 15:48:35,,1320788495,7/11/2014 15:48:13,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,217,161,,,225,172,MELANOMA,DACARBAZINE,metastatic malignant MELANOMA,196-207-217,161,DACARBAZINE,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999.",217,161,217,161,225,172,1,RO-may_treat,907722,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999",melanoma,dacarbazine
502252405,7/11/2014 15:51:21,,1320790341,7/11/2014 15:51:05,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,217,161,,,225,172,MELANOMA,DACARBAZINE,metastatic malignant MELANOMA,196-207-217,161,DACARBAZINE,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999.",217,161,217,161,225,172,1,RO-may_treat,907722,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (summary last modified 10/1999",melanoma,dacarbazine
502252406,7/11/2014 15:14:40,,1320774658,7/11/2014 15:14:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,149,93,,,161,103,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,149,93,TUBERCULIN,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis.,149,93,149,93,161,103,1,RO-may_diagnose,906725,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis,tuberculosis,tuberculin
502252406,7/11/2014 15:15:11,,1320774903,7/11/2014 15:14:50,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,149,93,,,161,103,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,149,83-93-104,increased TUBERCULIN responsiveness,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis.,149,93,149,93,161,103,1,RO-may_diagnose,906725,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis,tuberculosis,tuberculin
502252406,7/11/2014 15:15:11,,1320774907,7/11/2014 15:14:57,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,149,93,,,161,103,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,149,93,TUBERCULIN,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis.,149,93,149,93,161,103,1,RO-may_diagnose,906725,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis,tuberculosis,tuberculin
502252406,7/11/2014 15:20:15,,1320777146,7/11/2014 15:20:02,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,149,93,,,161,103,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,149,93-104,TUBERCULIN responsiveness,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis.,149,93,149,93,161,103,1,RO-may_diagnose,906725,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis,tuberculosis,tuberculin
502252406,7/11/2014 15:26:03,,1320780140,7/11/2014 15:25:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,149,93,,,161,103,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,149,93-104,TUBERCULIN responsiveness,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis.,149,93,149,93,161,103,1,RO-may_diagnose,906725,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis,tuberculosis,tuberculin
502252406,7/11/2014 15:28:18,,1320780918,7/11/2014 15:26:46,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,149,93,,,161,103,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,149,83-93-104-119-122-124,increased TUBERCULIN responsiveness of T cells,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis.,149,93,149,93,161,103,1,RO-may_diagnose,906725,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis,tuberculosis,tuberculin
502252406,7/11/2014 15:29:35,,1320781403,7/11/2014 15:29:26,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,149,93,,,161,103,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,149,93,TUBERCULIN,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis.,149,93,149,93,161,103,1,RO-may_diagnose,906725,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis,tuberculosis,tuberculin
502252406,7/11/2014 15:31:08,,1320781934,7/11/2014 15:31:04,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,149,93,,,161,103,TUBERCULOSIS,TUBERCULIN,from patients with TUBERCULOSIS.,130-135-144-149,67-71-83-93-104-119-122,and selectively increased TUBERCULIN responsiveness of T,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis.,149,93,149,93,161,103,1,RO-may_diagnose,906725,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis,tuberculosis,tuberculin
502252406,7/11/2014 15:46:52,,1320787761,7/11/2014 15:46:35,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,149,93,,,161,103,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,149,93,TUBERCULIN,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis.,149,93,149,93,161,103,1,RO-may_diagnose,906725,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis,tuberculosis,tuberculin
502252406,7/11/2014 15:47:01,,1320787814,7/11/2014 15:46:49,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,149,93,,,161,103,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,149,93,TUBERCULIN,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis.,149,93,149,93,161,103,1,RO-may_diagnose,906725,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased tuberculin responsiveness of T cells from patients with tuberculosis,tuberculosis,tuberculin
502252407,7/11/2014 15:14:52,,1320774764,7/11/2014 15:14:37,instagc,1.0,13763729,USA,"","",75.182.89.225,140,21,,,161,37,RESPIRATORY ALKALOSIS,HYPERVENTILATION,"RESPIRATORY ALKALOSIS,",140-152,21,HYPERVENTILATION,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction.",140 152,21,140,21,161,37,1,RO-cause_of,900387,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction",respiratory alkalosis,hyperventilation
502252407,7/11/2014 15:16:26,,1320775381,7/11/2014 15:16:23,instagc,1.0,27753923,GBR,"","",188.29.78.53,140,21,,,161,37,RESPIRATORY ALKALOSIS,HYPERVENTILATION,"syndrome to induce RESPIRATORY ALKALOSIS, which may attenuate",121-130-133-140-152-163-169-173,0-13-21-38-41-46,Mechanically induced HYPERVENTILATION is used in,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction.",140 152,21,140,21,161,37,1,RO-cause_of,900387,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction",respiratory alkalosis,hyperventilation
502252407,7/11/2014 15:16:52,,1320775508,7/11/2014 15:16:40,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,140,21,,,161,37,RESPIRATORY ALKALOSIS,HYPERVENTILATION,"RESPIRATORY ALKALOSIS,",140-152,21,HYPERVENTILATION,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction.",140 152,21,140,21,161,37,1,RO-cause_of,900387,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction",respiratory alkalosis,hyperventilation
502252407,7/11/2014 15:16:55,,1320775529,7/11/2014 15:16:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,140,21,,,161,37,RESPIRATORY ALKALOSIS,HYPERVENTILATION,"RESPIRATORY ALKALOSIS,",140-152,21,HYPERVENTILATION,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction.",140 152,21,140,21,161,37,1,RO-cause_of,900387,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction",respiratory alkalosis,hyperventilation
502252407,7/11/2014 15:20:49,,1320777523,7/11/2014 15:20:35,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,140,21,,,161,37,RESPIRATORY ALKALOSIS,HYPERVENTILATION,"RESPIRATORY ALKALOSIS,",140-152,0-13-21,Mechanically induced HYPERVENTILATION,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction.",140 152,21,140,21,161,37,1,RO-cause_of,900387,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction",respiratory alkalosis,hyperventilation
502252407,7/11/2014 15:21:18,,1320777791,7/11/2014 15:21:05,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,140,21,,,161,37,RESPIRATORY ALKALOSIS,HYPERVENTILATION,"RESPIRATORY ALKALOSIS,",140-152,21,HYPERVENTILATION,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction.",140 152,21,140,21,161,37,1,RO-cause_of,900387,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction",respiratory alkalosis,hyperventilation
502252407,7/11/2014 15:33:34,,1320782852,7/11/2014 15:33:16,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,140,21,,,161,37,RESPIRATORY ALKALOSIS,HYPERVENTILATION,"RESPIRATORY ALKALOSIS,",140-152,0-13-21,Mechanically induced HYPERVENTILATION,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction.",140 152,21,140,21,161,37,1,RO-cause_of,900387,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction",respiratory alkalosis,hyperventilation
502252407,7/11/2014 15:39:59,,1320785596,7/11/2014 15:39:21,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,140,21,,,161,37,RESPIRATORY ALKALOSIS,HYPERVENTILATION,"RESPIRATORY ALKALOSIS,",140-152,21,HYPERVENTILATION,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction.",140 152,21,140,21,161,37,1,RO-cause_of,900387,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction",respiratory alkalosis,hyperventilation
502252407,7/11/2014 15:46:06,,1320787509,7/11/2014 15:45:49,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,140,21,,,161,37,RESPIRATORY ALKALOSIS,HYPERVENTILATION,"RESPIRATORY ALKALOSIS,",140-152,0-13-21,Mechanically induced HYPERVENTILATION,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction.",140 152,21,140,21,161,37,1,RO-cause_of,900387,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction",respiratory alkalosis,hyperventilation
502252407,7/11/2014 15:48:06,,1320788277,7/11/2014 15:47:46,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,140,21,,,161,37,RESPIRATORY ALKALOSIS,HYPERVENTILATION,"RESPIRATORY ALKALOSIS,",140-152,0-13-21,Mechanically induced HYPERVENTILATION,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction.",140 152,21,140,21,161,37,1,RO-cause_of,900387,"Mechanically induced hyperventilation is used in the treatment of newborn infants with persistent pulmonary hypertension syndrome to induce respiratory alkalosis, which may attenuate their pulmonary vasoconstriction",respiratory alkalosis,hyperventilation
502252408,7/11/2014 15:11:31,,1320773278,7/11/2014 15:11:18,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,62,117,,,75,128,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,62-74,117-124,FACTOR VIII,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.",62 74,117 124,62,117,75,128,1,RO-may_treat,908218,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection",haemophilia A,factor VIII
502252408,7/11/2014 15:17:11,,1320775596,7/11/2014 15:17:06,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,62,117,,,75,128,HAEMOPHILIA A,FACTOR VIII,for patients with HAEMOPHILIA A because of the,44-48-57-62-74-76-84-87,99-110-113-117-124-129-135-139,"complexity of the FACTOR VIII gene, the recent","Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.",62 74,117 124,62,117,75,128,1,RO-may_treat,908218,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection",haemophilia A,factor VIII
502252408,7/11/2014 15:17:51,,1320775914,7/11/2014 15:17:37,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,62,117,,,75,128,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,62-74,117-124-129,"FACTOR VIII gene,","Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.",62 74,117 124,62,117,75,128,1,RO-may_treat,908218,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection",haemophilia A,factor VIII
502252408,7/11/2014 15:18:58,,1320776501,7/11/2014 15:18:37,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,62,117,,,75,128,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,62-74,117-124-129,"FACTOR VIII gene,","Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.",62 74,117 124,62,117,75,128,1,RO-may_treat,908218,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection",haemophilia A,factor VIII
502252408,7/11/2014 15:19:02,,1320776521,7/11/2014 15:18:40,instagc,1.0,13763729,USA,"","",75.182.89.225,62,117,,,75,128,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,62-74,117-124-129,"FACTOR VIII gene,","Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.",62 74,117 124,62,117,75,128,1,RO-may_treat,908218,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection",haemophilia A,factor VIII
502252408,7/11/2014 15:20:18,,1320777182,7/11/2014 15:19:59,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,62,117,,,75,128,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,62-74,117-124-129,"FACTOR VIII gene,","Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.",62 74,117 124,62,117,75,128,1,RO-may_treat,908218,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection",haemophilia A,factor VIII
502252408,7/11/2014 15:22:10,,1320778401,7/11/2014 15:21:55,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,62,117,,,75,128,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,62-74,117-124-129,"FACTOR VIII gene,","Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.",62 74,117 124,62,117,75,128,1,RO-may_treat,908218,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection",haemophilia A,factor VIII
502252408,7/11/2014 15:24:27,,1320779598,7/11/2014 15:24:14,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,62,117,,,75,128,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,62-74,117-124-129,"FACTOR VIII gene,","Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.",62 74,117 124,62,117,75,128,1,RO-may_treat,908218,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection",haemophilia A,factor VIII
502252408,7/11/2014 15:27:47,,1320780707,7/11/2014 15:27:06,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,62,117,,,75,128,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,62-74,117-124-129,"FACTOR VIII gene,","Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.",62 74,117 124,62,117,75,128,1,RO-may_treat,908218,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection",haemophilia A,factor VIII
502252408,7/11/2014 15:29:14,,1320781262,7/11/2014 15:28:44,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,62,117,,,75,128,HAEMOPHILIA A,FACTOR VIII,for patients with HAEMOPHILIA A because of the,44-48-57-62-74-76-84-87,99-110-113-117-124-129-135-139,"complexity of the FACTOR VIII gene, the recent","Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection.",62 74,117 124,62,117,75,128,1,RO-may_treat,908218,"Although this is more technically demanding for patients with haemophilia A because of the greater complexity of the factor VIII gene, the recent description of X-chromosome inversions as a cause of severe haemophilia A in almost 50% of patients has led to the ready detection of these inversions in such families with associated precise carrier detection",haemophilia A,factor VIII
502252409,7/11/2014 15:14:22,,1320774497,7/11/2014 15:14:11,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,184,140,,,205,157,DIABETIC KETOACIDOSIS,DIABETES MELLITUS,DIABETIC KETOACIDOSIS,184-193,140-149,DIABETES MELLITUS,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred.",184 193,140 149,184,140,205,157,-1,RO-cause_of,900345,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred",diabetic ketoacidosis,diabetes mellitus
502252409,7/11/2014 15:15:26,,1320774985,7/11/2014 15:15:21,instagc,1,27753923,GBR,"","",188.29.78.53,184,140,,,205,157,DIABETIC KETOACIDOSIS,DIABETES MELLITUS,use of PIs; DIABETIC KETOACIDOSIS has occurred.,172-176-179-184-193-206-210,112-125-128-140-149-158-167-172,exacerbation of preexisting DIABETES MELLITUS reported with use,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred.",184 193,140 149,184,140,205,157,-1,RO-cause_of,900345,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred",diabetic ketoacidosis,diabetes mellitus
502252409,7/11/2014 15:17:05,,1320775576,7/11/2014 15:16:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,184,140,,,205,157,DIABETIC KETOACIDOSIS,DIABETES MELLITUS,DIABETIC KETOACIDOSIS,184-193,112-125-128-140-149,exacerbation of preexisting DIABETES MELLITUS,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred.",184 193,140 149,184,140,205,157,-1,RO-cause_of,900345,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred",diabetic ketoacidosis,diabetes mellitus
502252409,7/11/2014 15:18:10,,1320776095,7/11/2014 15:17:42,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,184,140,,,205,157,DIABETIC KETOACIDOSIS,DIABETES MELLITUS,DIABETIC KETOACIDOSIS,184-193,140-149,DIABETES MELLITUS,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred.",184 193,140 149,184,140,205,157,-1,RO-cause_of,900345,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred",diabetic ketoacidosis,diabetes mellitus
502252409,7/11/2014 15:19:14,,1320776647,7/11/2014 15:19:02,neodev,1,14861092,GBR,I2,Manchester,90.194.137.76,184,140,,,205,157,DIABETIC KETOACIDOSIS,DIABETES MELLITUS,DIABETIC KETOACIDOSIS,184-193,140-149,DIABETES MELLITUS,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred.",184 193,140 149,184,140,205,157,-1,RO-cause_of,900345,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred",diabetic ketoacidosis,diabetes mellitus
502252409,7/11/2014 15:20:16,,1320777152,7/11/2014 15:19:59,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,184,140,,,205,157,DIABETIC KETOACIDOSIS,DIABETES MELLITUS,PIs; DIABETIC KETOACIDOSIS,184-193-179,140-149,DIABETES MELLITUS,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred.",184 193,140 149,184,140,205,157,-1,RO-cause_of,900345,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred",diabetic ketoacidosis,diabetes mellitus
502252409,7/11/2014 15:20:34,,1320777358,7/11/2014 15:20:21,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,184,140,,,205,157,DIABETIC KETOACIDOSIS,DIABETES MELLITUS,DIABETIC KETOACIDOSIS,184-193,140-149,DIABETES MELLITUS,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred.",184 193,140 149,184,140,205,157,-1,RO-cause_of,900345,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred",diabetic ketoacidosis,diabetes mellitus
502252409,7/11/2014 15:28:44,,1320781043,7/11/2014 15:28:32,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,184,140,,,205,157,DIABETIC KETOACIDOSIS,DIABETES MELLITUS,DIABETIC KETOACIDOSIS,184-193,140-149,DIABETES MELLITUS,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred.",184 193,140 149,184,140,205,157,-1,RO-cause_of,900345,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred",diabetic ketoacidosis,diabetes mellitus
502252409,7/11/2014 15:35:46,,1320784175,7/11/2014 15:35:31,zoombucks,1,5919735,USA,PA,Doylestown,173.49.91.231,184,140,,,205,157,DIABETIC KETOACIDOSIS,DIABETES MELLITUS,DIABETIC KETOACIDOSIS,184-193,128-140-149,preexisting DIABETES MELLITUS,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred.",184 193,140 149,184,140,205,157,-1,RO-cause_of,900345,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred",diabetic ketoacidosis,diabetes mellitus
502252409,7/11/2014 15:46:36,,1320787658,7/11/2014 15:46:21,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,184,140,,,205,157,DIABETIC KETOACIDOSIS,DIABETES MELLITUS,DIABETIC KETOACIDOSIS,184-193,140-149,DIABETES MELLITUS,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred.",184 193,140 149,184,140,205,157,-1,RO-cause_of,900345,"Hyperglycemic and Diabetogenic Effects  Hyperglycemia (potentially persistent), new-onset diabetes mellitus, or exacerbation of preexisting diabetes mellitus reported with use of PIs; diabetic ketoacidosis has occurred",diabetic ketoacidosis,diabetes mellitus
502252410,7/11/2014 15:14:59,,1320774809,7/11/2014 15:14:47,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,9,60,,,16,84,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES alpha fetoprotein,9-17-23,60-75,HEPATOCELLULAR CARCINOMA,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A.,9,60 75,9,60,16,84,-1,RO-disease_may_have_finding,902858,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A,ascites,hepatocellular carcinoma
502252410,7/11/2014 15:15:09,,1320774898,7/11/2014 15:14:58,instagc,1.0,27753923,GBR,"","",188.29.78.53,9,60,,,16,84,ASCITES,HEPATOCELLULAR CARCINOMA,Serum or ASCITES alpha fetoprotein,0-6-9-17-23,41-46-55-60-75-85-89-94,from patients with HEPATOCELLULAR CARCINOMA and from a,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A.,9,60 75,9,60,16,84,-1,RO-disease_may_have_finding,902858,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A,ascites,hepatocellular carcinoma
502252410,7/11/2014 15:26:47,,1320780433,7/11/2014 15:26:24,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,9,60,,,16,84,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES alpha - fetoprotein (AFP),9-17-22-23-35,60-75,HEPATOCELLULAR CARCINOMA,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A.,9,60 75,9,60,16,84,-1,RO-disease_may_have_finding,902858,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A,ascites,hepatocellular carcinoma
502252410,7/11/2014 15:27:28,,1320780614,7/11/2014 15:27:16,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,9,60,,,16,84,ASCITES,HEPATOCELLULAR CARCINOMA,Serum ASCITES,0-9,60-75,HEPATOCELLULAR CARCINOMA,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A.,9,60 75,9,60,16,84,-1,RO-disease_may_have_finding,902858,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A,ascites,hepatocellular carcinoma
502252410,7/11/2014 15:34:49,,1320783658,7/11/2014 15:34:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,9,60,,,16,84,ASCITES,HEPATOCELLULAR CARCINOMA,Serum or ASCITES alpha fetoprotein,0-6-9-17-23,60-75,HEPATOCELLULAR CARCINOMA,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A.,9,60 75,9,60,16,84,-1,RO-disease_may_have_finding,902858,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A,ascites,hepatocellular carcinoma
502252410,7/11/2014 15:41:27,,1320786115,7/11/2014 15:41:05,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,9,60,,,16,84,ASCITES,HEPATOCELLULAR CARCINOMA,Serum or ASCITES alpha fetoprotein (AFP),0-6-9-17-23-35,60-75,HEPATOCELLULAR CARCINOMA,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A.,9,60 75,9,60,16,84,-1,RO-disease_may_have_finding,902858,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A,ascites,hepatocellular carcinoma
502252410,7/11/2014 15:48:39,,1320788559,7/11/2014 15:48:25,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,9,60,,,16,84,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES alpha fetoprotein (AFP),9-17-23-35,60-75,HEPATOCELLULAR CARCINOMA,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A.,9,60 75,9,60,16,84,-1,RO-disease_may_have_finding,902858,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A,ascites,hepatocellular carcinoma
502252410,7/11/2014 15:51:36,,1320790553,7/11/2014 15:51:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,9,60,,,16,84,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES alpha fetoprotein,9-17-23,60-75,HEPATOCELLULAR CARCINOMA,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A.,9,60 75,9,60,16,84,-1,RO-disease_may_have_finding,902858,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A,ascites,hepatocellular carcinoma
502252410,7/11/2014 15:52:22,,1320791160,7/11/2014 15:52:07,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,9,60,,,16,84,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES alpha fetoprotein,9-17-23,60-75,HEPATOCELLULAR CARCINOMA,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A.,9,60 75,9,60,16,84,-1,RO-disease_may_have_finding,902858,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A,ascites,hepatocellular carcinoma
502252410,7/11/2014 15:54:11,,1320792467,7/11/2014 15:53:54,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,9,60,,,16,84,ASCITES,HEPATOCELLULAR CARCINOMA,ASCITES alpha fetoprotein,9-17-23,60-75,HEPATOCELLULAR CARCINOMA,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A.,9,60 75,9,60,16,84,-1,RO-disease_may_have_finding,902858,Serum or ascites alpha-fetoprotein (AFP) from patients with hepatocellular carcinoma and from a cord blood were analyzed by affinity electrophoresis with two lectins mixed in agarose gel in a combination of concanavalin A (Con A) and Lens culinaris agglutinin A (LCA-A) or of erythroagglutinating phytohemagglutinin (E-PHA) and Allomyrina dichotoma lectin (allo A,ascites,hepatocellular carcinoma
502252411,7/11/2014 15:15:38,,1320775060,7/11/2014 15:15:32,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,74,123,,,78,140,PAIN,NEUROPATHIC PAINS,"variety of difficult PAIN syndromes, including phantom",53-61-64-74-79-90-100,108-113-117-123-135-142-150-152,"pain and other NEUROPATHIC PAINS, remains a clinical","The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge.",74,123 135,74,123,78,140,-1,RO-has_definitional_manifestation,904784,"The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge",pain,neuropathic pains
502252411,7/11/2014 15:16:16,,1320775333,7/11/2014 15:15:34,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,74,123,,,78,140,PAIN,NEUROPATHIC PAINS,PAIN,74,123-135,"NEUROPATHIC PAINS,","The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge.",74,123 135,74,123,78,140,-1,RO-has_definitional_manifestation,904784,"The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge",pain,neuropathic pains
502252411,7/11/2014 15:16:48,,1320775496,7/11/2014 15:16:44,instagc,1.0,27753923,GBR,"","",188.29.78.53,74,123,,,78,140,PAIN,NEUROPATHIC PAINS,"variety of difficult PAIN syndromes, including phantom",53-61-64-74-79-90-100,108-113-117-123-135-142-150-152,"pain and other NEUROPATHIC PAINS, remains a clinical","The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge.",74,123 135,74,123,78,140,-1,RO-has_definitional_manifestation,904784,"The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge",pain,neuropathic pains
502252411,7/11/2014 15:17:38,,1320775783,7/11/2014 15:17:24,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,74,123,,,78,140,PAIN,NEUROPATHIC PAINS,"PAIN syndromes,",74-79,123-135,"NEUROPATHIC PAINS,","The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge.",74,123 135,74,123,78,140,-1,RO-has_definitional_manifestation,904784,"The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge",pain,neuropathic pains
502252411,7/11/2014 15:18:38,,1320776303,7/11/2014 15:18:26,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,74,123,,,78,140,PAIN,NEUROPATHIC PAINS,"PAIN syndromes,",74-79,123-135,"NEUROPATHIC PAINS,","The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge.",74,123 135,74,123,78,140,-1,RO-has_definitional_manifestation,904784,"The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge",pain,neuropathic pains
502252411,7/11/2014 15:22:22,,1320778562,7/11/2014 15:22:09,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,74,123,,,78,140,PAIN,NEUROPATHIC PAINS,"PAIN syndromes,",74-79,123-135,"NEUROPATHIC PAINS,","The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge.",74,123 135,74,123,78,140,-1,RO-has_definitional_manifestation,904784,"The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge",pain,neuropathic pains
502252411,7/11/2014 15:22:54,,1320778914,7/11/2014 15:22:08,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,74,123,,,78,140,PAIN,NEUROPATHIC PAINS,"variety of difficult PAIN syndromes,",53-61-64-74-79,74-79-100-108-113-117-123-135-90,"pain syndromes, including phantom pain and other NEUROPATHIC PAINS,","The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge.",74,123 135,74,123,78,140,-1,RO-has_definitional_manifestation,904784,"The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge",pain,neuropathic pains
502252411,7/11/2014 15:23:34,,1320779279,7/11/2014 15:22:53,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,74,123,,,78,140,PAIN,NEUROPATHIC PAINS,PAIN,74,123-135,"NEUROPATHIC PAINS,","The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge.",74,123 135,74,123,78,140,-1,RO-has_definitional_manifestation,904784,"The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge",pain,neuropathic pains
502252411,7/11/2014 15:25:35,,1320779899,7/11/2014 15:25:06,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,74,123,,,78,140,PAIN,NEUROPATHIC PAINS,"PAIN syndromes,",74-79,123-135,"NEUROPATHIC PAINS,","The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge.",74,123 135,74,123,78,140,-1,RO-has_definitional_manifestation,904784,"The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge",pain,neuropathic pains
502252411,7/11/2014 15:29:55,,1320781564,7/11/2014 15:29:46,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,74,123,,,78,140,PAIN,NEUROPATHIC PAINS,PAIN,74,123-135,"NEUROPATHIC PAINS,","The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge.",74,123 135,74,123,78,140,-1,RO-has_definitional_manifestation,904784,"The effective treatment of patients suffering from a variety of difficult pain syndromes, including phantom pain and other neuropathic pains, remains a clinical challenge",pain,neuropathic pains
502252412,7/11/2014 15:13:01,,1320773842,7/11/2014 15:12:50,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,114,149,,,118,157,PAIN,FENTANYL,PAIN:,114,149,FENTANYL,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.",114,149,114,149,118,157,1,RO-may_treat,907557,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems",pain,fentanyl
502252412,7/11/2014 15:13:45,,1320774181,7/11/2014 15:13:34,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,114,149,,,118,157,PAIN,FENTANYL,PAIN:,114,149,FENTANYL,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.",114,149,114,149,118,157,1,RO-may_treat,907557,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems",pain,fentanyl
502252412,7/11/2014 15:17:10,,1320775595,7/11/2014 15:17:07,instagc,1.0,27753923,GBR,"","",188.29.78.53,114,149,,,118,157,PAIN,FENTANYL,treatment of postoperative PAIN: a double blind,87-97-100-114-120-122-129,129-135-146-149-158-162-170,blind comparison of FENTANYL and placebo systems.,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.",114,149,114,149,118,157,1,RO-may_treat,907557,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems",pain,fentanyl
502252412,7/11/2014 15:18:20,,1320776146,7/11/2014 15:17:58,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,114,149,,,118,157,PAIN,FENTANYL,postoperative PAIN:,100-114,149,FENTANYL,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.",114,149,114,149,118,157,1,RO-may_treat,907557,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems",pain,fentanyl
502252412,7/11/2014 15:18:47,,1320776393,7/11/2014 15:18:31,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,114,149,,,118,157,PAIN,FENTANYL,postoperative PAIN:,100-114,149,FENTANYL,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.",114,149,114,149,118,157,1,RO-may_treat,907557,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems",pain,fentanyl
502252412,7/11/2014 15:22:52,,1320778863,7/11/2014 15:22:08,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,114,149,,,118,157,PAIN,FENTANYL,PAIN:,114,149,FENTANYL,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.",114,149,114,149,118,157,1,RO-may_treat,907557,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems",pain,fentanyl
502252412,7/11/2014 15:29:25,,1320781316,7/11/2014 15:29:09,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,114,149,,,118,157,PAIN,FENTANYL,PAIN:,114,149,FENTANYL,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.",114,149,114,149,118,157,1,RO-may_treat,907557,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems",pain,fentanyl
502252412,7/11/2014 15:34:01,,1320783134,7/11/2014 15:33:35,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,114,149,,,118,157,PAIN,FENTANYL,postoperative PAIN:,100-114,149-162-170-158,FENTANYL and placebo systems.,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.",114,149,114,149,118,157,1,RO-may_treat,907557,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems",pain,fentanyl
502252412,7/11/2014 15:42:56,,1320786442,7/11/2014 15:42:36,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,114,149,,,118,157,PAIN,FENTANYL,postoperative PAIN:,100-114,149,FENTANYL,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.",114,149,114,149,118,157,1,RO-may_treat,907557,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems",pain,fentanyl
502252412,7/11/2014 15:46:28,,1320787633,7/11/2014 15:46:11,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,114,149,,,118,157,PAIN,FENTANYL,postoperative PAIN:,100-114,149,FENTANYL,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems.",114,149,114,149,118,157,1,RO-may_treat,907557,"Gourlay GK, Kowalski SR, Plummer JL et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems",pain,fentanyl
502252413,7/11/2014 15:13:32,,1320774070,7/11/2014 15:13:15,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,59,37,,,72,45,BLOOD VESSELS,ISCHEMIA,BLOOD VESSELS,59-65,37,ISCHEMIA,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain.",59 65,37,59,37,72,45,1,RO-has_finding_site,905469,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain",blood vessels,ischemia
502252413,7/11/2014 15:13:49,,1320774202,7/11/2014 15:13:32,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,59,37,,,72,45,BLOOD VESSELS,ISCHEMIA,brain BLOOD VESSELS,53-59-65,37,ISCHEMIA,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain.",59 65,37,59,37,72,45,1,RO-has_finding_site,905469,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain",blood vessels,ischemia
502252413,7/11/2014 15:14:07,,1320774332,7/11/2014 15:13:58,instagc,1.0,27753923,GBR,"","",188.29.78.53,59,37,,,72,45,BLOOD VESSELS,ISCHEMIA,in the brain BLOOD VESSELS of rats exposed ischemia reperfusion,46-49-53-59-65-73-76-81-92-101,15-19-30-37-46-49-53,was determined during ISCHEMIA in the brain,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain.",59 65,37,59,37,72,45,1,RO-has_finding_site,905469,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain",blood vessels,ischemia
502252413,7/11/2014 15:15:52,,1320775158,7/11/2014 15:15:45,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,59,37,,,72,45,BLOOD VESSELS,ISCHEMIA,in the brain BLOOD VESSELS of rats exposed,46-49-53-59-65-73-76-81,15-19-30-37-46-49-53,was determined during ISCHEMIA in the brain,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain.",59 65,37,59,37,72,45,1,RO-has_finding_site,905469,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain",blood vessels,ischemia
502252413,7/11/2014 15:16:24,,1320775357,7/11/2014 15:16:07,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,59,37,,,72,45,BLOOD VESSELS,ISCHEMIA,BLOOD VESSELS,59-65,37,ISCHEMIA,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain.",59 65,37,59,37,72,45,1,RO-has_finding_site,905469,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain",blood vessels,ischemia
502252413,7/11/2014 15:22:11,,1320778414,7/11/2014 15:21:58,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,59,37,,,72,45,BLOOD VESSELS,ISCHEMIA,BLOOD VESSELS,59-65,37,ISCHEMIA,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain.",59 65,37,59,37,72,45,1,RO-has_finding_site,905469,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain",blood vessels,ischemia
502252413,7/11/2014 15:28:19,,1320780915,7/11/2014 15:28:07,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,59,37,,,72,45,BLOOD VESSELS,ISCHEMIA,BLOOD VESSELS,59-65,37,ISCHEMIA,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain.",59 65,37,59,37,72,45,1,RO-has_finding_site,905469,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain",blood vessels,ischemia
502252413,7/11/2014 15:31:38,,1320782114,7/11/2014 15:31:33,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,59,37,,,72,45,BLOOD VESSELS,ISCHEMIA,in the brain BLOOD VESSELS of rats exposed,46-49-53-59-65-73-76-81,15-19-30-37-46-49-53,was determined during ISCHEMIA in the brain,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain.",59 65,37,59,37,72,45,1,RO-has_finding_site,905469,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain",blood vessels,ischemia
502252413,7/11/2014 15:40:55,,1320785913,7/11/2014 15:40:37,bitcoinget,1.0,24792414,USA,"","",166.181.81.197,59,37,,,72,45,BLOOD VESSELS,ISCHEMIA,BLOOD VESSELS,59-65,37,ISCHEMIA,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain.",59 65,37,59,37,72,45,1,RO-has_finding_site,905469,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain",blood vessels,ischemia
502252413,7/11/2014 15:42:42,,1320786360,7/11/2014 15:42:03,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,59,37,,,72,45,BLOOD VESSELS,ISCHEMIA,ischemia in the brain BLOOD VESSELS,37-46-49-53-59-65,37-46-49-53,ISCHEMIA in the brain,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain.",59 65,37,59,37,72,45,1,RO-has_finding_site,905469,"Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain",blood vessels,ischemia
502252414,7/11/2014 15:10:52,,1320772913,7/11/2014 15:10:39,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,0,29,,,25,41,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,0-10,29,METHACHOLINE,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge.,0 10,29,0,29,25,41,1,RO-may_diagnose,906702,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge,Bronchial hyperreactivity,methacholine
502252414,7/11/2014 15:15:37,,1320775040,7/11/2014 15:15:34,instagc,1.0,27753923,GBR,"","",188.29.78.53,0,29,,,25,41,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY to methacholine was,0-10-26-29-42,0-10-26-29-42-46-56,Bronchial hyperreactivity to METHACHOLINE was confirmed at,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge.,0 10,29,0,29,25,41,1,RO-may_diagnose,906702,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge,Bronchial hyperreactivity,methacholine
502252414,7/11/2014 15:16:04,,1320775254,7/11/2014 15:15:58,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,0,29,,,25,41,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY to methacholine was,0-10-26-29-42,0-10-26-29-42-46-56,Bronchial hyperreactivity to METHACHOLINE was confirmed at,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge.,0 10,29,0,29,25,41,1,RO-may_diagnose,906702,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge,Bronchial hyperreactivity,methacholine
502252414,7/11/2014 15:16:41,,1320775448,7/11/2014 15:16:22,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,0,29,,,25,41,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,0-10,29,METHACHOLINE,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge.,0 10,29,0,29,25,41,1,RO-may_diagnose,906702,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge,Bronchial hyperreactivity,methacholine
502252414,7/11/2014 15:18:39,,1320776339,7/11/2014 15:18:26,instagc,1.0,13763729,USA,"","",75.182.89.225,0,29,,,25,41,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,0-10,29,METHACHOLINE,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge.,0 10,29,0,29,25,41,1,RO-may_diagnose,906702,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge,Bronchial hyperreactivity,methacholine
502252414,7/11/2014 15:19:16,,1320776655,7/11/2014 15:19:06,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,0,29,,,25,41,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,0-10,29,METHACHOLINE,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge.,0 10,29,0,29,25,41,1,RO-may_diagnose,906702,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge,Bronchial hyperreactivity,methacholine
502252414,7/11/2014 15:20:59,,1320777617,7/11/2014 15:20:47,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,0,29,,,25,41,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,0-10,29,METHACHOLINE,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge.,0 10,29,0,29,25,41,1,RO-may_diagnose,906702,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge,Bronchial hyperreactivity,methacholine
502252414,7/11/2014 15:27:16,,1320780542,7/11/2014 15:27:06,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,0,29,,,25,41,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY methacholine,0-10-29,0-10-29,Bronchial hyperreactivity METHACHOLINE,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge.,0 10,29,0,29,25,41,1,RO-may_diagnose,906702,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge,Bronchial hyperreactivity,methacholine
502252414,7/11/2014 15:31:40,,1320782125,7/11/2014 15:31:18,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,0,29,,,25,41,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,0-10,29,METHACHOLINE,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge.,0 10,29,0,29,25,41,1,RO-may_diagnose,906702,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge,Bronchial hyperreactivity,methacholine
502252414,7/11/2014 15:32:50,,1320782557,7/11/2014 15:32:13,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,0,29,,,25,41,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY to methacholine,0-10-26-29,0-10-26-29,Bronchial hyperreactivity to METHACHOLINE,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge.,0 10,29,0,29,25,41,1,RO-may_diagnose,906702,Bronchial hyperreactivity to methacholine was confirmed at a pretrial bronchial challenge,Bronchial hyperreactivity,methacholine
502252415,7/11/2014 15:12:08,,1320773514,7/11/2014 15:11:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,21,97,,,29,107,LEUKEMIA,CYTARABINE,LEUKEMIA,21,97,CYTARABINE,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,21,97,21,97,29,107,1,RO-may_treat,907968,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days,leukemia,cytarabine
502252415,7/11/2014 15:14:41,,1320774659,7/11/2014 15:14:31,instagc,1.0,27753923,GBR,"","",188.29.78.53,21,97,,,29,107,LEUKEMIA,CYTARABINE,Eleven patients with LEUKEMIA refractory to conventional,0-7-16-21-30-41-44,83-88-94-97-111-113,high doses of CYTARABINE g m2,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,21,97,21,97,29,107,1,RO-may_treat,907968,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days,leukemia,cytarabine
502252415,7/11/2014 15:19:47,,1320776916,7/11/2014 15:19:17,instagc,1.0,13763729,USA,"","",75.182.89.225,21,97,,,29,107,LEUKEMIA,CYTARABINE,LEUKEMIA,21,97,CYTARABINE,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,21,97,21,97,29,107,1,RO-may_treat,907968,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days,leukemia,cytarabine
502252415,7/11/2014 15:22:36,,1320778708,7/11/2014 15:22:22,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,21,97,,,29,107,LEUKEMIA,CYTARABINE,LEUKEMIA,21,97-111,CYTARABINE g,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,21,97,21,97,29,107,1,RO-may_treat,907968,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days,leukemia,cytarabine
502252415,7/11/2014 15:24:36,,1320779648,7/11/2014 15:23:08,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,21,97,,,29,107,LEUKEMIA,CYTARABINE,LEUKEMIA,21,97,CYTARABINE,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,21,97,21,97,29,107,1,RO-may_treat,907968,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days,leukemia,cytarabine
502252415,7/11/2014 15:24:49,,1320779721,7/11/2014 15:24:18,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,21,97,,,29,107,LEUKEMIA,CYTARABINE,LEUKEMIA,21,97,CYTARABINE,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,21,97,21,97,29,107,1,RO-may_treat,907968,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days,leukemia,cytarabine
502252415,7/11/2014 15:25:30,,1320779887,7/11/2014 15:25:11,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,21,97,,,29,107,LEUKEMIA,CYTARABINE,LEUKEMIA,21,97,CYTARABINE,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,21,97,21,97,29,107,1,RO-may_treat,907968,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days,leukemia,cytarabine
502252415,7/11/2014 15:30:20,,1320781723,7/11/2014 15:29:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,21,97,,,29,107,LEUKEMIA,CYTARABINE,LEUKEMIA refractory to conventional therapy,21-30-41-44-57,83-88-94-97-159-168-171-198,high doses of CYTARABINE followed by daunorubicin intravenously,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,21,97,21,97,29,107,1,RO-may_treat,907968,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days,leukemia,cytarabine
502252415,7/11/2014 15:30:52,,1320781884,7/11/2014 15:30:45,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,21,97,,,29,107,LEUKEMIA,CYTARABINE,Eleven patients with LEUKEMIA refractory to conventional,0-7-16-21-30-41-44,83-88-94-97-111-113,high doses of CYTARABINE g m2,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,21,97,21,97,29,107,1,RO-may_treat,907968,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days,leukemia,cytarabine
502252415,7/11/2014 15:34:47,,1320783644,7/11/2014 15:32:54,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,21,97,,,29,107,LEUKEMIA,CYTARABINE,LEUKEMIA refractory to conventional therapy,21-30-41-44-57,97-108-111-113-116-130-136-139-145-149-153-159-168-171-184-188-191-194-212-216-222-198,CYTARABINE (3 g m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg m2 day intravenously for three days.,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days.,21,97,21,97,29,107,1,RO-may_treat,907968,Eleven patients with leukemia refractory to conventional therapy were treated with high doses of cytarabine (3 g/m2 intravenously every 12 hours for six days) followed by daunorubicin (30 mg/m2/day intravenously for three days,leukemia,cytarabine
502252416,7/11/2014 15:16:04,,1320775260,7/11/2014 15:16:02,instagc,1.0,27753923,GBR,"","",188.29.78.53,134,149,,,145,173,BONE MARROW,MYELODYSPLASTIC SYNDROME,neoplastic transformation of BONE MARROW in myelodysplastic syndrome,105-116-131-134-139-146-149-165,134-139-146-149-165,bone marrow in MYELODYSPLASTIC SYNDROME,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS.,134 139,149 165,134,149,145,173,1,RO-has_finding_site,905277,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS,bone marrow,myelodysplastic syndrome
502252416,7/11/2014 15:16:43,,1320775455,7/11/2014 15:16:28,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,134,149,,,145,173,BONE MARROW,MYELODYSPLASTIC SYNDROME,BONE MARROW,134-139,149-165,MYELODYSPLASTIC SYNDROME,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS.,134 139,149 165,134,149,145,173,1,RO-has_finding_site,905277,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS,bone marrow,myelodysplastic syndrome
502252416,7/11/2014 15:17:23,,1320775669,7/11/2014 15:17:12,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,134,149,,,145,173,BONE MARROW,MYELODYSPLASTIC SYNDROME,BONE MARROW,134-139,149-165,MYELODYSPLASTIC SYNDROME,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS.,134 139,149 165,134,149,145,173,1,RO-has_finding_site,905277,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS,bone marrow,myelodysplastic syndrome
502252416,7/11/2014 15:17:44,,1320775842,7/11/2014 15:17:39,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,134,149,,,145,173,BONE MARROW,MYELODYSPLASTIC SYNDROME,neoplastic transformation of BONE MARROW in myelodysplastic syndrome,105-116-131-134-139-146-149-165,134-139-146-149-165,bone marrow in MYELODYSPLASTIC SYNDROME,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS.,134 139,149 165,134,149,145,173,1,RO-has_finding_site,905277,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS,bone marrow,myelodysplastic syndrome
502252416,7/11/2014 15:17:54,,1320775947,7/11/2014 15:17:26,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,134,149,,,145,173,BONE MARROW,MYELODYSPLASTIC SYNDROME,BONE MARROW,134-139,149-165,MYELODYSPLASTIC SYNDROME,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS.,134 139,149 165,134,149,145,173,1,RO-has_finding_site,905277,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS,bone marrow,myelodysplastic syndrome
502252416,7/11/2014 15:21:30,,1320777955,7/11/2014 15:21:19,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,134,149,,,145,173,BONE MARROW,MYELODYSPLASTIC SYNDROME,BONE MARROW,134-139,149-165,MYELODYSPLASTIC SYNDROME,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS.,134 139,149 165,134,149,145,173,1,RO-has_finding_site,905277,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS,bone marrow,myelodysplastic syndrome
502252416,7/11/2014 15:24:25,,1320779588,7/11/2014 15:24:13,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,134,149,,,145,173,BONE MARROW,MYELODYSPLASTIC SYNDROME,BONE MARROW,134-139,149-165,MYELODYSPLASTIC SYNDROME,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS.,134 139,149 165,134,149,145,173,1,RO-has_finding_site,905277,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS,bone marrow,myelodysplastic syndrome
502252416,7/11/2014 15:24:56,,1320779751,7/11/2014 15:24:42,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,134,149,,,145,173,BONE MARROW,MYELODYSPLASTIC SYNDROME,BONE MARROW myelodysplastic syndrome,134-139-149-165,149-165,MYELODYSPLASTIC SYNDROME,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS.,134 139,149 165,134,149,145,173,1,RO-has_finding_site,905277,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS,bone marrow,myelodysplastic syndrome
502252416,7/11/2014 15:26:44,,1320780419,7/11/2014 15:26:26,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,134,149,,,145,173,BONE MARROW,MYELODYSPLASTIC SYNDROME,BONE MARROW,134-139,149-165-174,MYELODYSPLASTIC SYNDROME (MDS.,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS.,134 139,149 165,134,149,145,173,1,RO-has_finding_site,905277,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS,bone marrow,myelodysplastic syndrome
502252416,7/11/2014 15:37:19,,1320784766,7/11/2014 15:36:55,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,134,149,,,145,173,BONE MARROW,MYELODYSPLASTIC SYNDROME,neoplastic transformation of BONE MARROW in myelodysplastic syndrome,105-116-131-134-139-146-149-165,134-139-146-149-165,bone marrow in MYELODYSPLASTIC SYNDROME,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS.,134 139,149 165,134,149,145,173,1,RO-has_finding_site,905277,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of bone marrow in myelodysplastic syndrome (MDS,bone marrow,myelodysplastic syndrome
502252417,7/11/2014 15:14:15,,1320774426,7/11/2014 15:13:58,instagc,1.0,13763729,USA,"","",75.182.89.225,259,242,,,262,257,PKU,PHENYLKETONURIA,(PKU.,258,242,PHENYLKETONURIA,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU.",,242,259,242,262,257,-1,RO-has_manifestation,906373,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU",PKU,phenylketonuria
502252417,7/11/2014 15:15:51,,1320775157,7/11/2014 15:14:59,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,259,242,,,262,257,PKU,PHENYLKETONURIA,tetrahydrobiopterin (BH 4 ) responsive phenylketonuria (PKU.,203-223-227-231-242-258-229,203-223-227-229-231-242-258,tetrahydrobiopterin (BH 4 ) responsive PHENYLKETONURIA (PKU.,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU.",,242,259,242,262,257,-1,RO-has_manifestation,906373,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU",PKU,phenylketonuria
502252417,7/11/2014 15:16:27,,1320775383,7/11/2014 15:16:12,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,259,242,,,262,257,PKU,PHENYLKETONURIA,(PKU.,258,242,PHENYLKETONURIA,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU.",,242,259,242,262,257,-1,RO-has_manifestation,906373,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU",PKU,phenylketonuria
502252417,7/11/2014 15:16:52,,1320775503,7/11/2014 15:16:41,clixsense,1.0,19190439,GBR,H9,London,86.15.32.131,259,242,,,262,257,PKU,PHENYLKETONURIA,(PKU.,258,242,PHENYLKETONURIA,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU.",,242,259,242,262,257,-1,RO-has_manifestation,906373,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU",PKU,phenylketonuria
502252417,7/11/2014 15:22:11,,1320778404,7/11/2014 15:21:49,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,259,242,,,262,257,PKU,PHENYLKETONURIA,responsive phenylketonuria (PKU.,231-242-258,231-242-258,responsive PHENYLKETONURIA (PKU.,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU.",,242,259,242,262,257,-1,RO-has_manifestation,906373,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU",PKU,phenylketonuria
502252417,7/11/2014 15:31:22,,1320782012,7/11/2014 15:31:09,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,259,242,,,262,257,PKU,PHENYLKETONURIA,responsive phenylketonuria (PKU.,231-242-258,227-229-231-242,4 ) responsive PHENYLKETONURIA,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU.",,242,259,242,262,257,-1,RO-has_manifestation,906373,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU",PKU,phenylketonuria
502252417,7/11/2014 15:38:12,,1320784994,7/11/2014 15:37:52,prodege,1.0,21865973,GBR,I7,Newcastle Upon Tyne,92.30.174.242,259,242,,,262,257,PKU,PHENYLKETONURIA,tetrahydrobiopterin (BH 4 ) - responsive phenylketonuria (PKU.,203-223-227-230-231-242-258-229,203-227-229-231-242-223,tetrahydrobiopterin (BH 4 ) responsive PHENYLKETONURIA,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU.",,242,259,242,262,257,-1,RO-has_manifestation,906373,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU",PKU,phenylketonuria
502252417,7/11/2014 15:47:59,,1320788240,7/11/2014 15:47:24,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,259,242,,,262,257,PKU,PHENYLKETONURIA,responsive phenylketonuria (PKU.,231-242-258,231-242,responsive PHENYLKETONURIA,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU.",,242,259,242,262,257,-1,RO-has_manifestation,906373,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU",PKU,phenylketonuria
502252417,7/11/2014 15:50:22,,1320789646,7/11/2014 15:49:58,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,259,242,,,262,257,PKU,PHENYLKETONURIA,tetrahydrobiopterin (BH 4 ) - responsive phenylketonuria (PKU.,203-223-227-229-231-242-258-230,223-227-229-231-242-258-203,tetrahydrobiopterin (BH 4 ) responsive PHENYLKETONURIA (PKU.,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU.",,242,259,242,262,257,-1,RO-has_manifestation,906373,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU",PKU,phenylketonuria
502252417,7/11/2014 15:50:28,,1320789689,7/11/2014 15:50:11,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,259,242,,,262,257,PKU,PHENYLKETONURIA,responsive phenylketonuria (PKU.,231-242-258,242-258,PHENYLKETONURIA (PKU.,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU.",,242,259,242,262,257,-1,RO-has_manifestation,906373,"1 ,   4 ,   5 ,   6  Class:  Other Miscellaneous Therapeutic Agents 92:92  Uses  Phenylketonuria  Used to reduce blood phenylalanine concentrations in patients with hyperphenylalaninemia associated with tetrahydrobiopterin (BH 4 )-responsive phenylketonuria (PKU",PKU,phenylketonuria
502252418,7/11/2014 15:13:11,,1320773897,7/11/2014 15:12:56,instagc,1.0,13763729,USA,"","",75.182.89.225,70,26,,,93,42,METASTATIC ANGIOSARCOMA,AICARDI SYNDROME,METASTATIC ANGIOSARCOMA.,70-81,26-34,AICARDI SYNDROME,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma.,70 81,26 34,70,26,93,42,1,RO-has_manifestation,906485,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma,metastatic angiosarcoma,Aicardi syndrome
502252418,7/11/2014 15:15:08,,1320774891,7/11/2014 15:15:00,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,70,26,,,93,42,METASTATIC ANGIOSARCOMA,AICARDI SYNDROME,METASTATIC ANGIOSARCOMA.,70-81,26-34,AICARDI SYNDROME,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma.,70 81,26 34,70,26,93,42,1,RO-has_manifestation,906485,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma,metastatic angiosarcoma,Aicardi syndrome
502252418,7/11/2014 15:18:27,,1320776200,7/11/2014 15:18:11,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,70,26,,,93,42,METASTATIC ANGIOSARCOMA,AICARDI SYNDROME,METASTATIC ANGIOSARCOMA.,70-81,26-34,AICARDI SYNDROME,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma.,70 81,26 34,70,26,93,42,1,RO-has_manifestation,906485,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma,metastatic angiosarcoma,Aicardi syndrome
502252418,7/11/2014 15:20:18,,1320777169,7/11/2014 15:20:03,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,70,26,,,93,42,METASTATIC ANGIOSARCOMA,AICARDI SYNDROME,METASTATIC ANGIOSARCOMA.,70-81,26-34,AICARDI SYNDROME,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma.,70 81,26 34,70,26,93,42,1,RO-has_manifestation,906485,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma,metastatic angiosarcoma,Aicardi syndrome
502252418,7/11/2014 15:21:39,,1320778046,7/11/2014 15:20:52,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,70,26,,,93,42,METASTATIC ANGIOSARCOMA,AICARDI SYNDROME,METASTATIC ANGIOSARCOMA.,70-81,26-34,AICARDI SYNDROME,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma.,70 81,26 34,70,26,93,42,1,RO-has_manifestation,906485,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma,metastatic angiosarcoma,Aicardi syndrome
502252418,7/11/2014 15:26:06,,1320780150,7/11/2014 15:25:42,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,70,26,,,93,42,METASTATIC ANGIOSARCOMA,AICARDI SYNDROME,lipoma METASTATIC ANGIOSARCOMA.,59-70-81,26-34-59,AICARDI SYNDROME lipoma,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma.,70 81,26 34,70,26,93,42,1,RO-has_manifestation,906485,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma,metastatic angiosarcoma,Aicardi syndrome
502252418,7/11/2014 15:28:54,,1320781130,7/11/2014 15:28:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,70,26,,,93,42,METASTATIC ANGIOSARCOMA,AICARDI SYNDROME,lipoma and METASTATIC ANGIOSARCOMA.,59-66-70-81,26-34-43-54-59-66-70-81,AICARDI SYNDROME associated with lipoma and metastatic angiosarcoma.,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma.,70 81,26 34,70,26,93,42,1,RO-has_manifestation,906485,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma,metastatic angiosarcoma,Aicardi syndrome
502252418,7/11/2014 15:31:27,,1320782038,7/11/2014 15:31:23,prodege,1.0,21435737,GBR,J1,Northampton,78.151.200.222,70,26,,,93,42,METASTATIC ANGIOSARCOMA,AICARDI SYNDROME,with lipoma and METASTATIC ANGIOSARCOMA.,54-59-66-70-81,12-18-23-26-34-43-54-59,first case of AICARDI SYNDROME associated with lipoma,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma.,70 81,26 34,70,26,93,42,1,RO-has_manifestation,906485,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma,metastatic angiosarcoma,Aicardi syndrome
502252418,7/11/2014 15:46:47,,1320787720,7/11/2014 15:46:35,bitcoinget,1.0,24792414,USA,WI,Juneau,166.181.83.197,70,26,,,93,42,METASTATIC ANGIOSARCOMA,AICARDI SYNDROME,METASTATIC ANGIOSARCOMA.,70-81,26-34,AICARDI SYNDROME,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma.,70 81,26 34,70,26,93,42,1,RO-has_manifestation,906485,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma,metastatic angiosarcoma,Aicardi syndrome
502252418,7/11/2014 15:47:45,,1320788132,7/11/2014 15:47:20,clixsense,1.0,28059098,USA,TN,Nashville,165.214.11.70,70,26,,,93,42,METASTATIC ANGIOSARCOMA,AICARDI SYNDROME,Aicardi syndrome associated with lipoma and METASTATIC ANGIOSARCOMA.,34-43-54-59-66-70-81-26,26-34-43-54-59-66-70-81,AICARDI SYNDROME associated with lipoma and metastatic angiosarcoma.,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma.,70 81,26 34,70,26,93,42,1,RO-has_manifestation,906485,This is the first case of Aicardi syndrome associated with lipoma and metastatic angiosarcoma,metastatic angiosarcoma,Aicardi syndrome
